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ABSTRACT	  
The diagnosis of breast cancer is attributed with increased stress, depressive 
mood, anxiety, mood and sleep disturbance. Bi-directional communication networks 
between the brain and the immune system allow for one’s emotions to impact immune 
function.  Psychological stress can impact immune function through the release of 
glucocorticoids that affect the immune system in both a time and dose dependent 
manner. One cell type particularly susceptible to both psychological stress and 
glucocorticoids are NK cells. The purpose of this study was to assess the impact of 
chronic glucocorticoid (GC) treatment on NK cells and use this in vitro system as a tool 
to investigate the regulation of the immune system during periods of psychological 
stress.  
Chronic in vitro treatment of NK92 cells produced a dichotomous NK phenotype 
in which enhanced proinflammatory cytokine production was accompanied by reduced 
NK cell lytic activity (NKCA).  The transcriptional profile of chronic GC treated NK 
cells reflected this dichotomous phenotype with mRNA and protein levels for interferon 
gamma (IFN-g) and for IL-6 increased while mRNA and protein levels for perforin and 
granzyme B decreased.  This dichotomy was at the individual cell level and was the first 
demonstration of such.  For perforin and granzyme B, time course analysis revealed 
reduced transcription related to recruitment of histone deacetylase 2 (HDAC2) with 
concomitant reduction in histone 3 lysine 9 acetylation (H3K9Ac).  In contrast, for IL-6
  xiii 
 and IFN-g, increased transcription upon cellular activation related to increased H4K8Ac 
with concomitant loss of HDAC1 and HDAC3 at genomic loci.  Hyper-acetylation of 
cytokine loci increased the sensitivity of these regions to nuclease digestion 
demonstrating increased accessibility of the chromatin structure, which was primed for 
enhanced transcription.  These results demonstrate chronic exposure to GC to impact 
NK cell effector function through the modification of the epigenetic status of NK cell 
effector genes through HDAC redistribution and subsequent epigenetic changes in a 
promoter specific manner.  
These observations were used to investigate the alterations in immune function 
during periods of psychological distress, at or within 10 days of cancer diagnosis. The 
perceived stress of cancer diagnosis was associated with increased daily cortisol 
production and thus enhanced activity of the hypothalamic-pituitary-adrenal gland 
(HPA) axis.  A similar dichotomous immune phenotype characterized by decreased 
NKCA and enhanced proinflammatory cytokine production was observed in the 
peripheral blood mononuclear cells (PBMC) of these individuals and was related to the 
increased activation of the HPA axis. Epigenetic analysis of PBMC demonstrated that 
the enhanced production of the proinflammatory cytokines IFN-g and IL-6 was related 
to H3K9Ac within critical regulatory regions. The mediation pathway of enhanced 
cytokine production by perceived stress through H3K9Ac was tested using the Sobel test. 
These results demonstrate that increased proinflammatory cytokine production by stress 
is partially mediated by promoter specific acetylation patterns on H3K9 within critical 
regulatory regions. In conjunction with pathways elucidated in vitro, epigenetic 
mechanisms regulate immune function during periods of psychological stress.
  1 
CHAPTER ONE 
 
LITERATURE REVIEW 
 
THE IMMUNE SYSTEM 
The immune system is the network of biological structures and cells that protects 
an organism from external threats such as pathogens and internal threats such as 
tumorigenesis.  Any condition that disrupts the normal homeostasis of the immune 
system can lead to pathogenesis by microorganisms, auto-immunity, and cancer.  The 
cells of the immune system are divided into two traditional categories; those of the 
innate and adaptive components.  If an invading pathogen is able to breach the physical 
barriers which protect an organism the cells of the innate immune system are the first 
responders and are poised to initiate a robust and non-specific response to aid in 
pathogen destruction and clearance.  These cells include neutrophils, monocytes, 
macrophages, dendritic cells, and natural killer (NK) cells.  Activation of the innate 
immune system provides the signals and mechanisms required for the initiation of the 
adaptive immune response.  Cells of the adaptive immune system are recruited and 
activated via a number of mechanisms to provide a pathogen specific response to clear 
the invading organism.  These adaptive immune cells, mainly T cells and B cells, 
possess an additional ability to remain dormant in the body poised to detect and 
eliminate the specific pathogen which they previously encountered, in a mechanism 
known as immunological memory.  Each cell of the immune system utilizes is own 
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unique repertoire of cellular responses to aid in pathogen elimination.  In a similar 
manner, cells of both the innate and adaptive compartments patrol the body and 
eliminate abnormal cells, either infected or cancerous, from healthy tissues.  The role of 
these many cell types in cancer detection, control, and eradication, as well as the 
mechanisms which control these processes are an intense area of research.    
 
Hematopoiesis 
 
Decades of research have illustrated that the cells of the immune system, 
including NK cells, develop through a regulated cascade known as hematopoiesis, 
outlined in Figure 1.  During this process, patterns of gene expression are reprogrammed 
in stages that ultimately restrict cell potential, leading to the fully differentiated 
specialized cells of the immune system.  The entire mammalian blood system is 
generated from a single primary pool of hematopoeitic stem cells (HSCs).  HSCs are the 
only cells with both self-renewing capability and the capacity to differentiate into the 
more than ten mature cell types in the blood.  These processes must be regulated in a 
highly orchestrated fashion to maintain the HSC and blood cell pool throughout life.  
The differentiation of HSCs into blood cells occurs in a hierarchical manner and 
includes clear-cut intermediate levels of lineage potential which decreases throughout 
the differentiation process.  The developmental network serves to provide the organism 
with stable intermediates and precursors to supply the appropriate downstream lineage 
cells when needed throughout life.  HSCs differentiate into multipotent  
3 
  
 
Figure 1. Schematic of hematopoiesis. Hematopoeitic hierarchy.  Adapted from Kuby 
Immunology Sixth Edition.  The hematopeoeitic stem cell (HSC) is the only cell in the 
hierarchy capable of self-renewal and pluripotency.  HSC give rise to the multi-potent 
progenitor (MMP) which maintains multipotency but lacks self renewing potential.  The 
MMP gives rise to both the common myeloid progenitor (CMP) and common lymphoid 
progenitor (CLP).  The CMP can differentiate into all cells of the myeloid lineage while 
the CLP gives rise to all of the cells of the lymphoid lineage including the early T cell 
progenitor (ETP).  The ETP differentiates into all T cell populations as well as NK cells. 
Not all intermediate and terminally differentiated cell populations are shown. 
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progenitor cells (MPPs) which lose their self-renewing properties but still maintain 
multipotency.  MPPs are then directed to differentiate into a specific branch either the 
common myeloid progenitor (CMP) or the common lymphoid progenitor (CLP) via 
regulated networks and integration of signals from the host and microenvironment of the 
bone marrow niche.  The CMP has the potential to differentiate into all the myeloid cells 
including erythrocytes, megakaryocytes, granulocytes, and macrophages.  The CLP can 
differentiate into three specific lymphocyte lineages B cells, T cells, and NK cells [1]. 
CLP can differentiate into the bipotent T/NK progenitor (T/NKP) [2].  This T/NKP 
progenitor can give rise to the early T cell progenitor (ETC) and thus the naïve CD4+ 
and CD8+ T cell pool, as well as the other CD3+ T cell populations.  Furthermore, this 
T/NKP gives rise to NK cells that share many functional properties with CD8+ cytotoxic 
T lymphocytes.  Although they share many functional attributes of T cells, the 
differentiation of NK cells is a unique developmental pathway demonstrated by the 
presence of NK cells in RAG1 [3] or RAG2 [4] knockout mice, scid mice [5], as well as 
athymic nude mice [6].  NK cells are an innate lymphocyte not only important in the 
surveillance and elimination of abnormal cells but a critical link between the innate and 
adaptive immune components.    
 
Natural Killer (NK) cells 
 
NK cells are classified as innate lymphocytes that comprise approximately 15% 
of peripheral blood mononuclear cells (PBMCs) and are characterized phenotypically by 
the presence of CD56 and lack of CD3 surface expression.  Two main subsets of NK 
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cells are found in human characterized by the levels of CD56 expression.  There are 
CD56bright and CD56dim NK cells which differ in function, phenotype, and tissue 
localization.  CD56dim NK cells constitute >90% of circulating NK cells in the blood.  
These CD56dim cells express perforin, killer Ig like receptors (KIRs), and the CD16 
FcγRIII and are thought to be more cytolytic and less immuno-regulatory [7].  CD56bright 
NK cells exhibit more immuno-regulatory functions through the secretion of cytokines, 
mainly IFN-g [8]. Bone marrow transplantation studies have suggested that CD56bright 
cells are precursors to the CD56dim populations [9,10].  Independent of the role CD56dim 
vs. CD56bright NK cells play in the immune response, NK cells were originally 
discovered through their unique ability to directly lyse cancer cells and virally infected 
cells without prior exposure [6,11].   
NK cells exhibit direct cytolytic activity through a complex process involving 
four main steps outlined in Figure 2.  First NK cells must bind and form a stable 
conjugate with the target cell (Figure 2A). Conjugate formation by the NK cell with a 
target cell is a process mediated by integrins and immunoglobulin superfamily of 
molecules including CD2, CD11a (LFA-1), CD11b, CD11c, and CD28 [12-14].  
Experiments have demonstrated that blocking these interactions with antibodies both 
suppressed adhesion and decreased target cell lysis by NK cells [15].  In the second step, 
stable conjugate formation is supported by and occurs concomitantly while the NK cell 
integrates a number of activating and inhibitory signals from ligands expressed on the 
target cell surface (Figure 2B).  Third, NK cells release the contents of their cytolytic 
granules into the immunological synapse formed during stable conjugate formation  
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Figure 2. Schematic of natural killer cell lytic activity. (A) Natural Killer cells bind to 
target cells via LFA-1 and CD2.  (B) NK cells integrate the expression of activating and 
inhibitory ligands presented on the target cell via germ-line encoded activating and 
inhibitory receptors. (C) Activation of NK cells leads to the release of cytolytic granules 
containing perforin and granzymes into the immunological synapse formed at the 
junction between the NK cell and the target cell. Molecules of perforin multimerizes on 
the plasma membrane of the target cell forming a pore-like structure.  Granzymes then 
enter the target cell cytoplasm and active the caspase system inducing apoptosis. 
 
 
!"#$%&'(%))'
*+',%))'
-./01' (23'
/4' 54'
!"#$%&'(%))'
*+',%))'
6789:9&;#<'
=%,%>&;#'
/,?@"?7$'
=%,%>&;#'
(4'
("A>"A%'/,?@"?;7'
B/>;>&;A9,'C"&8D"<E'
!"#$%&'(%))'
*+'(%))'
C%#F;#97'
G#"7H<I%A'
!"#$%&' ()'*"+#%+,'-.'/+0$%+1' 2"11&%' 3&11' 1453' +356"04)' B/E'*"&J#")' +9))%#' ,%))A' :97K' &;' &"#$%&'
,%))A' @9"' -./01' "7K'(234' ' B5E'*+' ,%))A' 97&%$#"&%' &8%' %L>#%AA9;7';F' ",?@"?7$' "7K' 9789:9&;#<'
)9$"7KA' >#%A%7&%K' ;7' &8%' &"#$%&' ,%))' @9"' $%#I0)97%' %7,;K%K' ",?@"?7$' "7K' 9789:9&;#<'
#%,%>&;#A4' B(E' /,?@"?;7' ;F' *+' ,%))A' )%"KA' &;' &8%' #%)%"A%' ;F' ,<&;)<?,' $#"7J)%A' ,;7&"9797$'
>%#F;#97'"7K'$#"7H<I%A'97&;'&8%'9IIJ7;);$9,")'A<7">A%'F;#I%K'"&'&8%'MJ7,?;7':%&D%%7'&8%'
*+',%))'"7K'&8%'&"#$%&',%))4'N;)%,J)%A';F'>%#F;#97'IJ)?I%#9H%A';7'&8%'>)"AI"'I%I:#"7%';F'
&8%'&"#$%&',%))'F;#I97$'"'>;#%0)9O%'A&#J,&J#%4''G#"7H<I%A'&8%7'%7&%#'&8%'&"#$%&',%))',<&;>)"AI'
"7K'",?@%'&8%',"A>"A%'A<A&%I'97KJ,97$'">;>&;A9A4'
7 
  
(Figure 2C).  In the final step, perforin and granzymes coordinate to activate the caspase 
system and thus apoptosis of the target cell (Figure 2C).   
The entire process of target cell lysis is contingent on the ability of an NK cell to 
determine if the target cell is healthy tissue or abnormal in some way, be it 
transformation or infection.  In order to determine whether a cell is infected, cancerous, 
or healthy tissue, NK cells possess a unique array of cell surface proteins that either 
stimulate (activating receptors) or dampen (inhibitory receptors) their activity when 
bound to their respective ligands. 
 
Killer immunoglobulin like receptors (KIRs) 
 
The effector functions of NK cells are controlled by germline encoded receptors 
that do not undergo somatic recombination, referred to as killer immunoglobulin like 
receptors (KIRs) [16-21].  KIRs fall into two main categories based on their structure: 
immunoglobulin-like and lectin-like receptors.  Neither structure is specific to the type 
(activating or inhibitory) of receptor and thus activating and inhibitory receptors fall into 
both categories.  NK cells integrate the signals from both these activating and inhibitory 
receptors to elicit the appropriate response either target cell killing or no cell killing 
(Figure 3).  The activating receptors possess cytoplasmic tails that contain ITAMs 
(immunoreceptor tyrosine based activating motif).  In contrast, inhibitory receptors 
possess cytoplasmic tails containing ITIMs (immunoreceptor tyrosine based inhibitory 
motif).  Inhibitory receptors are mainly composed of molecules that recognize MHC 
class I expression on target cells.  Lack of MHC class I  
8 
  
 
 
 
Figure 3. Integration of activating and inhibitory receptor by natural killer cells.  
Natural killer cells integrate the expression levels of both activating and inhibitory 
ligand expression on the surface of target cells through engagement to germ-line 
encoded activating and inhibitory receptors.  Binding of an activating receptor to its 
ligand induces an activation signal, indicating by a plus sign, that results in killing.  
However, engagement of an inhibitory receptor with its ligand results in an inhibitory 
signal, indicated by a minus sign, that opposes the activation signal thus preventing NK 
cell killing.  Loss of inhibitory ligand expression, a state normally associated with 
infection or transformation, allows for the activation signal to predominate resulting in 
target cell destruction.  
 
 
 
!"#$%&&%'(#
$%&&%'(#
!"
#"
#"
!")*+&#,-&&#
.+)(-/#,-&&#
0,12+1'(#
3-,-4/")#
5'6%7%/")8#
3-,-4/")#
5'6%7%/")8#
3-,-4/")#
0,12+1'(#
3-,-4/")#
!$#,-&&#
$%&'()" *+" ,%-&(-." /0" 1-2'(-3" 4%33)(" 5)33" %62)&(-7/6" /0" -578-76&" -69" %6:%;%2/(<" ()5)=2/(" >%&6-3%6&+" "!+/9)+&# :%&&-)# ,-&&;#
%'/-()+/-# /6-# -<4)-;;%"'# &-2-&;# "=# 7"/6# +,12+1'(# +'># %'6%7%/")8# &%(+'># -<4)-;;%"'# "'# /6-# ;9)=+,-# "=# /+)(-/# ,-&&;# /6)"9(6#
-'(+(-*-'/#/"#(-)*?&%'-#-',">->#+,12+1'(#+'>#%'6%7%/")8#)-,-4/");@##A%'>%'(#"=#+'#+,12+1'(#)-,-4/")#/"#%/;#&%(+'>#%'>9,-;#
+'#+,12+1"'#;%('+&B#%'>%,+1'(#78#+#4&9;#;%('B#/6+/#)-;9&/;#%'#:%&&%'(@##C"D-2-)B#-'(+(-*-'/#"=#+'#%'6%7%/")8#)-,-4/")#D%/6#%/;#
&%(+'>#)-;9&/;# %'#+'# %'6%7%/")8#;%('+&B# %'>%,+/->#78#+#*%'9;#;%('B# /6+/#"44";-;#/6-#+,12+1"'#;%('+&# /69;#4)-2-'1'(#!$#,-&&#
:%&&%'(@# # E";;# "=# %'6%7%/")8# &%(+'># -<4)-;;%"'B# +# ;/+/-# '")*+&&8# +;;",%+/->#D%/6# %'=-,1"'# ")# /)+';=")*+1"'B# +&&"D;# =")# /6-#
+,12+1"'#;%('+&#/"#4)->"*%'+/-#)-;9&1'(#%'#/+)(-/#,-&&#>-;/)9,1"'@##
A@#
0@#
07'")*+&#,-&&# !$#,-&&#
9 
  
on a potential target cell, which many times occurs during infection or cellular 
transformation, results in a lack of inhibitory signaling and thus results in NK cell 
activation and killing (Figure 3B).  This lack of MHC class I expression and NK cell 
activation has been termed “the missing self hypothesis” [18].  This posits that when a 
cell lacks or exhibits reduced surface expression of self MHC molecules (missing self), 
NK cells are activated and kill the target cell due to lack of inhibitory signaling via 
ITIMs within the NK cell.   
In addition to the inhibitory receptors there are also a wide variety of activating 
receptors present on NK cells.  Recently, a number of activating ligands have been 
identified including molecules that are upregulated on the cell surface in response to 
DNA damage [22], cellular stress [23-25], and viral or bacterial invasion [26,27].  It is 
believed that these activating ligands are upregulated and presented on the surface when 
a cell senses stress or abnormal processes. The expression levels of these ligands are 
then sensed and integrated into the complex signaling cascade within the NK cell, 
ultimately determining whether the cell is killed or spared.  More recently, the 
contribution of synergistic activation from multiple receptors is uncovering the dynamic 
and diverse array of signals that activate NK cells [28-30]. In summation, these NK cell 
receptor ligands are used to judge whether the normal processes of a cell are being 
altered due to cellular transformation or infection and regulate the activation of NK cells 
and their cytolytic activity.  
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Cytolytic Granules: Perforin and Granzyme 
 
The activation of NK cells culminates in the controlled release of cytoplasmic 
granules, which contain perforin and granzymes. Perforin and granzymes are 
constitutively expressed in natural killer cells and are contained within electron dense 
cytoplasmic granules even in resting NK cells.  Release of cytotoxin containing granules 
is directed toward the immunological synapse formed at the junction of the stable 
conjugate between the NK and target cells [31].  The granule-exocytosis pathway results 
in the activation of the caspase system and, ultimately, apoptosis of the target cell [32-
35].  Two prevailing mechanisms have been suggested for the perforin/granzyme 
mediated cell lysis pathway.  In the first model perforin is released into the 
immunological synapse and undergoes a conformational change when it encounters the 
target cell plasma membrane.  This conformational change exposes an amphipathic 
domain that inserts into the target cell plasma membrane.  Monomers of perforin then 
polymerize to form cylindrical pores between 5-20nm in diameter at neutral pH in the 
presence of calcium [36].  Further research revealed that perforin shares sequence and 
structural homology to the complement component C9 [37-39].  This pore is thought to 
allow granzymes, also released into the immunological synapse, access to the target cell 
cytoplasm. The granzymes, a class of serine proteases, cleave and activate members of 
the caspase system inducing apoptosis of the target cell [40]. 
In a second pathway, granzymes are thought to bind the mannose-6-phosphate 
receptor.  Granzyme binding to the mannose-6-phosphate receptor results in 
internalization of the complex [41].  It is believed that this endocytic pathway would 
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result in vesicles that also contain perforin monomers; thus the formation of perforin 
mediated pores within this vesicle allows granzymes entry to the cytoplasm [41].  
Ultimately, both pathways require perforin and result in the activation of the caspase 
pathway and subsequent apoptosis of the target cell via granzymes.    
The important role of perforin in NK cell immunomodulation has been 
elucidated by experiments in mice and natural human mutations in the perforin gene.  In 
a seminal study, perforin deficient mice showed a marked immunodeficiency [42].  
Other mouse studies have confirmed the importance of the perforin pathway in defense 
against viral infection and cancer [43-45].  Additionally, human diseases in which 
patients lack or have a mutated forms of perforin exhibit a decrease in 
immunosurvelliance mechanisms [46].  This work in total emphasizes the critical role of 
perforin in the control of both tumorogenesis and viral infection.   
The perforin gene, PRF1, is encoded on the human chromosome 10 band q22 
and is expressed by NK, CD8+ T cells, γδ T cells, and NKT cells. The upstream 5’ 
regulatory region of the PRF1 contains two distinct enhancer regions located at -15kb 
and -1kb from the transcriptional start site.  Perforin expression is regulated by STAT3 
[47], STAT4 [48,49], STAT5 [50], and NF-κB [51].  STAT5 binding has been 
demonstrated at both enhancer regions of the perforin gene [52].  NF-κB, STAT1a, and 
STAT4 binding has been demonstrated at the -1kb enhancer [49,50]. STAT3, a key 
transcription factor of NK cells, seems to be involved in the constitutive expression of 
perforin and can bind the -1kb enhancer region [53].  IL-2 mediated signaling can 
activate both NF-κB and STAT5 [50,52]and enhance perforin gene expression.  
Additionally, IL-12 mediated signaling via STAT1a and STAT4 upregulate perforin 
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gene expression [49,50]. Although perforin is required for NK cell lytic activity, it alone 
is not sufficient for cytolytic function, but is critical for granzyme entry into the target 
cell.    
Granzymes are a family of serine proteases and comprise a large portion of the 
proteins contained within NK cell cytotoxic granules.  There are 5 known human 
granzymes (A, B, H, K, and M) each with distinct substrate specificity and regulation. 
NK, NKT, and γδ T cells are the only immune cells that constitutively express 
granzymes; expression is thought to be restricted to the lymphoid lineage.  Granzyme A 
and B have been the most extensively studied of the granzyme family.  Granzyme A and 
B have been shown be cytolytic in vitro at micromolar and nanomolar concentrations, 
respectively [32,54].  Granzyme B can induce apoptosis by activating both caspase-3 
and -7 [55].  The cytolytic activity of Granzyme A is controversial as in vitro 
cytotoxicity only occurs at micromolar amounts, requires specific conditions, and is 
independent of the caspase system [56,57].  Emerging evidence links Granzyme A 
release during infection or disease with an inflammatory response via an extracellular 
mechanism.  Granzyme B is regulated by type I interferons [58], IL-2 [59], IL-12 
[59,60], IL-15 [61], and IL-18 [62,63].  The constitutive expression of granzymeB in 
CD8+ cytotoxic lymphocytes is regulated by the transcription factors AP-1, IKAROS, 
RUNX1, CREB1, and Eomes via binding to a hypersensitivity site in the granzymeB 
promoter approximately -250bp from the transcriptional start site [64,65].  Although not 
directly tested, it is assumed that granzymeB is regulated in a similar manner in NK cells 
as that demonstrated for CD8+ CTL.  Furthermore, STAT3 has been hypothesized to 
regulate granzyme B via binding at the -250kb hypersensitivity site due to the presence 
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of a STAT binding element, but this has not been directly tested.  The constituitive and 
cytokine induced regulation of both perforin and granzymes are thus vital to the 
cytolytic function of NK cells.  
 
NK cells and Cytokines 
 
NK cells not only have direct cytolytic activity but also produce a number of 
immunoregulatory cytokines [66,67]. NK cells have now been found to produce and 
secrete a variety of immunomodulatory cytokines such as IFN-γ, TNF-α, IL-10, IL-6, 
IL-5, IL-8, IL-1β, and TNF-β [47].  Although there is crosstalk between the signaling 
pathways that regulate lytic molecule and cytokine gene expression the pathway for 
cytokine secretion is distinct from that of the granule constituents [68].  The direct 
killing of infected or transformed cells is only one way NK cells are able to contain an 
infection and promote the appropriate immune response. The role of IFN-g secreted 
from NK cells and its role in the immune response is the most studied.  IFN-g 
production by NK cells stimulates macrophage activation.  Macrophage activation 
upregulates MHC expression and enhances phagocytosis, these mechanisms are thought 
to aid in clearance of apoptotic cell debris, tissue regeneration, and promote the adaptive 
immune response through the presentation of pathogen and/or tumor specific antigens.  
Furthermore, IFN-g activates CD8+ CTLs.  As CTLs are the adaptive counterpart to NK 
cells, it is thought that IFN-g production from NK cells promotes an antigen specific 
immune response to the pathogen or tumor.  IFN-g production from NK cells is also 
thought to direct the differentiation of naïve CD4+ T cells.  IFN-g inhibits Th2 and 
14 
  
promotes Th1 differentiation of naïve CD4+ T helper cells.  Th1 cells also secrete IFN-g 
and aid CD8+ CTL activation and thus an antigen specific response.  The initial 
recognition of infection or tumorogenesis by NK cells and their subsequent release of 
IFN-g provides a critical link between the innate and adaptive immune systems.  
Like all cytokines IFN-g transcription is tightly regulated to ensure that its 
production is maintained for the appropriate length of time and to the desired 
concentration.  The regulation of IFN-g transcription has mostly come from studies 
investigating the differentiation of CD4+ T helper cells into the Th1 lineage in mouse 
models and cell lines and is extensively reviewed [69].  These studies have revealed that 
the IFNG locus is composed of approximately 150,00 bp of DNA. Within the IFNG 
locus analysis of DNase hypersensitivity sites have revealed a number of cis-regulatory 
elements critical for differentiation and transcriptional activation [69]. These cis-
regulatory elements are conserved non-coding sequences (CNSs) which encode binding 
sites for transcription factors involved in the development of permenant epigenetic 
modifications important for the differentiation and structure of this locus throughout the 
differentiation process.  In naïve CD4+ T cells the IFNG locus contains DNase 
hypersensitivity sites at -22kb, -34kb, and -70kb downstream of the transcriptional start 
site (TSS).  Additional DNase hypersensitivity sites are located upstream of the TSS at 
+17-19kb, +30kb, +40kb, +46kb, and +66kb.  As the IFNG locus becomes fully 
differentiated DNase hypersensitivity sites open up at the proximal promoter, about -5-
6kb, and -34kb downstream of the TSS [69]. As NK cells are able to rapidly secrete 
IFN-g upon stimulation and do not require cellular proliferation for this function it is 
believed the IFNG locus contains an IFNG locus similar to that of fully differentiated 
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CD4+ Th1 cells.  One peticular enhancer 22 kilobases downstream in mice and 17 
kilobases downstream in human has been demonstrated to be required for IFN-g 
transcription in both T cells and NK cells [70,71,72]. IL-2 [73], IL-12, IL-15 and IL-18 
have been shown to upregulate IFN-g in NK cells [74,75,76].  These changes in gene 
expression have been attributed to NF-κB [77], STAT4 [78], STAT1 [79], STAT3 [80], 
and T-bet [81].  The bindings sites for NF-κB, STAT1, STAT3, and STAT4 are 
contained within the proximal promoter, -5kb enhancer, and -22kb enhancer regions of 
the IFNG locus and are critical for the regulation of IFN-g production.  
More recently NK cells have also been shown to produce IL-6 [47], although NK 
cells have been known to be responsive to IL-6 for years [82].  The IL6 gene is 
controlled via elements in the proximal promoter including an IL-1-response element as 
well as a CRE and NF-IL6 binding sites.  The IL6 gene is rapidly upregulated by LPS, 
IL-1, TNF, IL-2 [83], and IL-6 itself [84].  Most studies in the regulation of IL-6 have 
been elucidated in monocytes, which are the main producers of IL-6 within the immune 
cell pool.  The contribution of IL-6 production by NK cells and its role in the immune 
response remains unclear.    
NK cells can also produce TNF-alpha in response to external stimuli such as 
target cell recognition and is implicated in the clearance of both intracellular pathogens 
and tumors.  The TNF gene is clustered with lymphotoxin (LT)-α and LT-β, also 
members of the TNF superfamily, on human chromosome 6 within the MHC class III 
region.  The transcription of the TNF gene is regulated via the recruitment of 
transcription factors and other co-activators to the 5’ proximal promoter upstream of the 
TSS [53].  Two additional hypersensitivity sites -1.7kb and +1.4kb have also been 
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identified and might contribute to the regulation of TNF transcription [53].  The 
proximal promoter contains a binding site for AP-1, AP-2, CREB, and NF-κB and these 
factors have all been shown to upregulate TNF-alpha [85].  Unlike the other cytokines it 
has been shown in monocytes that TNF-alpha is constituitively expressed yielding 
productive transcripts; however, the mRNA is destabilized by its interaction with the 
RNA binding protein, tristetraprolin [86].  This minimizes TNF-alpha production in the 
absence of stimuli but also contributes a negative feedback loop to resolve the TNF-
alpha production after cellular activation with LPS, TNF-alpha, and IL-2 [86,87].    
 
Conclusions 
  
Natural killer cells constitute a critical member of the immune system.  Their 
ability to patrol the body using germline encoded receptors to detect abnormal cells is 
critical for host survival.  Constituitive expression and storage of lytic molecules within 
cytoplasmic granules allows for immediate and effective irradication of abnormal cells 
without prior exposure.  Additionally, NK cells are able to secrete a wide variety of 
immunoregulatory cytokines to modulate the activity of other immune cells and the 
subsequent immune response.  Like all cells of the body NK cells are regulated by the 
neuroendocrine systems.  Understanding how hormonal systems regulate NK cell 
effector function remains an active area of research.  This dissertation examines a 
particular hormone, glucocorticoids, and how they regulate both NK cell cytolytic 
function as well as cytokine production.  
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GLUCOCORTICOIDS AND THE GLUCOCORTICOID RECEPTOR 
 
Introduction 
Hormonal systems regulate human physiology and are a mechanism by which 
the brain comminicates with multiple body systems to maintain host homeostasis.  
Glucocorticoids (GC) are a class of steroid hormones whose name derives from their 
role in glucose metabolism (gluco), synthesis from the adrenal cortex (cortic), and their 
steroid structure (oid).  Glucocorticoids regulate many aspects of human physiology 
including metabolism, sleep, the cardiovascular system, as well as the immune system.   
 
The HPA axis and Diurnal Cortisol Rhythms   
 
Cortisol is the main glucocorticoid in human and its production and secretion is 
regulated by the hypothalamic pituitary adrenal gland (HPA) axis. Activation of the 
hypothalamus results in the secretion of corticotropin-releasing hormone (CRH).  CRH 
then triggers the anterior pituitary to secrete adrenocorticotropic hormone (ACTH).  
ACTH then travels through the vascular system to the adrenal glands situated above the 
kidneys.  ACTH then stimulates the production and secretion of cortisol by the zona 
fasciculate within the adrenal cortex.  The activity of the HPA axis is regulated in a 
circadian manner via circadian oscillators, which yields a distinct 24 hour cycle of 
cortisol secretion from the adrenal cortex known as the cortisol diurnal rhythm 
[88,89,90]. Figure 4 is a graphical representation of a typical diurnal cortisol rhythm in a  
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Figure 4. Schematic of Typical Diurnal Cortisol Rhythms.  A typical diurnal cortisol 
rhythm is characterized by an initial spike approximately 15-45 minutes post-awakening, 
termed the cortisol awakening response (CAR).  Cortisol levels then gradually subside 
throughout the day into the night, reaching a minimal level in the hours preceeding 
awakening.  The area under the curve (AUC) represents the total cortisol levels 
throughout the day (shaded in grey). 
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healthy individual.  Cortisol levels rapidly increase in serum and body fluids after 
awakening, termed the waking rise also known as the cortisol awakening response 
(CAR).  This 50-75% increase in cortisol occurs within 30 to 45 min post awakening 
when cortisol levels are at their peak.   Cortisol levels then decline throughout the day 
and into the night until cortisol levels are lowest in the hour preceding awakening.  The 
typical diurnal rhythm is detected in about 75% of healthy individuals [91].  Cortisol is a 
lipophilic hormone ligand that can freely diffuse through the plasma membrane and thus 
exert its biological effects through its binding to the cytoplasmic glucocorticoid receptor. 
 
The Glucocorticoid Receptor (GR) 
 
Glucocorticoids mediate their effects through the binding and activation of the 
glucocorticoid receptor (GR).  GR mRNA can be detected in almost all tissues in both 
mice and humans, and therefore, it is assumed that functional GR protein is also present 
and thus has the potential to regulate gene expression in almost all known cell 
types[92,93,94].  GR is a member of the nuclear receptor superfamily and is a ligand 
activated transcription factor which is maintained in the cytoplasm via a complex of 
inhibitory cytoplasmic heat shock proteins including both HSP70 and HSP90[95].  GR 
contains a zinc-finger motif DNA-binding domain, a dimerazation domain, and a ligand-
binding domain.  Upon ligand binding GR undergoes a conformational change, 
dissociates from the inhibitory complex, and translocates to the nucleus via its nuclear 
localization signal.  Once in the nucleus, GR interacts with DNA in a sequence specific 
manner and directly regulates gene transcription through the recruitment of co-activators 
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and co-repressors.  GR can both positively and negatively regulate transcription through 
its zinc-finger motif and binding to glucocorticoid response elements (GREs) and 
negative glucocorticoid response elements (nGREs), respectively [96].  The role of GRE 
and nGRE in the transcriptional regulation by GR has been further complicated with 
research demonstrating that sequence variation in the GREs can alter GR structure and 
activity in a promoter specific manner [97]. The number of genes negatively regulated 
by glucocorticoids is conservatively estimated at more than 100 while those that are 
positively regulated are conservatively estimated at over 400 [98-101]and more liberal 
estimates place the number of GC regulated genes at greater than 1,000 [102-104].  
Additionally, GR can interact with other transcription factors such as activator protein-1 
(AP-1) and nuclear factor-kappa B (NF-κB) and repress transcription indirectly via 
trans-repression [105-107].  
GR activity is regulated at multiple levels.  GR is encoded by the NCR1 gene 
and through alternative splicing results in two main mature mRNA forms which 
ultimately result in the translation of two distinct proteins, GR-alpha and GR-beta.  GR-
beta lacks the carboxy-terminus ligand binding domain and is thus insensitive to ligand 
and is hypothesized to act as a dominant negative isoform.  The GR-beta isoform is not 
ubiquitously expressed, is hypothesized to be involved in glucocorticoid resistance, and 
still is under intense investigation to understand its precise biological role(s).  Once 
ligand activated and translocated to the nucleus, GR-alpha is thought to be degraded by 
the proteasome and thus GR is thought to have a rapid turnover to facilitate integration 
of rapidly changing GC levels [108].  Furthermore, GR is both phosphorylated and 
acetylated which provides further levels of regulation via these posttranslational 
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modifications.  Although the regulation of GR is complex the effects of GC on the 
immune system have been used pharmacologically for decades.  
 
Glucocorticoids and Inflammation 
 
Many GR target genes are involved in modulation of the immune system and the 
inflammatory response.  For this reason the potent immunosuppressive effects of 
glucocorticoids have been used clinically to treat a wide variety or immunologic based 
diseases such as asthma, allergies, auto-immunity, and arthritis.  GR has been shown to 
downregulate a number of pro-inflammatory cytokines, including IL-1beta, IL-2, IL-3, 
IL-4, IL-5, IL-6, IL-11, TNF-alpha, and GM-CSF [109].  Conversely, GC upregulate the 
expression of a number of anti-inflammatory genes including; Lipocortin-1, CC10, IL-1 
receptor antagonist, and IkappaB, through a number of mechanisms dependent on the 
gene of interest [109].  Of the pro-inflammatory genes down-regulated by high 
glucocorticoid concentrations, the IL-6 promoter is the only promoter demonstrated to 
contain a GRE and recruit GR when glucocorticoids are present [110].  With the absence 
of cononical GREs within pro-inflammatory genes other mechanisms to explain the 
decrease in proinflammatory production by GR were investigated.   
Decades of research have uncovered a wide variety of mechanisms by which GR 
can modulate the transcription of genes independent of direct DNA binding.  One such 
mechanism involves the modulation of signaling cascades such as the JAK-STAT and 
NF-κB pathways.  GR has been shown to interact with IκBα maintaining NF-κB in an 
inactive state in the cytoplasm [111,112].  GR has now been shown to interact with a 
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number of members of the Jak-STAT pathway these interaction have mainly been 
shown to inhibit the stimulated production of inflammatory mediators [113,114].  The 
described mechanisms mainly involve the inhibition of nuclear translocation of the 
above signaling pathways resulting in decreased proinflammatory cytokine production.   
Another mechanism has been described involving the direct interaction between 
GR and transcription factors such as NF-κB and AP-1 known as tethering.  In this 
mechanism, GR can be recruited to genomic regulatory regions via this tethering 
mechanism and can thus increase or descrease the transcription of genes independent of   
GREs via transactivation or transrepression, respectively.  It is believed that this 
tethering involves GR monomers rather than the GR dimers recruited to GREs and the 
direct regulation of GR responsive genes such as GILZ [115].    
For decades GC were deemed potently anti-inflammatory; however, recent 
research suggests that GC can in fact be pro-inflammatory in nature dependent on both 
the dose and duration of GC exposure [116].  Furthermore, although GC alone can be 
anti-inflammatory, GC can synergize with cytokines to potentiate the inflammatory 
response [109].  Additionally, the finding that some individuals become insensitive to 
the anti-inflammatory effects of glucocorticoids also have demonstrated that the 
universal anti-inflammatory effects of GC are oversimplified.  The development of 
insensitivity to GC has been termed glucocorticoid resistance.  Mechanistically the 
resistance of individuals to GC has been attributed to alterations in the levels of GR 
within a given cell type.  GR is known to auto-regulate its own expression and GC 
administration results in the down-regulation of GR mRNA and thus GR protein, 
resulting in cells becoming insensitive to further GC administration.  Furthermore, GR is 
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regulated by post-translational modifications and has been demonstrated to be both 
phosphorylated and acetylated.  Phosphorylation of GR at has been shown to alter the 
activity of 
   
Glucocorticoids and Natural Killer cells 
 
A number of studies have demonstrated the effects of GC on NK cells.  We have 
previously shown that incubation of the NK cell line, NK92, with dexamethasone for 24 
hours decreased NK cell lytic ability in a dose dependent manner [117].  We confirmed 
these results in a second NK cell line YT-Indy [118].  These results have also been 
demonstrated with cortisol on NK3.3 cells which exhibited reduction in NKCA via 
decreases in the mRNA for both perforin and granzymes [119].  NK cells isolated from 
PBMC of humans and treated with dexamethasone also exhibited decreased NKCA 
[120]. NK cells isolated from PBMC and incubated with cortisol had decreased 
expression of NKp46 and NKp30 [121]. Direct treatment of human with cortisol 
resulted in a loss of circulating NK cells from the blood, implying that GC also can 
mediate redistribution of NK cells in vivo [122].  In addition to the effects of GC on NK 
cell lytic activity we have published that 24 hour dexamethasone treatment also inhibited 
the unstimulated and stimulated production of IFN-g by NK92 cells in a dose dependent 
manner [117].  All these studies used high concentrations of GC with incubations lasting 
no more than 24 hours.  As the effects of GC are known to be both dose and time 
dependent, the effects of extended GC treatment on NK cells remains unclear. A 
relationship between circulating cortisol and NK cells has also been observed 
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demonstrating that NK cell lytic activity is regulated by the diurnal cortisol rhythms 
[123].  
 
Conclusion 
 
 Glucocorticoids represent a critical regulator of immune function and thus have 
been used for decades pharmacologically.  Specifically for Natural Killer cell the effects 
of glucocorticoids have been demonstrated to regulate both lytic activity as well as 
cytokine production.  Furthermore, correlations between circulating cortisol levels and 
NK cell effector function in vivo indicate the physiological role glucocorticoids play in 
the immunoregulation of NK cells.  Many mechanisms have been proposed for the 
immune regulation by GC but come mainly from suprapysiological concentrations over 
short periods of time.  The effects of GC are both dose and time dependent and thus 
exhibit significantly different phenotypes when these parameters are altered.  
Furthermore, these mechanisms cannot fully explain the effects on immune function 
seen during alterations in the activity of the HPA axis.  This dissertation examines how 
glucocorticoids regulate the epigenome of NK cells and how these epigenetic 
mechanisms might be relevant during periods of altered immune function when HPA 
activity is dysregulated. 
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EPIGENETICS 
 
The DNA of eukaryotic cells is composed of repeating units of nucleosomes 
referred to as chromatin.  One hundred and fourty seven base pairs (bp) of DNA wraps 
around a dimer of four core histone proteins, H2A, H2B, H3, and H4.  Each of these 
histone proteins as well as the DNA sequence itself are subject to multiple 
posttranslational modifications which alter chromatin structure and function.  These 
covalent posttranslational modifications work by altering the overall charge of the 
nucleosome particle and/or create docking sites to recruit regulatory protein complexes.  
Histone modifications constitute a “Histone Code” which is read by the cell machinery 
to bring about a specific transcriptional profile.  The term epigenetics describes the 
process by which changes in this histone code impart heritable, but also reversible, 
changes in gene expression without changes to the DNA sequence itself.  These changes 
in chromatin structure yield two distinct types of genomic regions in the nucleus of a 
eukaryotic cell; condensed transcriptionally silent, heterochromatin, and less condensed 
transcriptionally active, euchromatin. 
Each of these regions is characterized by a specific epigenetic pattern which 
maintains this structure and gene expression pattern, even through cellular division.  The 
DNA itself can be methylated on CpG islands and has been demonstrated to strongly 
correlate with regions of heterochromatin and transcriptional repression [124].  DNA 
methylation is mediated by a class of enzymes known as DNA methyltransferases 
(DNMTs).  Further research has demonstrated that methylated DNA provides docking 
sites for proteins which not only maintain DNA methylation but recruit histone 
26 
  
modifying enzymes which inhibit histone acetylation and promote methylation of 
specific histone residues, maintaining heterochromatin condensed structure and gene 
repression. 
Histone proteins can be phosphorylated, acetylated, methylated, ubiquitynated, 
and sumoylated.  Phosphorylation and acetylation of histone proteins generally 
accompany gene transcription.  Sumoylation of histone protein accompanies repression 
while ubiquitynation and methylation are implicated in both activation and repression of 
transcription.  Methylation of histone proteins occurs on lysine residues and comes in 
three forms; mono (me1), di (me2), and tri-methylation (me3).  Methylation of lysine 
residues occurs via histone methyl transferases (HMTs). Methylation of histone tails 
creates docking site for additional co-activator and co-repressor complexes.  Methylated 
lysines are recognized by proteins which contain chromo-domains.  These chromo-
domain containing proteins recruit additional proteins and protein complexes which 
further modify the genomic locus for either gene silencing or gene activation.  
Acetylation of histones has been the most widely investigated epigenetic 
modification.  Two mechanisms for how histone acetylation regulates gene expression 
have been postulated.  First the acetylation of histones occurs on lysine residues, which 
possess a positive charge.  It is hypothesized that the positive charge associated with the 
lysine residue allows for condensation of the chromatin structure via interaction with the 
negatively charged DNA phosphate backbone or the neighboring nucleosome particles.  
Addition of an acetyl group by histone acetyltransferases (HATs) neutralizes this 
positive charge and results in decreased condensation and opening of the chromatin 
structure.  The role of acetylation and chromatin accessibility has been demonstrated in 
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many models.   Secondly, addition of the acetyl group on the lysine residue creates a 
docking site for other regulatory proteins.  Research has revealed a common domain 
among some regulatory proteins known as a bromo-domain.  The structure of these 
domains allows for recognition and binding to acetylated lysines but not unacetylated 
lysines.  From these observations histone acetylation is linked with transcriptional 
activation and recruitment of co-activator complexes.  
 
The Histone Code 
 
The transcription of a given gene is dependent not on a single epigenetic mark 
but the summation of the marks present in a specific loci termed the “Histone Code”.   
Figure 5 outlines the relevant histone modifications for this body of work.  
Transcriptionally inactive heterochromatin is marked by the inhibitory marks H3K9me3 
and H3K27me3 (black circles) [125-128].  The structure of this region is compact and 
inaccessible to transcription factors and transcriptionally machinery, indicated by the 
tight grouping of the nucleosome particles (Figure 5).  This structure is maintained 
within intergenic non-coding regions of DNA as well as in genes that are permanently 
repressed in a specific cell lineage.  This is in contrast to poised euchromatic genes 
which maintain H3K27me3 but possess H3K4me3 (grey circles) as well.  H3K4me3 is 
typical representative of transcription start sites and is strongly correlated with 
transcription potential [129,130].  These regions are termed bivalent as they have the 
potential to be expressed in a particular cell lineage, are more accessible than 
heterochromatin (indicated by a decrease in chromatin condensation), but are not  
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Figure 5. Diagram of histone tail modifications, changes in chromatin structure, 
and transcription.  Heterochromatic regions of DNA are associated with the repressive 
histone tail modifications tri-methylated H3K9 and H3K27 (black circles) and exhibit a 
condensed chromatin structure.  Bi-valent euchromatin is characterized by the loss of 
H3K9me3 and addition of H3K4me3 (grey circles) with slightly increased chromatin 
accessibility.  These regions are not transcribed but are accessible and poised for 
potential transcription.  Poised and primed euchromatin is characterized by the loss of 
H3K27me3 and addition of H3K27Ac and H4K8Ac (white circles).  These regions 
exhibit greater accessibility than bi-valent euchromatin but remain to the most part 
untranscribed.  The addition of H3K9Ac distinguishes poised and primed euchromatin 
from actively transcribed euchromatin and results in a completely accessible chromatin 
structure.  The levels of H3K9Ac are highly predictive of the rate of transcription and 
can be further divided via this histone modification.  
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actively transcribed requiring further differentiation and activation signals [131].  Poised 
euchromatin can be further primed for future transcription through the acquisition of 
H3K27Ac and/or H4K8Ac (white circles).  These modifications act via the mechanisms 
described previously opening up the chromatin structure and create docking sites for co-
activator complexes.  Lastly actively transcribed euchromatin possesses H3K9Ac (white 
circles) while maintaining all of the marks associated with poised and primed 
euchromatin.  The degree of transcription highly correlates with the level of H3K9Ac 
and thus can be divided further by the levels of this specific transcriptional mark.  Most 
work understanding this histone code and epigenetic patterns has come from studies in 
cell differentiation pathways.  Specifically in NK cells the epigenetic marks associated 
with the KIR locus through the differentiation process have been the most widely 
studied [132].  Thus by characterizing the epigenetic modifications at specific genomic 
loci not only provides insight into the differentiation state of the cell but also the 
activation, transcriptional status, and future transcriptional potential of the gene.  
 
Histone Modifying Enzymes 
 
HDACs deacetylate proteins through removal of an acetyl modification from 
lysine epsilon-amino group.  To date 18 HDACs have been described in humans. These 
HDACs are divided into 4 categories, Class I, II, III, and IV, based on their structural 
and enzymatic homologs in yeast and bacteria.  HDAC1, HDAC2, HDAC3, and 
HDAC8 comprise the class I HDAC family based on their homology to the yeast Rpd3 
family.  HDAC1, 2, and 3 seem to be ubiquitously expressed while HDAC8 activity is 
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primarily seen in smooth muscle [133,134,135].  Classically it was thought that class I 
HDACs were localized to the nucleus; however, recent evidence demonstrates that 
HDAC1, HDAC2, and HDAC3 all have cytoplasmic activity and can shuttle in and out 
of the nuclear compartment [133].  Class II HDACs are subdivided into two groups; 
Class IIa (HDAC4, 5, 7, and 9) and Class IIb (HDAC6 and 10).  Class II HDACs unlike 
class I HDACs seem to have tissue and developmental specific expression and are 
classified based on their homology to the yeast HdaI family [136].  Class II HDACs also 
dynamically shuttle between the cytoplasm and nuclear compartment [136]. Class IIb 
HDACs contain two enzymatic domains as compared to the one of class IIa proteins 
[136].  Furthermore, class IIa HDACs are expressed in the brain, HDAC6 is expressed 
primarily in the testis and HDAC10 is expressed in the liver, spleen, and kidneys [136]. 
Class III HDACs are also referred to as Sirtuins, based on structural and enzymatic 
homology to yeast SIR2 HDACs.  These sirtuins are not homologous to class I, II, or IV 
HDACs.  Furthermore the catalytic domains of this family require the cofactor NAD+ 
for activity.  HDAC11 is the only member of class IV HDACs and its separate 
classification is based on a conservation of HDAC domain stucture but significant 
sequence divergence from the other HDAC families [137].  
The role of histone deacetylases in the regulation of gene expression is 
highlighted by the findings using HDAC inhibitors (HDACi).  Treatment of ESC with 
vaproic acid an HDACi resulted in increased pluripotency and was correlated with an 
increase in both global and gene specific H3K9 acetylation [131,138].  Although many 
reports highlight increases in gene transcription and histone acetylation upon HDACi 
treatment, there are an increasing number of reports indicating that HDACi can also 
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inhibit gene transcription [139].  Further research has elucidated that HDACs are not 
only involved in gene repression but are enzymatically inactive structural components of 
both co-activator and co-repressor complexes.  Furthermore, HDACs are required to 
reset chromatin after each round to transcription by RNApol II and thus inhibition of 
HDACs can also decrease transcription [140].  These results highlight that HDACs are 
important regulators of gene transcription through their removal of acetyl group from 
lysines residues on histone proteins.   
As HDACs are not solely confined to the nucleus it was postulated and 
confirmed that they have non-histone targets.  Furthermore, their nuclear translocation is 
regulated via post-translational modifications in a manner similar to canonical 
transcription factors.  Thus HDAC nuclear localization and gene regulation is dependent 
upon the integration of a complex array of signaling cascades.  These findings are 
highlight by recent experiments with HDACi or siRNA knockdown experiments of 
specific HDACs.  HDACi treatment promotes Treg conversion in vivo [141].  
Furthermore, knock-down of HDAC6, HDAC9, and SIRT1 increased the suppressive 
activity of Tregs both in vivo and in vitro [142,143,144].  These along with other 
experiments highlight that global changes in HDAC activity and protein levels regulate 
cellular function.  Thus HDACs integrate signals and augment cellular function and 
processes accordingly.  Through modulation of HDAC localization and activity the 
glucocorticoid receptor and thus GC can regulated gene transcription through epigenetic 
modifications. 
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The Glucocorticoid Receptor and Epigenetics 
 
Many studies have demonstrated that exposure to glucocorticoids results in 
altered transcriptional rates as well as changes in histone modifications both globally 
and in a gene specific manner [117,118].  These changes in histone modifications 
prompted investigations in the mechanisms by which GC mediate these changes.  
Research has demonstrated that GR can interact with HDAC1[145], HDAC2[146], and 
HDAC3[147].  The observations that GR can interact with histone modifying enzymes 
prompted investigation into whether GR can recruit or dissociate histone modifying 
enzymes to and from specific genomic loci.  Experiments using the mouse mammory 
tumor virus (MMTV) promoter have clearly delineated that activation of GR results in 
recruitment of GR to the MMTV promoter region which is associated with an increase 
in HDAC1 recruitment.  Furthermore, GR dependent HDAC1 recruitment decreased 
histone acetylation at the MMTV promoter [145].  Using this same system, but with a 
different concentration of ligand, other studies have demonstrated that activation of GR 
recruits HDAC3 to the MMTV promoter reducing the acetylation of both H3 and H4 
[147].   Studies on the regulation of IL-1β demonstrate that activated GR recruits 
HDAC2 to the IL-1β promoter decreasing both H4 acetylation and transcription[146].  
GR also recruits HDAC2 to the GM-CSF promoter to antagonize its transcription[146].  
As GR can both upregulate and downregulate gene expression, it is not surprising that 
GR has also been found to interact with HATs and co-activator complexes, such as 
SRC-2 [148], pCAF [148], and CBP/p300 [149,150].  In summation of these studies GR 
can also recruit HATs in a gene specific manner, increase histone acetylation, and 
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transcription.   In addition to histone acetylation, GR can also regulate both histone and 
DNA methylation.  The role for GR dependent DNA and histone methylation has 
primarily been investigated in neuronal cell populations; however, recent research has 
also found that GC can alter DNA methylation at the Fkbp5 gene in non-neuronal cells 
potentially through the regulation of DNMT1[151]. Thus GR alters gene expression 
through changes in histone modifications via its association with histone modifying 
enzymes and subsequent recruitment or dissociation of these enzymes in a gene specific 
manner.   
The experiments described above demonstrate that GR itself modifies the 
epigenetic landscape.  Recently it has been demonstrated that genomic binding of the 
GR is targeted to pre-existing foci of accessible chromatin, and thus the epigenetic 
landscape impacts GR recruitment [152].  These results were confirmed using chromatin 
immunoprecipitation and nuclease digestion experiments that implicate cell-selective 
organization of the pre-existing chromatin structure as a critical factor in determining 
tissue specific receptor function [153].  Thus GR can further modify the pre-existing 
chromatin structure either enhancing or decreasing the relative accessibility of a specific 
genomic region.  Through the modulation of GC levels in the body each tissue with its 
specific preexisting chromatin structure results in a tissue specific response from GR.  
GR can respond to these changes in GC and immediately impart epigenetic changes that 
effect gene transcription and cellular function in a tissue specific manner.   
As previously described the subcellular localization and overall protein levels of 
HDACs also regulate cellular function.  Furthermore, GR can interact with a number of 
HDACs.  Thus GR can modulate cellular function through direct interaction with 
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histone modifying enzymes in a gene specific manner but also through changes in their 
subcellular localization or protein levels.  These results highlight the multitude of ways 
GC signaling can impact cellular function through the modulation of the epigenetic 
landscape. 
 
Conclusion 
 
Epigenetics provides a critical regulator of cellular function via cell type specific 
regulation of gene transcription.  This regulation occurs at multiple levels via changes in 
nucleosome charge, chromatin accessibility, and co-regulator binding sites.  Many 
mechanisms have been proposed for the immune regulation by GC but these 
mechanisms cannot fully explain the effects on immune function seen during alterations 
in the activity of the HPA axis. Furthermore, epigenetics provides a means by which the 
evironment, such as the perception can impart changes in gene expression and thus 
cellular function.  This dissertation examines how glucocorticoids regulate the 
epigenome of NK cells and how these epigenetic mechanisms might be relevant to the 
field of psychoneuroimmunology.  
 
 
35 
  
PSYCHONEUROIMMUNOLOGY 
 
Decades of research have illustrated that the brain, and thus perception of the 
environment, can control the activity of the immune system.  All primary and secondary 
lymphoid organs are directly innervated and provide a direct link between the nervous 
and immune systems. Receptors for neurotransmitters have been found on almost all 
immune cells including; macrophages[154], B cells[154,155], T cells[154,155], as well 
as NK cells[154,156].  Thus direct innervation of lymphoid organs and release of 
neurotransmitters provides direct regulation of the immune response by the nervous 
system.  Furthermore, macrophages have been shown to produce catecholamines upon 
stimulation[157].  These findings highlight that the activities of the central nervous and 
immune systems are intimately linked.  The brain also regulates the activation of the 
HPA axis and release of glucocorticoids, described previously. Furthermore, the GR is 
ubiquitously expressed by all immune cells investigated; therefore, glucocorticoids 
provide a second pathway by which the brain can regulate the activity of the immune 
system.    
In the reverse, cytokines released from immune cells can regulate the nervous 
system.  Cytokines can cross the blood-brain barrier (BBB) and cells of the nervous 
system possess the receptors to respond to these changes in cytokine levels.  IL-1, IL-6, 
and TNF have all been found to induce fever by the preoptic hypothalamic region 
involved in thermoregulation, and is just one demonstration of such bi-directional 
communication[158].  Direct experimental evidence shows that in the absence of 
infection, LPS or cytokine administration into mice can impart behavioral changes 
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similar to those seen during infection.   These behavioral changes associated with 
infection and cytokines have been termed sickness behavior and are characterized by 
anhedonia, lethargy, anorexia, fatigue, depression or irritability, increased pain 
sensitivity, sleep disturbance, and concentration difficulties[159].  This shared network 
of signaling molecules and receptors provide the basis of psychoneuroimmunology 
research and highlight the complex bi-directional communication between the central 
nervous and immune systems and are illustrated in Figure 6. 
 
Breast Cancer Diagnosis and the Psychological Consequences 
 
Cancer is the unregulated growth of abnormal cells within the body and is the 
second leading cause of death in the United States[160].  Among women breast cancer is 
the leading cancer diagnosis in the United States with 122 women per 100,000 
diagnosed each year, with roughly 40,000 women dying of breast cancer annually[161].  
After diagnosis breast cancer is staged between 0 and VI.  These stages categorize the 
location, size, progression, and dissemination of the disease and are used to determine 
the appropriate treatment.  Ductal carcinoma in situ (DCIS) or Stage 0 cancer is defined 
as a noninvasive carcinoma with abnormal cells located in the lining of the breast duct 
with no evidence of spreading to the adjacent stroma.  A body of literature has 
demonstrated that the diagnosis of cancer is accompanied by psychological 
consequences, which are both short and long-lived[162,163].  A diagnosis of breast 
cancer is accompanied by an increase in stress perception, anxiety, fear, uncertainty, and 
mood disturbance[164-169]. These psychological consequences are independent of the 
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Figure 6. Bi-directional communication between the immune and central nervous 
systems.  The brain perceives external stressors and activates the hypothalamic pituitary 
adrenal gland (HPA) axis resulting in the production and secretion of glucocorticoids by 
the adrenal cortex.  The main glucocorticoid in human is cortisol.  Cortisol diffuses 
through the circulatory system interacting with and modulating the activity of immune 
cells.  Additionally, the perception of stress activates sympathetic nerves which directly 
innervate both primary and secondary lymphoid organs providing a direct link between 
the central nervous and immune systems.  In the reverse, cytokines and chemokines 
secreted from immune cells are released into the circulator system and can pass through 
the blood brain barrier effecting both behavior and physiology.   
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disease state as women diagnosed from stage 0 to stage IV all report increases in 
psychological distress[170].  The individual response to the diagnosis of breast is 
diverse, in that there are both variations in the intensity and duration of the distress 
associated with diagnosis[171].  This variation makes understanding both the 
psychological and physiological outcomes of distress complex.  For some individuals 
the diagnosis of breast cancer elicits an appropriate allostatic response defined as “the 
active process of responding to a challenge to the body by triggering chemical mediators 
of adaptation”[172].  This appropriate emotional and biological response allows the 
body to both adapt to the stressor and return to allostasis.  However, if the distress is too 
great the resulting “wear and tear on the body and brain that results from chronic 
dysregulation (over activity or inactivity) of mediators of allostasis” leads to increased 
allostatic load [172].   Psychosocial distress is reported in approximately 80% of women 
diagnosed with breast cancer during the initial treatment phase[173].  Although some 
women continue to exhibit negative psychological distress after cancer treatment, ample 
evidence shows that many women have reductions in distress upon treatment 
completion[163,174].   
Psychoneuroimmunology (PNI) has demonstrated that psychological distress 
impacts multiple organ and body systems and specifically impairs immune function.  
Psychological distress can have a number of biological outcomes, most importantly for 
this study the immune dysregulation observed during stress could adversely affect 
cancer control[165].  Reciprocal neuro-immune pathways and shared receptor and 
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signaling systems link the brain and immune system and provide a network whereby 
one’s emotions to impact immune function. 
 
Psychological Distress and the HPA axis 
 
One hallmark feature of all known life forms is their ability to respond and adapt 
to their environment.  Cortisol has effects both physiologically, as previously discussed, 
and affects aspects of cognitive as well as emotional networks[175,176,177,178]. During 
periods of stress, the brain initiates the activation of the hypothalamic-pituitary-adrenal 
(HPA) axis, which produces a cascade of neuroendocrine products resulting in altered 
circulating adrenal derived glucocorticoids (GC).  Modulation of the HPA axis and thus 
the production and secretion of the glucocorticoid, cortisol, is one mechanism that 
allows the brain to perceive the environment and respond (either to the benefit or 
detriment of the organism).  Under normal conditions allostasis is maintained resulting 
in proper immune cell function and homeostasis.  If the perception of stress is chronic, 
disruption of the diurnal cortisol rhythm occurs[162,179], resulting in increased 
circulating GC[180,181,182].  Many psychological disorders such as depression and 
post tramatic stress disorder (PTSD) are characterized by alterations in HPA regulation.  
Additionally, HPA axis activation and increased cortisol is observed in individuals 
experiencing psychological distress.  Increases in psychological distress and depressive 
mood were associated with both an increase in the cortisol awakening response and 
activation of the HPA[183,184,185].   
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More specifically, for the stress attributed to the diagnosis of breast cancer a 
relationship between increased mood disturbance and increased evening cortisol was 
found[186].  Other studies have demonstrated that the analysis of total cortisol levels 
throughout the day, by calculating the area under the curve of the diurnal cortisol rhythm, 
is decreased in individuals with metastatic breast cancer who report increased perceived 
stress[179,187,188]. These experiments not only highlight the complex relationship 
between psychological stress and the HPA axis but implicate its dysregulation in the 
immune outcomes observed during periods of stress. 
Although stress is traditionally associated with increased cortisol secretion and 
HPA axis activity, there is a growing body of literature finding differential interplay 
between cortisol rhythms and psychological disturbances.  Low cortisol levels, or a 
hypoactive HPA axis, have been observed in a number of stress related disorders 
[189,190] such as; posttraumatic stress disorder (PTSD) [191,192], chronic fatigue 
syndrome[193,194,195], burnout [196,197], and irritable bowel syndrome[198].  
Hypocortisolism can be the result of several mechanisms, but a recent meta-review 
concluded that hypocortisolism commonly develops out of long term chronic stress, 
where an initial stage of a hyperactive HPA axis eventually evolves into a hypoactive 
HPA axis [188]. Although mechanisms at different levels of the HPA axis are 
potentially capable of producing a hypocortisolemic net effect, one of the earliest and 
most common findings in this development might be an exaggerated negative feedback 
response of the HPA axis [189]. 
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Psychological Distress, Natural Killer cells, and Inflammation 
 
Psychological stress reduces NKCA, the response of NK cells to cytokines, IFN-
g synthesis, antibody responses, and T-lymphocyte responses [199,200,201,202,203].  
Our lab and others have shown that the diagnosis of breast cancer results in significant 
psychosocial distress in women that is accompanied by dysregulated Natural Killer cell 
activity (NKCA) and cytokine production[202,203,204,205].  Women with breast cancer 
who report greater distress exhibit lower basal and augmented NKCA and reduced T cell 
proliferative responses[204,205]. The implications of altered immune function from 
cancer diagnosis are noteworthy because both NK cells and IFN-g have been shown to 
contribute to tumor control and destruction[206,207,208,209]. Abnormal cells arise 
continually throughout life and increase with age.  Under normal homeostatic conditions 
the body controls cancer through immune surveillance.  Studies reveal that NK cells can 
effectively protect against primary solid tumors[210,211].  Autopsy has revealed that 
even in healthy women, breast cancer cells can be identified in the bone marrow 
suggesting that the tumor cells are kept in check while the woman is alive [212,213].  
The immune dyregulation associated with stress is of particular relevance to 
breast cancer because epithelial tumors are responsive to the immune protective effects 
of NK cells and IFN-g[206,207,208,209].  The importance of NK cell activity is 
highlighted by findings involving the relationships between cancer and NKCA.  First, 
high levels of NKCA in cancer patients correlate with a good 
prognosis[214,215,216,217].  Impaired NKCA also correlates with invasiveness of 
human malignancy[218].  NK cell infiltration into primary tumors is associated with 
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fewer metastases to the lymph nodes and less lymphatic invasion[214].  Lastly, overall 
survival for patients with high and low NKCA was 71 vs. 30 weeks, respectively and 
NKCA was an independent prognostic factor for overall survival [215].  These findings 
illustrate the relevance of NK cell dysregulation during stress as NK cell activity has 
profound implications for cancer free survival.   
 
Conclusions 
 
The mechanisms for the NK cell dysregulation associated with stress remain 
incompletely understood.  While abundant research focuses on the treatment of the 
cancer it is clear that treating the stress of cancer diagnosis is of critical relevance.  
Therefore, determining the mechanism(s) by which distress precipitates negative health 
outcomes is critical in potential avenues for advancement of treatment cancer free 
survival.  Epigenetic regulation through the glucocorticoid receptor provides one 
potential mechanism for the regulation of NK cell function in response to their 
environment in the context of psychological stress. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
In vitro Analysis: Cell Culture  
 
NK92 cells (established from a patient with non-Hodgkin’s lymphoma with the capacity 
to lyse a broad range of leukemia, lymphoma and myeloma cell lines at low effector to 
target ratio in vitro) was obtained from the American Type Culture Collection, Rockville, 
MD and maintained in alpha MEM with 12.5% horse serum (Gibco Laboratories, Grand 
Island, NY), 12.5% fetal bovine serum (FBS) (Gibco Laboratories, Grand Island, NY), 
penicillin, streptomycin (Whittaker M. A. Bioproducts, Walkersville, MD), 0.2 mM 
inositol: (Sigma Aldrich, St. Louis, MO), 0.1 mM 2-mercaptoethanol; (Gibco 
Laboratories, Grand Island, NY) and 0.02  mM folic acid: (Sigma Aldrich, St. Louis, 
MO).  NK92 cell cultures were also supplemented with IL-2 (100 units/ml).  The human 
erythroleukemic like cell line, K562, was obtained from the American Type Culture 
Collection, Rockville, MD.  K562 cells were maintained in suspension in RPMI 1640 
(Gibco Laboratories, Grand Island, NY) supplemented with 10% FBS (Gibco 
Laboratories, Grand Island, NY), 100 units/ml penicillin, 100ug/ml streptomycin 
(Whittaker M. A. Bioproducts, Walkersville, MD), 0.1 mM non-essential amino acids 
and 2 mM L-glutamine (Gibco Laboratories, Grand Island, NY)
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Cellular Treatment.  
 
NK92s, cultured at 2.5x105 cells/mL, were treated with or without dexamethasone 
(Sigma Aldrich, St. Louis, MO) (10-10 M) for 4 days in the presence of IL-2 (100 
units/mL), every 48 hours cultures were collected, washed, and resuspended in fresh 
media to a concentration of 2.5x105 cells/mL supplemented with or without 
dexamethasone and IL-2 (100 units/mL).  For the final 24 hours of treatment cells were 
collected, washed, and resuspended to a concentration of 2.5x105 cells/mL with or 
without dexamethasone in the absence of IL-2.  Following treatment NK92s were 
washed with media and resuspended to 1 x 106 cells/ml and used for analysis. In all 
cases, cell number and viability were determined by exclusion of 0.1% Trypan blue.  
Viability was maintained between 85 and 95% in all cases.  In some experiments 
cultures described above were subjected to an additional 24hr treatment in the presence 
of dexamethasone (10-7M) to determine the sensitivity of the cells to further GC 
stimulation (switch to -7).  For RU-486 treatments cells were cultured as described 
above in the presence or absence of 10-10M RU-486 (Sigma Aldrich, St. Louis, MO) 
dissolved in EtOH or EtOH alone as vehicle throughout treatments.  
 
Natural killer cell activity (NKCA) 
 
K562 tumor cells were radioactively labeled with 100 uCi of [51Cr] (New England 
Nuclear, Boston, MA). Radiolabled K562 cells were washed and then incubated for 4 hr 
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with NK92 cells.  Following incubation, the supernatants were removed using a Skatron 
harvesting press (Skatron Inc., Sterling, VA) and the associated radioactivity was 
determined.   Effector to target ratios for NKCA was 2, 1, 0.5 and 0.25:1. 
 
Results are expressed as % cytotoxicity and calculated by the formula: 
 
 %  Cytotoxicity =     (experimental DPM*) - (minimum DPM)    x  100.  
    (maximum DPM) - ( minimum DPM)          
     
All experimental means were calculated from triplicate values.  Lytic units (LU) were 
calculated by a program written by David Coggins, FCRC, Frederick, MD and 
represents the number of cells per 107 effectors required to achieve 20% lysis of the tar-
gets. *DPM=disintegrations per minute. 
 
Evaluation of cytokine production  
 
Cytokines were measured in NK92 culture supernatants as described previously [117]. 
To assess stimulated cytokine production, NK92s (2.5X 105 cells/ml) were treated as 
described above and then stimulated with IL-2 (5,000 U) or IL-12 (40 pg/mL) for an 
additional 4 hours.  Cell culture supernatants were harvested and aliquots of the 
supernatants were stored at -80 0C for subsequent cytokine determination by ELISA 
(R&D Systems, Minneapolis, MN).  
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Table 1. Primers used for gene expression studies 
AMPLICON PRIMERS (5’ 3’) 
B-actin Forward: ATGGGTCAGAAGGATTCCTATGTG 
Reverse: CTTCATGAGGTAGTCAGTCAGGTC 
IFNG Forward: TGGAAAGAGGAGAGTGACAG 
Reverse: ATTCATGTCTTCCTTGATGG 
IL6 Forward: CAACCTGAACCTTCCAAAGATG 
Reverse: ACCTCAAACTCCAAAAGACCAG 
PRF1 Forward: GGAGTGCCGCTTCTACAG 
Reverse: CGTAGTTGGAGATAAGCCTGAG 
GZMB Forward: AAGACGACTTCGTGCTGACA 
Reverse: CCCCAAGGTGACATTTATGG 
HDAC1 Forward: GTCCAGATAACATGTCGGAGTACAGC 
Reverse: CGATGTCCGTCTGCTGCTTATTAAG 
HDAC2 Forward: CCTCATAGAATCCGCATGACCCATAAC 
Reverse: AGACATGTTATCTGGTCTTATTGACCGTAG 
HDAC3 Forward: CAAGCCATACCAGGCCTCCCAGC 
Reverse: GAGATGCGCCTGTGTAACGCGAG 
HDAC4 Forward: CCTGCACAGACACGGGGAAGGTG 
Reverse: GAGCTGCTCTTCAGACAGCAAGC 
SIRT1 Forward: TGCGGGAATCCAAAGGATAATTCAGTGTC 
Reverse: CCTCATCTTTGTCATACTTCATGGCTCTATG 
CBP Forward: TCAGTCAACATCTCCTTCGC 
Reverse: TGTTGAACATGAGCCAGACG 
P/CAF Forward: AGAACATTGCTTCGCTCGG 
Reverse: TGCCTCAAGTCCAGAAGAGG 
N-COR Forward: GCTGATGAGGATGTGGATGG 
Reverse: TTGGACTCTTGGATGTGCC 
SMRT Forward: TGTGGTTCATAAGCCATCTGC 
Reverse: CGGAATCTTCCCCTCCTCCC 
p300 Forward: CATATTTCCTACGCCGGATCC 
Reverse: AGTATTCCGCTCGATTGTTTGC 
  
 
 
 
47 
  
 
 
Analysis of Gene Expression 
Messenger RNA from NK92 cell line was obtained using the RNeasy Plus Mini Kit 
(Qiagen, Valencia, CA).  RevertAid First Strand cDNA Synthesis Kit (Fermentas, 
Burlington, ON) was used to generate cDNA for quantitative real-time PCR from 500ng 
total RNA.  Negative reverse transcriptase samples confirmed absence of contaminating 
DNA.  All reactions were performed in triplicate using SYBRgreen supermix (Biorad). 
PCR cycles were denaturation at 94°C (30 s) and annealing at 55-61°C (30 s), no 
extension phase was necessary and performed using the Opticon 2 Real-Time Detector 
(Bio-Rad, Hercules, CA) and analyzed using the Opticon Monitor Software (Bio-Rad, 
Hercules, CA).  The ΔΔC(t) method was used to determine changes in transcript levels 
between untreated and chronic glucocorticoid treated cells using beta-actin as a 
reference gene. 
 
Fold Change   =     Efficiency(target) ^ (ΔC(t) target (control-treatment))  
     Efficiency(reference) ^ (ΔC(t) reference (control-treatment)) 
 
 
Immunofluorescent Flow Cytometric Analysis of Intracellular and Surface 
Proteins.  
 
 
For surface stains NK92 cells (1.0 X 105/assessment) were incubated with antibodies for 
30 minutes on ice (agitated after 15 minutes).  Cells were then washed twice with 0.1% 
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BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand Island, NY) and 
resuspended in 1% paraformaldehyde (PFA) (Sigma Aldrich, St. Louis, MO).  Surface 
staining antibodies included- anti-CD337 (NKp30) (AlexaFluor 647 conjugated) (BD 
Biosciences, San Jose, CA), anti-NKp46 (PE conjugated) (BD Biosciences), anti-
IL12Rβ2 (PerCP conjugated) (R&D, anti-IL-2Rα/CD25 (Alexa488 conjugated), and 
anti-CD11a/LFA-1 (FITC conjugated) (BD Biosciences, San Jose, CA).  For 
intracellular protein analysis, cells were washed twice with 0.1%BSA following surface 
staining, then fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen, 
San Jose, CA) for 20 min at 4°C. The cells were then washed twice with Perm/Wash 
Buffer (BD Biosciences, San Jose, CA) and probed with antibodies specific for 
molecules of interest including anti-granzyme B (Alexa Fluor 647 conjugated) (BD 
Biosciences, San Jose, CA), anti-perforin (PE-conjugated) (BD Biosciences, San Jose, 
CA), and anti-glucocorticoid receptor (GR) (unconjugated) (Abcam, Cambridge, MA).  
For chromatin remodeling protein analysis, cells were permeabilized and then incubated 
with antibodies specific for chromatin remodeling protein for 1 hour at 4°C.  For 
chromatin remodeling proteins, cells were probed with antibodies specific for histone 
deacetylase 1 (HDAC1) (Alexa-647-conjugated)  (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA), HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 
phosphorylated-HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), HDAC3 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), p300 
(Alexa 647-conjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  Secondary 
anti-IgG (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min at 4°C to 
unconjugated primary antibodies.  For intracellular cytokine analysis of IFN-g (PE 
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conjugated) (BD Biosciences, San Jose, CA) and TNF alpha (PE-conjugated) (BD 
Biosciences, San Jose, CA), cells were incubated in leukocyte activation cocktail (BD 
Pharmigen, San Jose, CA) at 37°C for 4 hrs prior to permeabilization and antibody 
staining. Samples were analyzed with a FACSCanto (Fluorescence-Activated Cell Sorter 
(FACS) Core Laboratory (FCL) at the Cardinal Bernardin Loyola University Cancer 
Center) equipped with a 15mW argon-ion laser and a red diode laser using FACSDiva 
software for data acquisition. After staining, cells were analyzed by flow cytometry.  
10,000-30,000 events were recorded and analyzed with FlowJo v8.4.1. Flow cytometric 
analysis was confirmed by microscopy. 
 
Western Blot 
 
   For Western Blot analysis, nuclear and cytoplasmic compartments of NK92 cells were 
extracted from 1-3 X 106 cells via the Fermentas ProteoJET Cytoplasmic and Nuclear 
Protein Extraction protocol (Fermentas, Burlington, ON).  Nuclei were lysed using 
Nuclear Lysis Buffer (Fermentas, Burlington, ON) both lysed nuclei and cytoplasm 
were both resuspended in Laemmlis SDS-Sample Buffer (4x) (Boston Bioproducts, 
Boston, MA).  Samples were boiled for 10 minutes and proteins separated by 
electrophoresis with a 12% agarose gel and transferred to a nitrocellulose membrane for 
blotting. Proteins were visualized with anti-NFκB p65 (Abcam, Cambridge, MA), anti-
cJun (Abcam, Cambridge, MA), anti-STAT4 (Santa Cruz, Santa Cruz, CA), anti-GR 
(Abcam, Cambridge, MA), anti-HDAC3 (Abcam, Cambridge, MA), and HRP 
conjugated goat anti-rabbit IgG secondary antibody (Millipore, Temecula, CA) and 
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chemiluminescence reagent (ThermoScientific, Rockford, IL).  Quality of nuclear and 
cytoplasmic compartment extraction was determined by LamininB and GAPDH, 
respectively (Abcam, Cambridge, MA). Blot density was quantified using Image J 
software.   
 
Chromatin Immunoprecipitation (ChIP) Assay.  
 
NK92 cells (5 x 106) were cross-linked with 1% formaldehyde for 10 min and 
terminated by the addition of glycine to a final concentration of 125 mM for 5 min. The 
cells were washed twice with ice-cold PBS.  Crosslinked nuclei were extracted using the 
Fermentas ProteoJET Cytoplasmic and Nuclear Protein Extraction protocol (Fermentas, 
Burlington, ON) and lysed with 500 µL of high salt lysis buffer (Santa Cruz, Santa Cruz, 
CA). The samples were sonicated using a Branson Sonifier 250 on ice for a total of four, 
15 second cycles per sample.  Sonicated samples were diluted and aliquoted into 100µl 
volumes.  Pre-cleared supernatant with ChIP-Grade ProteinG Magnetic Beads (Cell 
Signaling, Danvers, MA) was collected and immunoprecipitated overnight at 4°C with 
the following antibodies: anti-acetyl-H4K8 (Millipore, Temecula, CA), anti-acetyl-
H3K9  (Cell Signaling, Danvers, MA), anti-acetyl H3K27 (Abcam, Cambridge, MA), 
anti-trimethyl H3K4 (Cell Signaling, Danvers, MA), anti-trimethyl H3K9 (Cell 
Signaling, Danvers, MA), anti-trimethyl H3K27 (Cell Signaling, Danvers, MA), anti-
HDAC1 (Abcam, Cambridge, MA), anti-HDAC2 (Abcam, Cambridge, MA), anti-
HDAC3 (Abcam, Cambridge, MA), and control rabbit Ig (Cell Signaling, Danvers, MA).  
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ChIP-Grade ProteinG Magnetic Beads (Cell Signaling, Danvers, MA) were added and 
incubated an additional 4HR at 4°C.  The immune complexes were collected, washed, 
and eluted.  Cross-linking was reversed by heating at 65°C overnight and 10min at 95°C 
in elution buffer (Santa Cruz, Santa Cruz, CA).  DNA was recovered using the 
MiniElute Reaction Cleanup Kit (Qiagen, Valencia, CA) and resuspended in 50 µl of 
dH2O. Quantitative real-time PCR was performed using an Opticon 2 Real-Time 
Detector; PCR cycles were denaturation at 94°C (30 s) and annealing at 55-61°C (30 s), 
no extension phase was necessary.  The DNA samples were amplified with primer pairs 
to the -22KB enhancer and proximal promoter of the IFNG locus, the proximal 
promoters of PRF1, GZMB, TNF, and IL6. PCR data was analyzed using Opticon 
Monitor 3 Software (BioRad, Hercules, CA). Modification levels were calculated as 
percent input using the equation. 
 
Percent Input = 100 x 2^(C(t)untreated – C(t)treated cells). 
 
Chromatin Accessibility 
The EpiQ Chromatin Analysis Kit (BioRad, Hercules, CA) was used to determine the 
accessibility of the IFNG enhancer, IL6 proximal promoter, TNF proximal promoter, 
GZMB proximal promoter, GAPDH gene, and RHO gene.  The methodology supplied in 
the kit was as directed for cells in suspension.  Briefly, 250,000 NK92 cells were 
collected from treatments and resuspended in the supplied EpiQ chromatin buffer and 
either left undigested or nuclease digested.  DNA was then isolated and quantification of 
accessibility as a measure of intact genomic regions was performed by q-RT-PCR.  The 
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EpiQ Chromatin Analysis Kit Data Analysis Tool was used to determine percent 
accessibility.  The control primers for the genomic regions RHO and GAPDH were used 
as directed and used as 0% and >95% respectively.    
 
 
Table 2. Primers used for ChIP and Chromatin Accessibility Studies 
 
 
 
 
 
 
 
 
 
 
AMPLICON PRIMERS (5’  3’) 
IFNG promoter Forward: TCATCGTCAAAGGACCCAAGGAGT 
Reverse: ATGGTGACAGATAGGCAGGGATGA 
IFNG enhancer Forward: GAATTGGCTTGACACCTCTGTCCT 
Reverse: TTCCATCTCTCGGCAAAGAGCAGT 
IL6 promoter Forward: CAGAAGAACTCAGATGACTGG 
Reverse: GCTGGGCTCCTGGAGGGG 
TNF promoter Forward: CGCTTCCTCCAGATGAGCTC 
Reverse: TGCTCTCCTTGCTGAGGGA 
PFR1 promoter Forward: GGCACAGTTCCAAGCACTTCACAA 
Reverse: AGCCTCACTGTGCCTCAGTTTCTT 
GZMB promoter Forward: AGCCTGTTGCCTCTGTGAGAAAGT 
Reverse: TGGGATTTGCTGGCAACCTAGACA 
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Immunofluorescent Microscopy 
 
Glass coverslips (Fisher Scientific) were sterilized with 100% ethanol (Sigma Aldrich, 
St. Louis, MO). Coverslips were treated with Cell Tak poly-L-lysine (BD Biosciences, 
Bedford, MA) for 10 minutes to aid adherence of NK92s to coverslips. Dex treated and 
untreated NK92 cells (500,000 cells/coverslip) were added to the coverslips for 10 
minutes. Coverslips were treated with methanol-free formaldehyde (Polysciences Inc., 
Warrington, PA) diluted in saponin buffer (Sigma Aldrich, St. Louis, MO) for 10 
minutes. This fixed cells to coverslips while maintaining 3D structure of cells. 
Coverslips were washed with PBS. Cells were permeabilized with 0.2% Triton-X 
(Sigma Aldrich, St. Louis, MO) for 12 minutes. Coverslips and cells were blocked for 
15-60 minutes with 0.1% BSA in PBS. Next, antibodies specific for chromatin 
remodeling proteins were added for 1 hour at room temperature. Primary antibodies 
were added at a 2.5:100 dilution in 0.1% BSA in PBS. Antibodies used included: anti-
HDAC1 (Cell Signaling, Danvers, MA) (Abcam, Cambridge, MA), anti-HDAC2 (Cell 
Signaling, Danvers, MA), anti-HDAC3 (Cell Signaling, Danvers, MA) (Abcam, 
Cambridge, MA) and anti-GR (Abcam, Cambridge, MA).  Coverslips were washed with 
0.1% BSA in PBS. After primary antibodies, secondary antibodies were added for 20-30 
minutes at room temperature. Secondary antibodies were added at a 1:500 dilution. 
Secondary antibodies to be used were: donkey-anti-mouse IgG (Cy3-conjugated) 
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(Jackson Immunoresearch, West Grove, PA) and donkey-anti-rabbit IgG (Alexa 488-
conjugated) (Jackson Immunoresearch, West Grove, PA). Coverslips were washed with 
0.1% BSA in PBS. After washing coverslips were fixed to slides with Prolong Gold 
(Invitrogen, Carlsbad, CA) containing DAPI stain for nuclear identification. Images 
were collected with a DeltaVision microscope (Applied Precision) equipped with a 
digital camera (CoolSNAP HQ; Photometrics), using a 1.4-numerical aperture 100× 
objective lens, and were recorded with SoftWoRx software (Applied Precision). Images 
were assessed and analyzed with Imaris Software. 
 
NK92 Cells- Image Stream 
Cellular permeabilization, reagents and antibody staining procedures as described above 
in Intracellular Staining by Flow Cytometry Section.  Fluorescent images were 
visualized (500-3000 events per condition) on Amnis Imagestream.  A mask on the 
nucleus was created; within this area, colocalization of HDACs and nuclear dye (DAPI) 
was measured by similarity (IDEAS software, Amnis).  
 
Co-immunoprecipitation experiments 
To determine protein-protein interactions the DynaBeads Co-Immunoprecipitation Kit 
(Invitrogen, Grand Island, NY) using anti-HDAC3 (unconjugated) (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) or rabbit IgG (Cell Signaling, Danvers, MA).  
Immunoprecipitates were collected via magnetic separation and analyzed by western 
blot analysis using the procedures described above in Western blot analysis section.  
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Ex vivo analysis of human PBMC 
 
Recruitment/Enrollment: 
Women 43-75 years of age, with early stage, breast cancer, treated with breast 
conserving surgery were enrolled.  Some women also underwent radiotherapy and/or 
hormonal therapy. Women were excluded if they are treated with systemic 
chemotherapy, have recurrent breast cancer or other cancers (within the last 5 years), 
immune-based disease (e.g. multiple sclerosis, HIV), psychoses, cognitive dysfunction; 
are not fluent in English, abused controlled substances, were under psychotherapy, took 
anxiolytics, hypnotics, psychotropics, cortico-steroids, or immune-altering drugs.  At 
each time point subjects were screened for infections.  These criteria applied equally to a 
Comparison Group (Control). 
Missing data were minimal for both psychological and immune data.  Reasons 
for missing immune data were inadequate specimen blood volume, inability to perform 
venipuncture or frank refusal of venipuncture. 
 
Study Outline: 
For all women enrolled psychological instruments were administered, salivary 
cortisol was collected and peripheral blood was obtained.  Women were assessed as they 
respond to and recover from breast cancer diagnosis at four time points (See Figure 19).  
Data were collected at the initial cancer diagnosis (T1), 10-12 days post breast surgery 
and before any adjuvant therapy was initiated (T2).  An interval of 10-12 days after 
surgery provided ample time for surgical or anesthesia-induced effects to 
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dissipate[214,219,220,221,222]. Hence, this window of time permitted analysis of 
variables without confounds of surgery or adjuvant therapy.  The third time point (T3) was 
two months following radiation treatment completion or approximately four months after 
diagnosis and the fourth time point (T4) was six months after radiation treatment 
completion or approximately 8 months after diagnosis.  PBMCs were isolated from blood 
specimens obtained from these women by a ficol histopaque gradient density separation 
as described previously[223]. 
 
Psychological Assessments: 
 Women completed the Perceived Stress Scale (PSS) which provided a general 
measure of stress (i.e., controllability of life events). Women with breast cancer may 
exhibit depressive symptoms, so the Center for Epidemiologic Studies–Depression 
(CES-D) was administered, which captured depressive symptoms, as well as monitored 
for risk of depression. PSS is a 10-item scale that assesses the degree to which a person 
finds their lives as unpredictable, uncontrollable or overloaded (i.e., exceeding their 
adaptive capacities). It is a measure of global stress appraisal, as opposed to a specific 
event which evokes a stress response[224]. Reliability (stability) was 0.85 and Cronbach 
alphas range from 0.75-0.86[224]. The PSS is widely used in studies of stress on 
immunity, including studies of the stress-immune response of women with breast 
cancer[203,205]. PSS was shown to be strongly related to trajectories of change in 
NKCA observed in women as they adapted to a diagnosis of breast cancer[205]. CES-D 
provided a measure of depressive symptoms. CES-D assesses frequency and duration of 
depressive symptoms[225]. Scores range from 0-60 and >16 suggests depression risk. 
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CES-D is widely used in studies of women with breast cancer[226,227]. It has good 
construct validity, good test-retest reliability [225]. In cancer patients and healthy 
controls CES-D showed internal consistency (alpha=0.87 and alpha=0.89), 
respectively[228]. 
 
Salivary Cortisol: 
Women collected saliva for measurement of cortisol two days prior to a blood 
draw at each time point. On each of the two collection days, saliva was obtained at 
awakening (“when your eyes open and you are ready to get up”), at 30 minutes after 
wakening, noon, 5 PM and at bedtime (“right before getting into bed”). Women 
recorded collection times on saliva vials. They did not brush their teeth for at least 15 
minutes prior to collection and abstained from smoking at least 1 hour before sampling. 
Using salivettes (Salimetrics™), subjects gently chewed (60-90 seconds) on a soft swab 
that fits into a holder resting in a centrifuge tube. The morning sample was obtained 
within 15 minutes of each person’s wake time[229,230,231,232], while compliance for 
the later samples was ± 60 min around the sampling time. Women who woke after 11 
AM and night shift workers were excluded[233]. Centrifuged samples were frozen (-
200C) and assayed in duplicate within 6 months using immunoassay kits (Salimetrics™). 
Intra-assay coefficient of variation was 3.35-3.65%. Inter-assay coefficient of variation 
is 3.75-6.41%. The minimal detectable cortisol concentration < 0.003 µg/dL.  The diurnal 
cortisol rhythms generated a curve consisting of 4 trapezoids.  The area under the curve was 
calculated by summing the area of these 4 trapezoids using the equation.   
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Where x1, x2, x3, x4, and x5 represent awakening, 30min post awakening, noon, 5pm, and 
bedtime, respectively.  Additionally y1, y2, y3, y4, and y5 representing cortisol levels at 
these timepoints.  
 
Statistical methods 
 Data are expressed as means with the standard error of the mean (SEM) or 
standard deviation (SD) as noted.  Main study variables were analyzed using Student’s t 
test, a two-sided alpha of 0.05 was set for significance.  The Statistical Package for 
Social Sciences (SPSS: version 13.0) was used for data analysis. Pearson correlations 
and regression analysis 
All experimental means were calculated from triplicate values.  Lytic units (LU) were 
calculated by a program written by David Coggins, FCRC, Frederick, MD and 
represents the number of cells per 107 effectors required to achieve 20% lysis of the tar-
gets. *DPM=disintegrations per minute. 
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The Statistical Package for Social Sciences (SPSS: version 13.0) was used to 
generated standardized scores for variables used for classification.  Clusters were 
generated by using the standardized scores to determine hierarchical clustering based on 
Euclidean mean squared distance. This is a statistical method that merges attributes into 
clusters based on the residual error within the differences of the instance attributes from 
those of another group. This method minimizes the variance of the differences in 
attributes within a cluster using the distance algorithm based on the sum of squares of 
the difference of the attributes. It joins cluster pairs whose merger minimizes the 
increase in the total sum of squares within-group error.  The resulting groups were used 
for analysis and are statistically graphed using dendograms.  
 
Cytokine Production (ELISA):  
 NK92 (2.5 x 105 cells/ml) cells were incubated in 24 well plates for 24 hours at 
37 0C. All molecules were measured using quantitative sandwich enzyme immunoassay 
techniques (Quantikine kits, R & D Systems, Minneapolis, MN). Sensitivities for 
cytokines were; (interleukin-6 (IL-6) <0.7 pg/ml, interferon gamma (IFN-g) <3 pg/ml, 
tumor necrosis factor alpha (TNF alpha) <1.6 pg/ml, and Perforin<40 pg/ml). The 
coefficient of variation ranged between 2.6 – 8.1% for the individually assessed 
molecules. 
PBMCs were unstimulated or stimulated for 48 hours with phorbol 12-myristate 
13-acetate (PMA) and phytoheamagglutin (PHA) (Sigma Aldrich, St. Louis, MO).  
PMA is a phorbol ester that is a polyclonal activator of PBMCs through activation of 
protein kinase C which leads to protein production.  PHA is able to crosslink proteins 
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expressed on the surface of PBMCs causing stimulation.  After 48 hours, supernatants 
were collected and an ELISA was performed.   
 
Intracellular Staining by Flow Cytometry: 
PBMCs: 
PBMCs were aliquoted into fluorescent activated cell sorting (FACS) tubes 
(500,000 cells/tube).  Surface staining antibodies were added for 30 minutes on ice, 
agitated every 15 minutes to identify PBMC sub populations. Surface antibodies used 
included anti-CD4 (Pacific Blue conjugated), anti-CD8 (PerCP-Cy5.5 conjugated), anti-
CD56 (APC conjugated), anti-CD56 (PE conjugated), anti-CD45RO (APC conjugated), 
anti-CD3 (APC-Cy7 conjugated) and anti-CD14 (APC conjugated) (BD Pharmingen, 
San Jose, CA).  PBMC sub populations were identified as: CD4+ T lymphocytes (CD4+, 
CD8-, CD56-), CD8+ T lymphocytes (CD8+, CD4-, CD56-), Natural Killer (NK) cells 
(CD56+, CD4-, CD8-) and CD14+ Monocytes (CD14+).  Following surface antibody 
staining, the cells were washed twice with 0.1% bovine serum albumin (BSA) (Sigma 
Aldrich, St. Louis, MO) in phosphate buffer solution (PBS) (Gibco, Grand Island, NY).  
PBMCs were fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen, 
San Jose, CA) for 20 min at 4°C. The cells were then washed twice with Perm/Wash 
Buffer (BD Biosciences, San Jose, CA) and probed with antibodies specific for 
intracellular molecules of interest for 1 hour at 4°C.   
For histone residues, anti-acetylated (Ac)-histone 4 lysine 8 (H4-K8) (Millipore, 
Temecula, CA) (unconjugated), anti- H3K9-Ac (Alexa 488 conjugated) (Cell Signalling 
Beverly, MA), anti-trimethylated (me3)-H3K4 (unconjugated ) (Cell Signalling Beverly, 
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MA), anti-phosphorylated (P)-H3S10 (Alexa 488 conjugated) (Cell Signalling Beverly, 
MA) were added to cells in FACS tubes. The cells were washed twice with Perm/Wash 
Buffer (BD Biosciences, San Jose, CA), after which secondary anti-immunoglobulin 
gamma (IgG) (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min at 
4°C to the H4-K8-Ac and H3-K4-me3 tubes.  Following this treatment, the cells were 
washed twice with Perm/Wash Buffer (BD Biosciences, San Jose, CA) and resuspended 
in 0.1% BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand Island, NY).  
For intracellular cytokine analysis, cells were permeabilized and then incubated 
with antibodies specific for intracellular proteins for 1 hour at 4°C.  Antibodies for 
intracellular staining used included anti-IFN gamma (PE conjugated) (BD Biosciences, 
San Jose, CA), anti-granzyme B (Alexa Fluor 647 conjugated) (BD Biosciences, San 
Jose, CA), anti-TNF alpha (PE-conjugated) (BD Biosciences, San Jose, CA), anti-TNF 
alpha (Alexa 488-conjugated) (BD Biosciences, San Jose, CA), anti-IL-6 (PE 
conjugated) (BD Biosciences, San Jose, CA) and anti-perforin (PE conjugated) (BD 
Biosciences, San Jose, CA). For intracellular cytokine analysis of IFN gamma and TNF 
alpha, cells were incubated in leukocyte activation cocktail (LAC) (BD Pharmingen, San 
Jose, CA) at 37°C for 4 hours prior to permeabilization and antibody staining.  LAC 
contains PMA, ionomycin and brefeldin A.  PMA is a phorbol ester which is a 
polyclonal activator of PBMCs, ionomycin is a calcium ionophore which increases 
calcium levels in the cell resulting in PBMC stimulation.  Brefeldin A is a protein 
transport inhibitor which allowed for intracellular assessment of cytokines.  For 
intracellular cytokine analysis of IL-6, cells were incubated in leukocyte activation 
cocktail (BD Pharmingen, San Jose, CA) and 100 ng of sonicated lipopolysaccharide 
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(LPS) (Sigma Aldrich, St. Louis, MO) at 37°C for 4 hours prior to permeabilization and 
antibody staining.    
For chromatin remodeling protein analysis, cells were permeabilized and then 
incubated with antibodies specific for chromatin remodeling protein for 1 hour at 4°C.  
For chromatin remodeling proteins, cells were probed with antibodies specific for 
histone deacetylase 1 (HDAC1) (Alexa-647-conjugated)  (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA), phosphorylated-HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA), HDAC3 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), p300 (Alexa 647-conjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  
Secondary anti-IgG (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min 
at 4°C to unconjugated primary antibodies.   
For all PBMCs, cytokine and histone mean fluorescent intensities (MFIs) were 
standardized to cytokine and histone MFIs of HiCK Control Cells (BD Pharmingen, San 
Jose, CA). Surface antibodies were not added to HiCK Control Cells; intracellular and 
histone antibodies were added as described above.  HiCK Control Cells were thawed 
and aliquoted into individual microcentrifuge tubes before storage at -80 °C.  On the day 
of PBMC staining, HiCK Control Cells were thawed at 37°C for 2 minutes and then 
aliqoted into FACS tubes for staining.  HiCK Control Cells were stained concurrently 
with PBMCs, therefore staining times, incubations and washes were identical to PBMCs. 
No change in HiCK cell staining was observed over time.  
 
For MFI calculations, the following formula was used: 
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MFI= Cytokine or Histone MFI of sample/Cytokine or Histone MFI of HiCK 
cell. 
 
After staining, samples were analyzed by flow cytometry with a FACS CantoII 
Fluorescence-Activated Cell Sorter or a LSR Fortessa using FACS Diva software for 
data acquisition[223,234,235]. 10,000-30,000 events were recorded and analyzed with 
FlowJo v8.4.1.
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CHAPTER THREE 
 
EXPERIMENTAL RESULTS 
 
Development of an in vitro system to investigate the effects of chronic 
glucocorticoid exposure on Natural Killer cell function 
 
Previous studies have demonstrated that 24 hour incubation of human derived CD56+ 
cells as well as the NK cell lines; NK3.3, YT, and NK92, with dexamethasone or 
cortisol reduces NK cell lytic activity [117,118,119].  Furthermore, we have published 
that 24 hour incubation of the NK cell line, NK92, with dexamethasone resulted in a 
dose dependent inhibition of NK cell lytic ability [117,118].  Results from all studies 
concluded that this is in part mediated through a reduction in lytic molecule transcription, 
both perforin[117,119] and/or granzymes [119].  Furthermore, 24 hour treatment of both 
ex vivo cultured human derived CD56+ NK cells or NK cell lines treated with high 
concentrations of dexamethasone or cortisol resulted in decreased proinflammatory 
cytokine production[117,118,236,237].   Together these studies demonstrated that short 
term (24-hour) high concentration exposure to glucocorticoids is both 
immunosuppressive and anti-inflammatory in nature.  However, these studies did not 
investigate the effects of longer duration glucocorticoid exposure on NK cells. Therefore, 
we developed a culture system to investigate the effects of chronic exposure to 
glucocorticoids, termed chronic GC treatment, for a total of 5 days and performed time 
course analysis, characterizing cytokine production and lytic activity of the NK92 cell
65 
  
 
 
Figure	  7.	  The	  effect	  of	  chronic	  glucocorticoid	  (GC)	  treatment	  on	  pro-­
inflammatory	  cytokine	  production	  by	  NK92.	  	  (A)	  MFI	  of	  IFN-­‐g	  production	  as	  measured	  flow	  cytometry	  in	  untreated	  or	  chronic	  GC	  treated	  NK92	  cells	  with	  a	  range	  of	  dexamethasone	  from	  10-­‐7	  to	  10-­‐10	  M	  .(B)	  IFN-­‐g	  production	  as	  measured	  by	  ELISA	  from	  NK92	  cells	  either	  untreated	  or	  treated	  with	  GC	  and	  harvested	  at	  various	  times	  and	  then	  either	  stimulated	  or	  unstimulated	  with	  IL-­‐12	  for	  4	  hours,	  n=3.	  (C)	  IFN-­‐g	  transcript	  levels	  for	  IL-­‐12	  stimulated	  and	  unstimulated	  cultures	  with	  and	  without	  chronic	  (5	  day)	  GC	  exposure.	  IFN-­‐g	  transcript	  levels	  from	  unstimulated,	  untreated	  cells	  were	  set	  to	  1.	  (D)	  IL-­‐6	  production	  as	  measured	  by	  ELISA	  from	  NK92	  cells	  harvested	  from	  5	  day	  cultures	  either	  unstimulated	  or	  stimulated	  with	  IL-­‐2	  for	  4	  hours,	  n=3.	  *;	  p<0.05,	  **;	  p<0.01. 
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line. Treatment of NK92 cells for five days demonstrated that high concentrations of 
dexamethasone, both 10-7M or 10-8M, reduced IFN-g production as judged by a decrease 
in the mean fluorescence intensity (MFI) of IFN-g staining by flow cytometry (Figure 
7A).  In contrast, there was a trend for increased IFN-g production at dexamethasone 
(10-9M) and a significant increase in IFN-g MFI was observed after 5 day treatment with 
10-10M dexamethasone (Figure 7A). Intracellular cytokine staining demonstrated that 
there was a 32±3.8% increase in intracellular IFN-g mean fluorescence intensity (MFI) 
in 5 day chronic GC (10-10M) treated NK92 cells compared to untreated cells (Table 3). 
The shift in MFI was accompanied by a modest increase in IFNg positive cells (90% vs 
85%) (Table 3) indicated that NK92s in culture shift as a population towards increased 
cytokine production.  This apparent pro-inflammatory effect of GC on NK cells when 
exposed for extended time prompted further analysis.  Therefore, for this body of work 
the effects of chronic 5 day GC treatment (10-10M  dexamethasone) were analyzed, 
termed chronic GC treatment.   
NK cells were harvested at indicated days of treatment, stimulated with IL-12, 
and the production of interferon gamma (IFN-g) was analyzed in the culture 
supernatants by ELISA.  Chronic GC treatment had no impact on basal IFN-g 
(Untreated vs. Chronic GC) production. However, when stimulated with IL-12, chronic 
GC treated cells exhibited increased IFN-g production (Untreated + IL-12 vs. Chronic 
GC + IL-12) reaching a 2-fold increase at day 5 (Figure 7B). This was not an IFNg 
specific phenomenon, as IL-2 stimulated IL-6 production increased from 32.2±1.8pg/mL 
to 61.6±2.4pg/mL after day 5 of chronic GC treatment (Figure 7D).  Furthermore, flow 
cytometry demonstrated an increase in TNF-alpha MFI after chronic GC treatment 
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Table 3. Effect of chronic GC treatment on proinflammatory cytokine production and 
granule constituent levels in NK92 by flow cytometry 
 
 Values	  are	  mean	  fluorescent	  intensity	  (MFI)	  of	  	  intracellular	  proteins	  ±	  S.E.M.,	  n=	  at	  
least	  three	  independent	  experiments.	  Isotype	  control	  MFI	  was	  always	  <	  150.	  %	  Change=	  (MFI	  Untreated	  	  -­‐	  MFI	  Chronic	  GC	  treatment)/(MFI	  Untreated)	  X	  100.	  Statistically	  significant	  difference,	  Untreated	  vs.	  Chronic	  GC	  Treatment.	  
 
 
 
 
 
 
 
Table 1.  Effect of chronic GC treatment on proinflammatory cytokine production 
and granule constituent levels in NK92 by flow cytometric analysis. 
 
 
 
Mean Fluorescent Intensity (MFI) and/or Percentages of Cytokine and Intracellular Protein Positive Cells 
 
 
Cellular Protein 
 
Untreated 
 
Chronic GC Treatment 
(5 day) 
 
P value 
 
(%) Change 
 
 
 
      
IFN-gamma 
(MFI) 
1452 ± 71 1922 ± 91 0.0005 32.4 ± 3.8  
      
IFN-gamma 
positive (%) 
85.0 ± 1.0 90.0 ± 1.7 0.001 5.7 ± 0.37  
      
Perforin 
(MFI) 
7421 ± 192 6371 ± 138 0.017 -14.1 ± 1.86  
      
Perforin 
Positive (%) 
95.3 ± 0.29 94.3 ± 1.36 0.309 -0.98 ± 1.42  
      
Granzyme B 
(MFI) 
11009 ± 150 10115 ± 188 0.017 -8.13 ± 1.71  
      
Granzyme B 
Positive (%) 
98.2 ± 0.40 97.8 ± 0.31 0.318 -0.34 ± 0.31  
      
Values are mean fluorescent intensity (MFI) of surface and intracellular proteins ± 
S.E.M., N= at least three independent experiments. Isotype control MFI was always < 
150. % Change= (MFI Untreated - MFI Chronic GC Treated)/(MFI Untreated) X 100. 
Statistically significant difference, Untreated vs. Chronic GC Treatment. 
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(Figure 7E).  IL-6 protein levels could not be analyzed by intracellular cytokine staining 
due to low intracellular accumulation of protein levels.  Additionally, no mature active 
TNF-alpha was detected in culture supernatants, most likely due to a lack of TNF-alpha 
converting enzyme (TACE) expression.  mRNA isolated and quantified from NK92 
cells after 5 days of chronic GC treatment exhibited a 23- fold induction of IFN-g 
mRNA after IL-12 stimulation while untreated cultures exhibited only a 14-fold 
induction (Figure 7C).  These results taken together demonstrated that chronic GC 
treatment primes NK cells to produce proinflammatory cytokines via enhanced 
transcription of cytokine genes after cellular stimulation.  
 
Effect of chronic GC treatment on natural killer cell activity (NKCA) 
 
NK cells not only produce proinflammatory cytokines but also have direct 
cytolytic activity.  NK cells were harvested at indicated days during chronic GC 
treatment and NKCA assessed via chromium release.  NK92 cells exhibited a time 
dependent decrease in NKCA with a decrease at day 4 (18%), and a significant decrease 
at day 5 (25%)(Figure 8A). Human NKCA is primarily mediated via granule dependent 
lysis of tumor cells; therefore, the mRNA levels of two key NK cell granule constituents, 
perforin and granzyme B, were assessed. mRNA expression and levels for both perforin 
(PRF1) and granzyme B (GZMB) were reduced throughout chronic GC treatment and 
observed as early as day 2 of treatment (Figure 8B).  At day 5 of chronic GC treatment 
PRF1 transcripts were reduced by 60% and GZMB transcripts were reduced 40% 
compared to untreated cells (Figure 8B).  Flow cytometry confirmed reductions in both  
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Figure	  8.	  Effect	  of	  chronic	  glucocorticoid	  treatment	  on	  NKCA	  and	  lytic	  
molecule	  production.	  	  (A)	  NKCA	  presented	  as	  percent	  change	  in	  lytic	  units	  ±	  SEM	  of	  NK92	  harvested	  at	  indicated	  days	  of	  treatment	  for	  target	  K562	  cells,	  n=3.	  (B)	  Relative	  transcript	  levels	  for	  two	  granule	  constituents,	  perforin	  (PRF1)	  and	  granzymeB	  (GZMB),	  in	  NK92	  cells	  harvested	  at	  indicated	  days	  during	  treatment	  and	  standardized	  to	  transcript	  levels	  in	  untreated	  (grey	  bars)	  cells	  set	  to	  1.	  	  (C)	  Flow	  cytometric	  analysis	  of	  granule	  constituent	  protein	  levels	  after	  5	  day	  chronic	  GC	  treatment.	  	  Graphs	  represent	  mean	  fluorescent	  intensity	  of	  PRF1	  and	  GZMB	  levels	  compared	  to	  untreated	  cells	  set	  to	  100%.	  *;	  p<0.05,	  **;	  p<0.01.	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Table 4.  Effects of chronic GC treatment on surface receptor expression by NK92 
cells 
 Values	  are	  mean	  fluorescent	  intensity	  (MFI)	  of	  surface	  proteins	  ±	  S.E.M.,	  n=	  at	  least	  three	  independent	  experiments.	  Isotype	  control	  MFI	  was	  always	  <	  150.	  %	  Change=	  (MFI	  Untreated	  -­‐	  MFI	  Chronic	  GC	  treatment)/(MFI	  Untreated)	  X	  100.	  Statistically	  significant	  difference,	  Untreated	  vs.	  Chronic	  GC	  Treatment.	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perforin and granzyme B protein levels after 5 days of chronic GC treatment (Figure 8C 
and Table 3).  These data demonstrate chronic GC treatment to reduce perforin and 
granzyme B levels with concomitant reductions in NKCA.  Furthermore, the 
percentages of perforin or granzyme B positive cells were unchanged after chronic GC 
treatment (Table 3).  NKCA is also regulated by the expression of activating and 
inhibitory receptors on NK cells as well as the ability of NK cells to form stable 
conjugates with target cells and exocytose granules.  I found no significant difference in 
the ability of NK92 cells after chronic GC treatment to form stable conjugates with 
target tumor cells using a flow cytometric assay presented as % conjugate formation 
(data not shown).  Furthermore, chronic GC treatment had no impact on the ability of 
NK92 cells to exocytose granules as measured by CD107a surface expression after 
target cell contact (Table 4).  The surface expression of NKp46 were unaffected by 
chronic GC treatment (Table 4).  We did observe a small but significant increase in 
NKp30 expression; however, this increase in activating receptor expression could not 
explain the significant decrease in NKCA (Table 4).  Hence, chronic GC treatment shifts 
NK cell effector function to a less cytolytic and more proinflammatory NK cell 
phenotype through the dichotomous transcriptional regulation of the respective effector 
genes.  
 
Effect of chronic GC treatment on NK cell signaling pathways  
 
The transcriptional changes described above prompted investigation into the effect of 
GC on signaling pathways that regulate NK cell effector function.  IFN-g and 
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Figure	  9.	  	  Effects	  of	  chronic	  GC	  treatment	  on	  proinflammatory	  cytokine	  
signaling	  pathways.	  	  Flow	  cytometric	  analysis	  of	  (A)	  IL-­‐12	  and	  (B)	  IL-­‐2	  receptor	  surface	  expression	  for	  chronic	  GC	  treatment	  (5	  days)	  or	  untreated	  cells.	  (C)	  ImageJ	  quantification	  of	  whole	  cell	  lysates	  probed	  by	  western	  blot	  analysis	  for	  c-­‐Jun,	  Stat4,	  and	  NFkB	  levels	  in	  chronic	  GC	  treated	  and	  untreated	  cells.	  (D)	  Flow	  cytometric	  analysis	  of	  NFkB	  in	  5	  day	  chronic	  GC	  and	  untreated	  cells.	  	  ImageJ	  quantification	  of	  nuclear	  (E)	  c-­‐Jun	  and	  (F)	  NFkBp65	  in	  chronic	  GC	  and	  untreated	  cells	  prior	  to	  and	  after	  IL-­‐12	  stimulation. 
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IL-6 mRNA and protein were increased after cellular stimulation with IL-12 and IL-2, 
respectively (Figure 7A-D).  At the cell surface, chronic GC treatment had no impact on 
the levels of the IL-12 receptor beta chain or the IL-2 receptor alpha chain, implying that 
chronic GC did not alter receptor density of NK92 cells for the cytokines used for 
stimulation. (Figure 9A-B).  Downstream of receptor signaling is the activation and 
subsequent nuclear localization of the canonical proinflammatory signaling transcription 
factors NFκBp65 and AP-1 (c-Jun) as well as STAT4, the signaling molecule directly 
downstream of the IL-12 receptor.  Western blot analysis and ImageJ quantification 
demonstrated 5 days of chronic GC treatment had no impact on the total cellular levels 
of these three transcription factors (Figure 9C). Flow cytometry confirmed that 5 day 
chronic GC treatment did not alter the cellular levels of NFκBp65 (Figure 9D).  Western 
blot analysis and quantification of nuclear fractions isolated from 5 day chronic GC 
treated and untreated cells before and after IL-12 stimulation revealed that IL-12 
stimulation significantly increased the nuclear localization of NFκBp65 and AP-1 (c-
Jun) in both untreated and 5 day chronic GC treated cells (Figure 9E-F). However, no 
significant difference was observed in the nuclear translocation of either cJun or 
NFκBp65 between untreated and chronic GC treated cells stimulated with IL-12 (Figure 
9E-F). These data demonstrate that NK cells exposed to chronic GC are able to sense 
and respond to cellular activation to the same degree as untreated cells.   
 
Chronic GC induced histone modifications at proinflammatory regulatory regions 
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Post translational epigenetic modifications at genomic regulatory regions can 
affect both active transcriptional rates as well as priming genes for future transcription. 
GR have been shown to interact with histone modifying enzymes and to influence 
histone tail post-translational modifications at genomic regulatory regions [117,146,238].  
To assess the effect of chronic GC treatment on histone tail modifications at the 
regulatory regions of NK cell effector genes, chromatin immunoprecipitation (ChIP) 
followed by qRT-PCR was performed. Enhanced production after 4 hours of IL-12 
stimulation was observed after 5 but not 2 days of chronic GC treatment (Figure 7B); 
therefore, a comparison of the epigenetic patterns at cytokine regulatory regions (the 
promoter and -22KB enhancer region of the IFNG locus, and the IL6 promoter) was 
performed.  The levels of 6 histone modifications, referred to as the epigenetic pattern, 
in a particular region for untreated cells in comparison to chronic GC treated cells is 
presented in Figure 10.  ChIP analysis demonstrated that in untreated cells all three 
regions exhibited moderate H4K8Ac, H3K27Ac, and H3K4me3; low but detectable 
H3K9Ac and H3K27me3; and undetectable/below background H3K9me3 levels.  This 
epigenetic pattern is indicative of a poised promoter region defined as a gene able to be 
expressed in a specific cell lineage (undetectable H3K9me3 and H3K27me3) and poised 
for future transcription, moderate H3K9Ac and H3K27Ac [239]. The IFNG enhancer, 
which is critical for IFNG transcription[70,72], exhibited a significant increase in H3K4-
trimethylation (me3) at day 2 of GC treatment (grey bars) (Figure 10A).  However, at 
day 5 of chronic GC treatment (dark grey bars) the IFNG enhancer had similar levels of 
H3K4me3 as untreated but did exhibit increased H4K8Ac as well as a time dependent 
increase in H3K27Ac (Figure 10A). This pattern of acetylation for H4K8 and H3K27  
75 
  
 
  
Figure	  10.	  Histone	  modifications	  at	  NK	  proinflammatory	  regulatory	  regions.	  	  Schematic	  diagrams	  and	  percent	  input	  calculations	  of	  posttranslational	  histone	  modifications	  at	  the	  (A)	  IFNG	  enhancer,	  (B)	  IFNG	  promoter,	  and	  (C)	  the	  IL6	  promoter	  after	  day	  2	  (grey	  bars)	  and	  day	  5	  (dark	  grey	  bars)	  of	  chronic	  glucocorticoid	  treatment	  or	  in	  untreated	  cells	  (white	  bars)	  compared	  to	  the	  IgG	  (black	  bars)	  negative	  control	  immunoprecipitations.	  	  Untreated	  values	  are	  the	  average	  of	  the	  levels	  of	  each	  modification	  on	  both	  day	  2	  and	  day	  5	  from	  untreated	  cultures	  as	  no	  difference	  in	  the	  levels	  over	  time	  was	  observed.	  n=6	  ±	  SEM	  *;	  p<0.05.	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corresponded to the enhanced IFN-g production and secretion following chronic GC 
treatment and IL-12 stimulation (Figure 7A-C).  No GC treatment effects were observed 
at the proximal promoter of IFNG (Figure 10B) or the TNF-alpha promoter (Figure 
10D). The IL6 promoter exhibited a similar chronic GC dependent change in histone 
modification as the IFNG enhancer; increased H3K4me3 at day 2 of GC treatment (gray 
bars) and after 5 days of treatment (dark gray bars) H4K8Ac was significantly increased 
as well as a time dependent increase in H3K27Ac (Figure 10C).  These changes 
corresponded with the two fold increase in IL-6 production following chronic GC 
treatment and IL-2 stimulation (Figure 7D).  These data indicate that proinflammatory 
gene regulatory regions become hyperacetylated following chronic GC treatment and 
that acetylation of histone proteins contributes to the enhanced proinflammatory 
cytokine production following cellular activation.  
 
Chronic GC induced histone modifications at lytic molecule regulatory regions 
 
 The regulatory regions of the granule constituents exhibited a different 
epigenetic pattern compared to the cytokine loci in untreated NK92 cells, demonstrating 
high H4K8Ac, H3K9Ac, H3K27Ac, and H3K4me3 while H3K9me3 and H3K27me3 
were at or below background (IgG) levels (Figure 11A-B).  This pattern is indicative of 
genes undergoing active transcription (high H3K9Ac and H3K27Ac) with no 
heterochromatin marks (H3K9me3 and H3K27me3) [131,138,239]. The perforin 
(PRF1) promoter after 5 days of chronic GC treatment (dark grey bars) exhibited  
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Figure	  11.	  Histone	  modifications	  present	  at	  NK	  cell	  granule	  constituent	  
regulatory	  regions.	  	  Schematic	  diagrams	  and	  percent	  input	  calculations	  of	  posttranslational	  histone	  modifications	  at	  the	  (A)	  proximal	  promoter	  of	  the	  PRF1	  gene	  and	  the	  (B)	  proximal	  promoter	  of	  the	  GZMB	  gene	  after	  day	  2	  (grey	  bars)	  and	  day	  5	  (dark	  grey	  bars)	  chronic	  glucocorticoid	  treatment	  or	  untreated	  (white	  bars)	  cultures	  compared	  to	  the	  IgG	  (black	  bars)	  negative	  control	  immunoprecipitation.	  	  Untreated	  values	  are	  the	  average	  of	  the	  levels	  of	  each	  modification	  on	  both	  day	  2	  and	  day	  5	  from	  untreated	  cultures	  as	  no	  difference	  in	  the	  levels	  over	  time	  was	  observed.	  	  Data	  represents	  the	  average	  of	  three	  independent	  experiments	  performed	  in	  duplicate	  n=6	  ±	  SEM	  *;	  p<0.05. 
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significantly reduced H3K9Ac, marking this region for reduced transcription 
corresponding with the reduction in perforin transcripts shown previously (Figure 11B 
and 8B).  A trend for reduced H3K9Ac was observed at day 2 of GC treatment and was 
significant at day 5 of treatment, which is consistent with the gradual time dependent 
reduction in NKCA (Figure 11A and 8A).  The proximal promoter of the granzymeB 
(GZMB) gene exhibited a similar pattern as the PRF1 promoter for untreated cells, and 
including a significant reduction in H3K9Ac at day 5. Additionally, the GZMB promoter 
demonstrated a decrease in H4K8Ac (Figure 11B).  Furthermore, H3K4me3 was 
reduced at day 2 but returned to untreated levels at day 5 of chronic GC treatment.  The 
decrease in the active transcriptional mark H3K9Ac corresponded with the reduction in 
granzyme B mRNA after chronic GC treatment (Figure 8B).  These data together 
suggest that chronic GC decreases NKCA at least in part through epigenetic 
modifications that result in the transcriptional repression of these two granule 
constituents. 
 
Chronic GC induce changes in chromatin accessibility  
 
 Hyperacetylation has been shown to increase the accessibility of regulatory regions 
and to enhance the transcription of genes upon cellular activation. Chromatin from 5 day 
chronic GC treated and untreated cells was subjected to nuclease digestion or left 
undigested and qRT-PCR was used to quantify the degree to which each regulatory 
region was resistant to digestion compared to GAPDH, a constitutively open and  
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Figure	  12.	  	  Effect	  of	  chronic	  GC	  treatment	  on	  chromatin	  accessibility	  and	  
RNApol	  II	  deposition.	  (A)	  Percent	  change	  in	  sensitivity	  of	  indicated	  genomic	  regions	  to	  nuclease	  digestion	  as	  determined	  by	  the	  Bio-­‐Rad	  EpiQ	  chromatin	  accessibility	  kit.	  	  Accessibility	  is	  calculated	  as	  the	  ability	  of	  nuclease	  to	  digest	  indicated	  regions	  setting	  GAPDH	  accessibility	  as	  100%	  in	  untreated	  (white	  bars)	  and	  5	  day	  chronic	  GC	  treated	  cells	  (black	  bars).	  (B)	  Percent	  input	  calculation	  for	  RNApol	  II	  deposition	  at	  NK	  cell	  effector	  genes	  after	  day	  5	  (dark	  grey	  bars)	  chronic	  GC	  treatment	  or	  untreated	  (white	  bars)	  cultures	  compared	  to	  the	  IgG	  (black	  bars)	  negative	  control	  immunoprecipitation.	  	  Untreated	  values	  are	  the	  average	  of	  the	  levels	  of	  each	  modification	  on	  both	  day	  2	  and	  day	  5	  from	  untreated	  cultures	  as	  no	  difference	  in	  the	  levels	  over	  time	  was	  observed.	  Data	  represent	  the	  average	  of	  three	  independent	  experiments	  performed	  in	  duplicate	  n=3	  ±	  SEM	  *;	  p<0.05. 
 
 
 
 
 
 
 
!"
#"
$"
%"
&"
'"
("
)"
!"#$% &'()% **+)% ,#-&% ,./% 0-#%
*+
,-
+.
/"
0.
12
/"
34516700"8+169:;6."
0<=" >./,+?/+@" AB,6.:-"=A"
)%1%
!C"
$!C"
&!C"
(!C"
D!C"
#!!C"
#$!C"
=5*8E" =FGH" 0IJ(" J$$KH"
*+
,-
+.
/"
5
--
+9
9:
L:
7:/
M"
AB,6N?;."5--+99:L:7:/M"
>./,+?/+@" AB,6.:-"=A"
2% 2% 2%
2% 2%
O:<2,+"#$P"QR+-/"6S"-B,6.:-"=A"/,+?/N+./"6."-B,6N?;."?--+99:L:7:/M"?.@"34516700",+-,2:/N+./P%
80 
  
transcribed gene. Chronic GC treatment increased the accessibility of the IL6 promoter 
by 18% and increased the accessibility of the IFNG enhancer by 37% (Figure 12A).  As 
no increase in transcription was observed prior to activation (Figure 7C) it is likely that 
this increased accessibility is the result of the hyperacetylation of proinflammatory 
cytokine regulatory regions (Figure 10A and C) which primes NK cells for enhanced 
cytokine production when stimulated.  Analysis of the GZMB promoter yielded no 
significant difference in accessibility (Figure 12A).  Although GZMB transcripts were 
diminished and the GZMB promoter exhibited decreased histone acetylation, chronic GC 
treatment did not appear to alter the chromatin structure, suggesting that granule 
constituent regulatory regions are affected by GC in a manner different from cytokine 
regulatory regions. 
 The changes in histone acetylation and chromatin accessibility, as well as the 
enhanced transcription of cytokine regulatory regions upon cellular stimulation 
prompted investigation into the depostition of RNApol II at these loci.  ChIP 
demonstrated a quantitative increase in RNApol II deposition at the IL6 promoter and 
IFNG enhancer after chronic GC treatment compared to untreated cells (Figure 12B).  
No changes were observed in cytokine loci (i.e. IFN-g and TNF-alpha promoters) that 
did not exhibit changes in histone acetylation upon chronic GC treatment.  A significant 
decrease in RNApol II deposition was observed at the GZMB promoter which is in 
accordance with the significant decrease in transcripts following chronic GC treatment.  
Lastly, a significant increase in RNApol II deposition was observed at the PRF1 
promoter in chronic GC treated cells.  The increased deposition of RNApol II at the 
cytokine regions without any increase in basal cytokine production implys that increase 
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represents stalled RNApol II at these loci.  Again the granule constituents seem to be 
regulated in a different manner than the cytokine loci after chronic GC treatment.   
 
Chronic GC induced effects on histone deacetylases (HDACs) 
 
Histone acetylation is mediated by two classes of enzymes, histone 
acetyltransferases and histone deacetylases (HDACs).  Modulation of these enzymes 
impacts gene transcription and cellular function [140,240,241].  GR can interact with 
members of the class I HDAC family[118,145], HDAC2[146] and HDAC3[147].  
Therefore, the presence of HDACs 1, 2, and 3 at NK cell effector genes was assessed by 
ChIP. Both the IL6 promoter and the IFNG locus had detectable levels of all 3 HDACs 
in untreated (white bars) cells (Figure 13A and B).  At both day 2 and day 5 of chronic 
GC treatment the level of resident HDAC3 was significantly decreased at the IFNG 
enhancer and the IL6 promoter (Figure 13A and B). Additionally, the level of HDAC1 at 
both the IFNG enhancer as well as the IL6 promoter was significantly decreased after 5 
days (black bars) of chronic GC treatment compared to untreated cells (Figure 13A and 
B).  Thus chronic GC treatment resulted in significant reductions in both HDAC1 and 
HDAC3 at the IFNG enhancer and IL6 promoter corresponding to the increase in 
histone acetylation and accessibility previously observed (Figure 10A and C).  These 
data imply that the hyperacetylation and increased chromatin accessibility observed at 
proinflammatory cytokine regulatory regions following chronic GC treatment is at least 
in part due to reductions in resident HDACs at these loci. The PRF1 and GZMB 
promoter regions had extremely low but detectable levels of HDAC1 and moderate  
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Figure	  13.	  Class	  I	  histone	  deacetylase	  (HDAC)	  deposition	  at	  NK	  cell	  effector	  
gene	  loci.	  	  Schematic	  diagrams	  and	  percent	  input	  calculations	  of	  HDAC1,	  2,	  and	  3	  deposition	  at	  the	  (A)	  IFNG	  enhancer,	  (B)	  IL6	  promoter,	  (C)	  PRF1	  promoter,	  and	  (D)	  
GZMB	  promoter	  after	  day	  2	  (grey	  bars)	  and	  day	  5	  (dark	  grey	  bars)	  chronic	  glucocorticoid	  treatment	  or	  untreated	  cultures	  (white	  bars)	  compared	  to	  the	  IgG	  (black	  bars)	  negative	  control	  immunoprecipitation.	  Untreated	  values	  are	  the	  average	  of	  the	  levels	  of	  each	  modification	  on	  both	  day	  2	  and	  day	  5	  from	  untreated	  cultures	  as	  no	  difference	  in	  the	  levels	  over	  time	  was	  observed.	  	  Data	  represents	  the	  average	  of	  three	  independent	  experiments	  performed	  in	  duplicate	  n=6	  ±	  SEM	  *;	  p<0.05.	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levels of HDAC2 as resident HDACs in untreated cells (white bars) (Figure 13C and D).  
After day 2 of chronic GC treatment there was a significant increase in the presence of 
both HDAC1 and HDAC2 at both the PRF1 and GZMB promoters that returned to initial 
levels by day 5 (Fig 13C and D).  Increased HDAC1 and HDAC2 deposition after GC 
treatment corresponded to the decreased histone acetylation observed during chronic GC 
treatment (Figure 11A and B).  Together these data demonstrate that chronic GC 
exposure decreased the deposition of HDAC1 and HDAC3 at proinflammatory cytokine 
regulatory regions increasing acetylation and accessibility for enhanced cytokine 
production following stimulation.  In contrast, chronic GC treatment increased HDAC1 
and HDAC2 deposition at lytic molecule regulatory regions at day 2 of treatment 
decreasing histone acetylation at day 5 of GC treatment, which ultimately reduced 
NKCA. 
 
Class I HDAC subcellular redistribution during chronic GC treatment 
 
To investigate class I HDAC genomic deposition, the levels and subcellular 
distribution of these enzymes was assessed using cytometric and microscopic techniques.  
Representative histograms of flow cytometric analysis of cellular HDAC protein 
levelsafter 5 days of chronic GC treatment revealed that HDAC1 and HDAC2 protein 
levels remained unchanged (Figure 14A, left and middle panels).  In contrast, HDAC3 
staining was markedly reduced after 5 days of chronic GC treatment compared to 
untreated cells (Figure 14A, right panel).  Quantitation of the relative MFIs for HDAC1, 
2, and 3 at both day 2 and day 5 of chronic GC treatment revealed no change in either  
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Figure	  14.	  Class	  I	  HDAC	  levels	  and	  subcellular	  distribution	  following	  chronic	  
glucocorticoid	  treatment.	  	  	  (A)	  Representative	  histograms	  of	  HDAC1,	  HDAC2,	  and	  HDAC3	  staining	  in	  5	  day	  chronic	  GC	  treated	  and	  untreated	  cells.	  (B)	  Percent	  change	  in	  HDAC1,	  2,	  and	  3	  MFI	  after	  day	  2	  and	  day	  5	  of	  chronic	  GC	  treatment.	  	  The	  MFI	  of	  each	  molecule	  in	  untreated	  cells	  is	  set	  to	  100%.	  (C)	  Representative	  confocal	  pictures	  of	  HDAC1,	  2,	  and	  3	  cellular	  staining	  in	  untreated	  and	  chronic	  (5	  day)	  GC	  treated	  cells.	  (D)	  Representative	  histogram	  of	  phosphorylated	  HDAC2	  in	  untreated	  and	  chronic	  GC	  treated	  cells	  harvested	  and	  analyzed	  by	  flow	  cytometry	  at	  day	  2.	  (E)	  Quantification	  of	  phospho-­‐HDAC2	  in	  untreated	  and	  chronic	  GC	  treated	  cells	  at	  day	  2	  and	  day	  5	  where	  the	  MFI	  of	  phospho-­‐HDAC2	  in	  untreated	  cells	  is	  set	  to	  1.	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Figure	  15.	  Chronic	  GC	  induced	  HDAC2	  nuclear	  localization	  .	  (A)	  	  Graphs	  showing	  the	  similarity	  dilate	  (nuclear	  localization)	  of	  DAPI	  and	  HDAC2	  from	  untreated	  and	  chronic	  GC	  treated	  cells	  harvested	  at	  day	  2.	  (B)	  Quantification	  of	  similarity	  dilate	  (nuclear	  localization)	  medians	  from	  three	  independent	  experiments	  comparing	  the	  similarity	  of	  DAPI	  and	  HDAC2	  signals	  in	  chronic	  GC	  treated	  or	  untreated	  cells	  harvested	  at	  day	  2	  of	  treatment.	  (C)	  Representative	  images	  of	  multispectral	  flow	  cytometry	  used	  for	  nuclear	  localization	  analysis. 
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HDAC1, 2, or 3 after 2 days of chronic treatment but a GC specific decrease in HDAC3 
levels at day 5 (Figure 14B). Fluorescence microscopy confirmed that HDAC3 staining 
decreased after 5 day chronic GC treatment confirming the flow cytometry data (Figure 
14C, lower panel).  Chronic GC treatment induced a subcellular redistribution of both 
HDAC1 and HDAC2.  After 5 days of chronic GC treatment HDAC1 exhibited a more 
intense cytoplasmic (Figure 14C, upper panel).  Conversely, HDAC2 appeared to have 
an increase in nuclear staining after 5 days of chronic GC treatment (Figure 14C, middle 
panel).  Phosphorylation of HDAC2 at serine 394 is associated with nuclear localization 
and enzymatic activity [242].  Using flow cytometry we measured the levels of 
phosphorylated HDAC2 at both day 2 and day 5 of chronic GC treatment as a measure 
of relative nuclear localization. A representative histogram of phospho-HDAC2 staining 
from day 2 of chronic treatment reveals the increase in phospho-HDAC2 MFI in chronic 
GC treated cells (Figure 14D). In accordance with the apparent increase in nuclear 
staining, quantification of the MFI of phospho-HDAC2 staining demonstrated increased 
levels of phospho-HDAC2 at both day 2 and day 5 of chronic GC treatment (Figure 
14E).  Using multispectral flow cytometry of individual cells, HDAC2 nuclear 
localization was assessed.  Nuclear localization was defined by a positive 
similarityindex (co-localization), indicating the correlation coefficient between the two 
fluorescent signals: that of the nuclear dye DAPI and that of HDAC2 as a measure of 
nuclear localization.  Untreated cells had a positive similarity index of 1.62 indicating 
that HDAC2 is both nuclear and cytoplasmic in untreated NK92 cells (Figure 15A, left 
panel).  This is in comparison to the 3.5 similarity index of NK92 cells harvest at day 2 
of GC treatment (Figure 15A, right panel).  Figure 15B represents the quantification of 
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the similarity index of nuclear localization of HDAC2 from untreated and 2 day chronic 
GC treated cells.  Representative images used for quantification of nuclear HDAC2 
following chronic GC treatment from the AMNIS Image Stream and IDEAS software 
analysis are presented in Figure 15C.  The first column shows DAPI, channel 01, 
staining in two representative cells from both untreated and 2 day GC treated cells.  The 
second column, channel 02, illustrates HDAC2 staining and the third column, 
channel01/channel02, the merged images.  The data demonstrate that chronic GC 
treatment increased nuclear HDAC2 at day 2 which continues throughout treatment.  
These data provide insight into the decreased acetylation and increased HDAC2 present 
at the PRF1 and GZMB regulatory regions following chronic GC treatment.  These 
results implicate the redistribution of HDAC 1 and 2 and the loss of resident HDAC3 to 
result in the changes observed in acetylation status of individual regulatory regions of 
NK effector genes after chronic GC treatment. 
 
Regulation and role of GR after chronic GC treatment 
 
GC have been shown to reduce the sensitivity of the glucocorticoid receptor (GR), 
making it unresponsive to subsequent high anti-inflammatory concentrations of GC 
[243].  Flow cytometry demonstrated no change in GR MFI at day 2 or day 5 of chronic 
GC treatment of NK92 cells when compared to untreated cells.  A representative 
histogram is shown in Figure 16A and quantification of GR MFI in Figure 16B, with 
untreated cells set to 100%.  To assess the functional activity of GR in NK cells 
following 5 days  
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Figure	  16.	  Effect	  of	  chronic	  GC	  treatment	  on	  GR	  signaling.	  	  (A)	  Representative	  histogram	  of	  GR	  protein	  levels	  in	  untreated	  and	  chronic	  GC	  treated	  NK92	  cells	  assessed	  by	  flow	  cytometric	  analysis.	  	  (B)	  Quantification	  of	  MFI	  from	  flow	  cytometric	  analysis	  of	  GR	  levels	  in	  cells	  harvested	  at	  day	  2	  and	  day	  5	  from	  untreated	  and	  chronic	  GC	  treated	  cultures	  where	  the	  MFI	  of	  untreated	  cells	  is	  set	  to	  100%.	  	  	  (C)	  IFN-­‐g	  production	  from	  untreated	  (black	  bars)	  and	  chronic	  GC	  (white	  bars)	  treated	  cells	  with	  a	  subsequent	  addition	  of	  4hr	  treatment	  with	  high	  concentration	  of	  dexamethasone	  (10-­‐7M)	  (switch	  to	  -­‐7)	  during	  a	  4	  hour	  stimulation	  with	  IL-­‐12.	  (D)	  Lytic	  activity	  of	  NK92	  cells	  after	  5	  day	  chronic	  GC	  treatment	  or	  left	  untreated	  in	  the	  presence	  of	  RU-­‐486	  (10-­‐10M)	  throughout	  treatment.	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of chronic GC treatment, cells were exposed to a high concentration of GC (10-7M) 
during the 4 hours of IL-12 stimulation.  Figure 16C demonstrates that when cells were 
exposed to 10-7M GC the untreated and 5 day chronic GC treated NK92 cells 
wereequally reduced in their capacity to produce IFN-g when stimulated with IL-12.  
Addition of 10-10M RU-486, a GR antagonist, throughout the 5 days of chronic GC 
treatment was able to reverse the GC dependent reductions in NKCA (Figure 16D).  In 
contrast, RU-486 did not restore IFN-g production to untreated levels. NK92 cells 
cultured in the presence of RU-486 through the 5 day chronic GC treatment, exhibited a 
numerical increase in IFN-g MFI (Figure 17A, white bars).  Flow cytometric analysis of 
HDAC3 MFI within chronic GC treated NK92 cells cultured in the presence of both 
RU-486 and chronic GC exhibited an even greater decrement in HDAC3 levels (Figure 
17A, black line) and was inversely related to the production of IFN-g.  When analyzed 
by co-immunoprecipititation, GR was demonstrated to directly interact with HDAC3 
(Figure 17B). Taken together these data suggest that the effects on NKCA and on IFN-g 
production are via separate and distinct mechanisms.  
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Figure	  17.	  Interaction	  between	  HDAC3	  and	  GR	  pathways.	  	  (A)	  MFI	  of	  IFN-­‐g	  (white	  bars)	  and	  MFI	  of	  HDAC3	  (black	  line)	  in	  NK92	  cells	  with	  and	  without	  chronic	  GC	  treatment	  in	  the	  presence	  or	  absence	  of	  RU-­‐486	  (10-­‐10M),	  harvested	  and	  analyzed	  on	  5	  day	  of	  treatment.	  	  (B)	  Anti-­‐IgG	  or	  anti-­‐HDAC3	  immunoprecipitations	  were	  performed	  on	  total	  cell	  extracts	  from	  4	  hour	  dexamethasone	  	  (10-­‐7M)	  treated	  or	  untreated	  NK92	  cells	  followed	  by	  anti-­‐GR	  (upper	  panel)	  or	  anti-­‐HDAC3	  (lower	  panel)	  Western	  blots. 
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Proposed Model for the effects of chronic GC treatment on NK92 cells 
 
A model for the dichotomous effect of GC on NK cell effector function (Figure 
18).  After 2 days of GC treatment, increased levels of HDAC2 were observed in the 
nucleus (Figure 14E - 15) with HDAC 2 detected at the promoter regions of both PRF1 
and GZMB (Figure 13C-D).  After 2, 4 and 5 days of GC treatment, transcription of 
perforin and granzyme B were reduced, with concomitant reductions NK cell cytolytic 
activity (Figure 8A-B).  After 2 days of GC treatment no significant change in the 
acetylation status of either promoter regions was noted, however, a slight reduction in 
H3K9Ac was noted at day 2 and by day 5 of GC treatment, significant reductions in 
H3K9Ac were identified (Figure 11A and B), suggesting that acetylation status may 
relate to the maximal reductions in perforin and granzyme B levels as well as maximal 
reductions in NK cell cytolytic activity at day 5 of GC treatment.  In contrast, the 
acetylation status of the enhancer region of IFNG and the promoter region of IL6 was 
increased upon 5 days of chronic GC treatment (Figure 10A and C). This increase in 
acetylation was associated with a decrease in overall cellular levels of HDAC3 (Figure 
14A-B), relocalization of HDAC1 to the cytoplasm (Figure 14C), and with reduced 
HDAC1 and HDAC 3 at the IFNG enhancer and the IL6 promoter (Figure 13A and B).  
These epigenetic modifications coincided with increased transcription and protein levels 
of these proinflammatory cytokines when NK cells were stimulated (Figure 7A-C), 
suggesting that reduced occupancy by HDACs and increased acetylation status relate to 
priming of these promoters regions for increased transcription of these genes with 
cellular stimulation.  
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Figure 18. Proposed Model for the effects of chronic GC effects on NK92 cells 
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Analysis of ex vivo derived PBMC from women diagnosed with  
 
Introduction 
Breast cancer diagnosis results in increased stress, anxiety, fear, as well as mood 
and sleep disturbance[164,165,166,167,168,169,244].  Psychological distress reduces 
NKCA, the response of NK cells to cytokines, IFN-g synthesis, antibody responses, as 
well as T-lymphocyte responses[202,203,204,205].  We have shown that the diagnosis 
of breast cancer results in significant psychosocial distress in women which is 
accompanied by altered NKCA and cytokine production[202,203].  The effect of 
psychological distress on NK cells has been particularly attributed to stress-induced 
activation of the hypothalamic-pituitary-adrenocortical (HPA) axis [245].  Individuals 
experiencing chronic psychological distress exhibit HPA dysregulation resulting in 
altered glucocorticoid (GC) levels[202,203] and disruption of the diurnal cortisol rhythm 
[162,179].  The effects of GC have been readily demonstrable in peripheral blood 
mononuclear cells (PBMC)[246] and are primarily due to GC action at the 
transcriptional level.  Our in vitro data demonstrate that chronic exposure to GC 
dichotomously regulates the phenotypic profile of NK cells (See Figures 7-8). Chronic 
exposure to GC resulted in increased pro-inflammatory cytokine production upon 
stimulation which was associated with increased histone acetylation in critical regulatory 
loci.  Furthermore chronic exposure to GC reduced NKCA and was associated with 
decreased histone acetylation at regulatory regions for lytic molecules.  These in vitro 
findings were used to test hypotheses regarding the relationships between psychological 
stress, glucocorticoid production, and immune function using the diagnosis of breast  
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Figure 19.  Subject Enrollment Time Line.  Each arrow denotes a time period for 
psychological assessment, immunologica, and epigenetic analysis.  Salivary cortisol 
assessment occurred 2 days prior to blood draw (not shown). 
 
 
 
 
 
 
 
Time 1: 
After breast biopsy 
and diagnosis, but 
before treatment. 
Time 2: 
After surgery, but 
before radiation 
Surgery +/-Radiation 
Time 3: 
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Approximately 8 
months after 
diagnosis 
2 weeks 4 months 2 months 1.5 months 
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Table 5. Demographic characteristics of individuals enrolled in human study 
SD= standard deviation. a=missing data for some women in cohort; answers were 
omitted and no imputation technique was used for missing data. *p=0.05, p value for 
Cancer v. Cancer Free. 
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cancer as a model of psychological stress.  I sough to determine whether the immune 
alterations during periods of stress could mechanistically be explained through 
epigenetic modifications.  Therefore, the acetylation patterns at proinflammatory 
cytokine regulatory regions were assessed in women as they respond to the diagnosis of 
breast cancer in order to understand whether these epigenetic patterns related to stress, 
cortisol levels, and immune function.    
 
Analysis of psychological assessments across timepoints 
 
Women diagnosed with ductal carcinoma in situ (DCIS) and a matched control 
group were enrolled in the study.  Enrollment criteria are outlined in Materials and 
Methods.  Demographics, disease, and treatment characteristics are summarized in Table 
5.  Study participants were evaluated longitudinally at 4 time points (T1-T4, Figure 19). 
The Perceived Stress Scale (PSS), a measure of the general appraisal of stress, and the 
Centers for Epidemiologic Studies-Depression Scale (CES-D), a measure of depressive 
mood, were used for psychological assessments at each timepoint. The mean, standard 
deviation, range, and distribution of both perceived stress and depressive mood across 
all timepoints were analyzed between the cancer and cancer free groups and are 
presented in Table 6.  Women in the Cancer group had increased PSS scores compared 
to the Cancer Free group at T1 (T1; p<0.001). These increases in PSS were evident at T2, 
T3, and T4 (Figure 20A). These results indicate that the perceived stress of breast cancer 
diagnosis is greatest at T1 and T2 at diagnosis and prior to radiation therapy, 
respectively.  However, the perceived stress of breast cancer diagnosis is still elevated 4  
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Figure 20.  Psychological Assessments across timepoints.  Global appraisal of (A) 
stress as measured by the perceived stressor scale (PSS) and (B) depressive mood as 
measured by the Centers for Epidemiologic Studies-Depression Scale (CES-D)  at T1-
T4 for Cancer and Control groups.  Values are presented in box plots where the black 
line represents the median and the tinted area box represents 50% (quartile) of the data 
set.  The whiskers represent the upper 25% and lower 25% of the data set. Open circles 
represent outliers. *=p,0.05, **=p<0.01, Cancer vs. Cancer Free.  T1= T2= T3= T4=.  
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Table 6. Comparison of psychological parameters across timepoints. 
Data are mean values ± S.E.M. p value for Cancer v. Cancer Free.  
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and 8 months after diagnosis, T3 and T4, respectively. Women diagnosed with breast 
cancer also exhibited increased levels of depressive mood as measure by CES-D at T1 
(Figure 20B), which continued to T2 but returned to levels equivalent to the Cancer Free 
group at both T3 and T4 (Figure 20B).  The range (0-35) and normal distribution (black 
line) in PSS scores at T1 of all individuals enrolled in the study is shown in histogram 
form (Figure 21A).  Separation of the Cancer and Cancer Free groups demonstrates that 
the Cancer group alone exhibits a large range in PSS scores (0-35) and normal Gaussian 
distribution (black line)(Figure 21B, top panel).  The Cancer Free group exhibits a 
smaller range in PSS scores (0-29) and a positively skewed distribution (Figure 21B, 
bottom panel). Although PSS scores were significantly different between the cancer and 
cancer free groups at T1, the distribution demonstrated that 37% of the women in the 
cancer free group reported perceived stressor scores above a score of 14 indicated by 
vertical black line (Figure 21B, bottom panel). CES-D scores for all individuals 
recruited are present in histogram form (Figure 21C).  CES-D scores exhibited a large 
range (0-38) but a positively skewed distribution (Figure 21C). Separation of the Cancer 
and Cancer Free groups demonstrates that the Cancer group alone exhibits a large range 
in CES-D scores (0-38) and normal Gaussian distribution (black line)(Figure 21D, top 
panel).  The Cancer Free group exhibits a smaller range in CES-D scores (0-26) and a 
positively skewed distribution (Figure 21D, bottom panel). The mean difference in 
perceived stress and depressive mood was greatest at T1; therefore, timepoint 1 (T1) was 
used to evaluate the stress induced immune alterations and potential epigenetic 
mechanism(s) involved. 
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Figure 21.  Distribution analysis of psychological parameters at T1.  (A) Histogram 
representing the range and distribution of PSS scores among all individuals at T1. (B) 
Histograms representing the range and distribution of PSS scores within the Cancer 
(upper panel) and Cancer Free (lower panel) groups.  (C) Histogram representing the 
range and distribution of CES-D scores within all individual at T1. (D) Histograms 
representing the range and distribution of CES-D scores within the Cancer (upper panel) 
and Cancer Free (lower panel) groups. 
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Comparison of the Cancer and Cancer Free Groups at T1 
 
We have published that the diagnosis of breast cancer results in significant 
psychosocial distress in women which is accompanied by altered NKCA and cytokine 
production [202,203].  In this study we reconfirm our previous findings demonstrating 
that the diagnosis of breast cancer results in significant psychological distress as 
measure by elevated PSS and CES-D scores (Figure 20A and B).  The differences in 
immune function between the cancer and cancer free groupings at T1 were investigated 
using a Student’s two-tailed T-test.  Analysis of NKCA from ex vivo derived PBMC 
standardized to the percent of CD56+ NK cells exhibited no significant differences 
between the cancer and cancer free groups (Figure 22A).  Analysis of IFN-g and IL-6 
production from ex vivo stimulated PBMC yielded no significant differences between 
the cancer and cancer free groups (Figures 22B and C). The effect of psychological 
distress on NK cells has been particularly attributed to stress-induced activation of the 
hypothalamic-pituitary-adrenocortical (HPA) axis [245]. Thus comparison of the 
immune regulation by stress could not be attained through comparison of the cancer and 
cancer free groups in part due to the large percentage (37%) of women in our cancer free 
group with elevated perceived stressor scale (PSS) scores.    
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Figure 22.  Analysis of biological parameters between Cancer and Cancer Free 
groups. Values are presented in box plots where the black line represents the median 
and the tinted area box represents 50% (quartile) of the data set.  The whiskers represent 
the upper 25% and lower 25% of the data set. Open circles represent outliers. *=p,0.05, 
**=p<0.01, Cancer vs. Cancer Free.   
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Comparison of high, intermediate, and low stress groups 
 
In order to investigate the immune phenotypes associated with psychological 
distress and the mechanisms mediating these immune changes, a tertile split on the 
entire cohort of women enrolled at T1 was performed, creating equal groups based on 
their PSS scores, independent of cancer diagnosis.  Binning produced three groups; 
PSS<=14 (low stress), PSS 15-21 (intermediate stress), PSS>=22 (high stress) (Figure 
23A).  Individuals experiencing psychological distress exhibit HPA dysregulation 
resulting in altered glucocorticoid (GC) levels[202,203] and disruption of the diurnal 
cortisol rhythm [162,179].  Comparison of diurnal cortisol levels for these three groups 
demonstrated those individuals with higher perceived stress to have significantly higher 
daily cortisol levels than those with lower perceived stress (Figure 23B).  Individuals 
with intermediate stress exhibited numerically elevated cortisol levels compared to those 
with low perceived stress but less than those with higher perceived stress (Figure 23B).  
Thus perceived stress is associated with activation of the HPA axis. 
Abundant evidence demonstrates that psychological stress precipitates alterations 
in immune function.  Therefore, a comparison of immune function between individuals 
who exhibit high and low perceived stress was performed using a Student’s two-tailed t-
test. Analysis of supernatants from ex vivo derived PBMC stimulated for 48 hour with 
PMA/PHA by ELISA revealed increased IFN-g production in individuals who exhibit 
high stress compared to low stress (Figure 23C).  Individuals who exhibited high stress 
also displayed increased circulating IL-6 levels in plasma compared to individuals with 
low stress as measured by ELISA (Figure 23D).  Analysis of NK cell lytic  
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Figure 23. Analysis of biological parameters between high, intermediate, and low 
stress groups.  (A) Histogram representing the distribution of PSS scores indicating 
cutoffs (vertical lines) for tertile splits of low, intermediate, and high scores.  Boxplots 
representing differences in (B) AUC, (C) IFN-g production, (D) plasma IL-6 levels, and 
(E) NKCA standardized to CD56% in the PBMC from individuals in the low, 
intermediate, and high PSS groups. Values are presented in box plots where the black 
line represents the median and the tinted area box represents 50% (quartile) of the data 
set.  The whiskers represent the upper 25% and lower 25% of the data set. Open circles 
represent outliers. A student’s two-tailed t-test was used for comparison. *=p<0.05. 
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function demonstrated that individuals with high stress exhibited decreased NKCA 
standardized to the percent CD56+ in ex vivo derived PBMC compared to low stress 
individuals (Figure 23E).   
These observations demonstrate that individuals grouped by their perceived 
stress scores exhibit increased daily cortisol production.  Increased daily cortisol 
production indicates that individuals with increased perceived stress exhibit a 
corresponding increase in HPA activity.  Individuals with increased perceived stress also 
exhibited altered immune function characterized by increased proinflammatory cytokine 
production and decreased NKCA.  We hypothesize that this dichotomous immune 
phenotype occurs via the overactivity of the HPA activity observed.  Therefore to more 
clearly delineate that the observed immune phenotypes result from the biological 
manifestation of stress of increased activity of the HPA axis individuals were reclustered 
by their perception of stress and biological output.      
 
Categorization of Individuals based on PSS scores and Daily Cortisol Levels  
 
Individual responses to the diagnosis of breast cancer are varied and although 
individuals report increased perceived stress many physiological and social factors can 
impact the biological output of this psychological stress.  Wards Method of Cluster 
Analysis was used to statistically classify the women based on their perceived stress 
(PSS) and daily cortisol levels (AUC) into distinct clusters based on the Euclidean mean 
squared distance. This classification allowed categorization of the women based on both 
their perception of the stress as well as the associated biological response to stress, i.e.  
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Figure 24. Wards Method of Classification by PSS and Cortisol Rhythms.  (A) A 
dendogram representing the Euclidean mean squared distance between patients 
classified by their PSS scores and AUC levels. (B) Scatterplot of PSS scores and AUC 
levels representing the groups created using the Wards Method of cluster analysis  
????????????????????
????????????????????
??????????????????????
??????????????????????
??????????????????????
????????????????????????
????????????????????????
????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
????????????????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????????????
??????????????????????
??????????????????????
??????????????????????
??????????????????????
??????????????????????
??????????????????????
????????????????????
????????????????????
????????????????????
????????????????????
????????????????????
????????????????????
????????????????????
????????????????????
????????????????????
?????????????????????
?????
?????????????????????????????? ?????????????????????????????????????????????
??? ????????????????
??????????????????????????
??? ?????? ???
??? ??????????????
???????????????
?????????????????
??????????????????????????
?????????????????????
???????
?????
?????????????? ???????????????????????
????????
????? ???? ?????????????????????? ???????? ???????????????????????
?????????????
?????????????? ????????
?????? ??????
?????? ??????
?????????? ??????
????????????? ???????????
???? ??
?????????????????????? ?????????????? ?????? ????????????? ????????????????????????????? ???????
?????????? ?????????????????????????????????????? ?????????????????????
??????????????
?????? ????????????????????????
? ?????? ???
? ??????????????
?????????????
???????????????
????????????????????????
???????????????????
????????? ???????????? ? ???????????
?????????? ? ???????????
????????????????????
????????
???????
??????????
?????? ????? ?????
?????? ????? ?????
?????? ????? ?????
?????? ????? ?????
?????? ????? ?????
????????????????????????????????? ???????? ?????????????????????????????????????
??????????????????????????
?????
????? ??????? ?????
? ??????? ? ??????? ? ???????
?? ???? ?? ???? ?? ?????
??????????????????????????????????
??? ???????????
????????????
??????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????
??????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
???????????
?????
??? ?? ???? ? ? ? ? ?? ? ?? ? ?? ? ? ???????????????
?? ? ????????????? !"
#$
"%
&"
'(
)*
#"
++
,#
()
$,
#"
+(
-!
))
.(
/#"0(12'"#(*3"(45#&"(-4,#6+,7.(
8%95#"(:;<(="2',9#0>(02'(+$0?"#@7,*(#"@#"+"2629($75+*"#+(A#,>(B0#'(C"*3,'(,A(
$70++%D$06,2(E0+"'(,2(!))(02'(/14<((
F#,5@(G(
H5*7%"#+(
F#,5@(;(
F#,5@(:(
/<(
I<(
107 
  
cortisol production, into groups with similar phenotypes.  Figure 24A shows the 
dendogram representation of the Ward Method of Clustering.  Three groups emerged 
from this classification methodology and are shown in a scatterplot of PSS vs. AUC 
(Figure 24B).  The first cluster was of individuals exhibited low PSS scores and low 
AUC (Figure 24B, green circles), the second cluster of individuals exhibited high PSS 
scores and high AUC values (Figure 24B, blue circles), the third and final cluster had 
low PSS yet high AUC (Figure 24B, brown circles).  I investigated this third cluster and 
found that they were individuals within the cancer free group who had low PSS but high 
CES-D scores (data not shown).  Thus this group of women were statistically different 
from the other groups had the biological alterations most likely due to their depressive 
mood.  Immune parameters were compared between individuals who exhibited both the 
perception (i.e. high PSS) and biological output (i.e. high cortisol by AUC) of 
psychological stress (high stress) with the individuals of group 2 (i.e. low PSS and low 
cortisol by AUC). 
Comparison of PSS and AUC between the high stress and low stress groupings 
demonstrated that indeed both were statistically elevated compared to the low stress 
group (Figure 25A and B).  IFN-g production from ex vivo stimulated PBMC as well as 
circulating IL-6 plasma levels were increased within individuals with increased daily 
cortisol and PSS compared to low daily cortisol and low PSS (Figure 25C and D).  
Additionally, NKCA standardized to the percent CD56+ from ex vivo derived PBMC 
was decreased in the high stress group (Figure 25E).  These results highlight that 
individuals who report increased perceived stress and exhibit the biological output of  
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Figure 25.  Comparison of immune phenotypes within selected groups.  Boxplots 
representing the differences in (A) PSS scores, (B) AUC cortisol, (C) IFN-g production, 
(D) NKCA, and (E) IL-6 plasma levels between individuals exhibiting high and low 
biological stress. Values are presented in box plots where the black line represents the 
median and the tinted area box represents 50% (quartile) of the data set.  The whiskers 
represent the upper 25% and lower 25% of the data set. Open circles represent outliers. 
*=p,0.05, **=p<0.01.  
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Figure 26. Comparison of promoter specific acetylation pattern between selected 
groups. Boxplots representing the differences in the ratio of acetylated H3K9 to 
trimethylated H3K9 at the (A) IFNG enhancer and (B) IL6 promoter between 
individuals exhibiting high and low biological stress.Values are presented in box plots 
where the black line represents the median and the tinted area box represents 50% 
(quartile) of the data set.  The whiskers represent the upper 25% and lower 25% of the 
data set. Open circles represent outliers. *=p,0.05, **=p<0.01, High Stress vs. Low 
Stress.   
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stress, altered cortisol rhythms, display a dichotomous regulation of immune function 
(i.e. increased pro-inflammatory cytokine production and reduced NKCA).  
Data presented in this dissertation as well as our previously published data 
indicated that these immune phenotypes result from transcriptional changes in NK cell 
effector genes [117,118].  As transcriptional rates are regulated via post-translational 
modifications on histone tails, the histone acetylation and methylation patterns were 
investigated within proinflammatory cytokine regulatory regions.  Chromatin 
immunoprecipitation (ChIP) was used to quantify the levels of acetylated H4K8, 
acetylated H3K9, and tri-methylated H3K9 at the IFNG enhancer and IL6 promoter 
from 5.0x106 PBMCs.  I then quantified the ratio of acetylated H3K9 to tri-methylated 
H3K9.  This was used as a measure of ex vivo derived PBMC containing acetylated 
histones (open chromatin) compared to methylated histones (closed chromatin) at 
proinflammatory cytokine regulatory regions.  Comparison of the ratio of acetylated to 
trimethylated H3K9 at the IFNG enhancer region demonstrated that individuals with 
high stress exhibited a statistically significant increase compared to individuals with low 
stress (Figure 26A).  An increase in the ratio of acetylated to trimethylated H3K9 was 
also evident at the IL6 promoter between individuals exhibiting high stress and low 
stress (Figure 26B).  No difference in the presence of acetylated H4K8 was observed at 
either the IFNG locus or IL6 promoter (data not shown).   
These data in total demonstrate that individuals in our study who report increased 
perceived stress exhibit the biological output of this stress as increased daily salivary 
levels of cortisol.  Individuals with increased stress exhibit immune alterations 
characterized by increased proinflammatory cytokine production as well as reduced 
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NKCA.  Lastly, increased histone acetylation can be observed in the regulatory regions 
of proinflammatory cytokine genes in individuals with increased stress and increased 
proinflammatory cytokine production.  The above data demonstrate that differences are 
evident between high and low stress groups but do not provide insight into the 
relationships between these variables and possible mediators of these effects. 
 
Relationships between psychological and immunological variables 
 
Bivariate Pearson correlations were used to evaluate the relationships between 
psychological stress, daily cortisol, and immune function in the population of 
individuals at T1.  A significant positive correlation was observed between PSS scores 
and AUC in all individuals including both the cancer and cancer free groups (Figure 
27A).  The relationship between perceived stress and cortisol production demonstrates 
that not only were cortisol levels difference between high and low stressed individuals 
but the greater stress an individual perceives corresponds to an increase in their daily 
cortisol production.  Additionally, both proinflammatory cytokines (IL-6 and IFN-g) 
exhibited a significant positive correlation with AUC (Figure 27D-E).  Indicating that 
increased HPA activity results in increased proinflammatory cytokine production. A 
positive correlation was also observed between IFN-g and IL-6 production from ex vivo 
stimulated PBMC indicating a coordination in proinflammatory cytokine regulation in 
response to increased HPA activity (Figure 27C).  Results from this body of work 
demonstrate that NK cell effector functions are dichotomously 
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Figure 27.  Pearson correlations at T1. Scatterplots representing the relationship 
between (A) PSS scores and AUC levels at T1.  (B) IFN-g production versus NKCA. 
(C) IFN-g versus IL-6 production. (D) AUC levels versus IL-6 production. (E) AUC 
levels versus IFN-g production.   
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regulated following chronic GC treatment.  In support of this dichotomous regulation ex 
vivo, a negative relationship between IFN-g production from ex vivo stimulated PBMC 
and NKCA standardized to the percent of CD56+ NK cells per individual was observed 
(Figure 27B). These relationships demonstrate that as perceived stress increases HPA 
activity is increased and a subsequent dichotomy in immune function is observed.     
As histone acetylation corresponds with transcription, the relationship between 
promoter specific epigenetic patterns and proinflammatory cytokine production was 
investigated.  The ratio of acetylated to tri-methylated H3K9 was positively related to 
IFN-g production at T1 (Figure 28B).  Furthermore, PSS scores were also positively 
related to the ratio of acetylated to tri-methylated H3K9 (Figure 28C).  These three 
relationships allowed statistical testing of mediation, through a mediator model (Figure 
28E) whereby the increases in IFN-g associated with PSS are mediated by histone 
acetylation patterns.   
 
Statistical testing of a Mediator Model 
 
The mediation pathway from perceived stress (PSS) to IFN-g production through 
histone acetylation at the IFNG enhancer was tested using the Sobel mediation equation 
(Figure 29).  The multistage linear regression model of testing mediation depicted in 
Figure 29 includes four tests. 1) PSS is associated with IFN-g production (path c). 2) 
PSS is associated with histone acetylation at the IFNG enhancer (path a).  3) When 
controlling for PSS, histone acetylation at the IFNG enhancer is associated with  
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Figure 28.  Relationships to test mediation model. Scatterplots representing the 
relationships between (A) PSS scores and IFN-g production, (B) IFN-g production and 
the ratio of H3K9 acetylation and H3K9 trimethylation at the IFNG locus and (C) PSS 
scores versus the ratio of H3K9 acetylation and H3K9 trimethylation at the IFNG locus  
(D) Sobel test equation. 
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Figure 29.  Diagram of Mediation Model. The multistage linear regression model of 
testing mediation is depicted.  1) PSS is associated with IFN-g production (path c). 2) 
PSS is associated with histone acetylation at the IFNG enhancer (path a).  3) When 
controlling for PSS, histone acetylation at the IFNG enhancer is associated with IFN-g 
production (path b), and the association between PSS and IFN-g production (path c) is 
either no longer statistically significant (full mediation) or reduced significantly (partial 
mediation).   
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IFN-g production (path b), and the association between PSS and IFN-g production (path 
c) is either no longer statistically significant (full mediation) or reduced significantly 
(partial mediation).  4) A statistically significant indirect path exists between perceived 
stress and IFN-g production through histone acetylation at the IFNG enhancer.  The 
Sorbel mediation test (Figure 29D) demonstrated that the indirect effect of PSS on IFN-
g production through the mediator, histone acetylation, is significant (p=0.029).  These 
analyses were confirmed using two additional variations of the Sobel test, the Aroian 
and Goodman tests both reaching significance (p<0.05) (data not shown). CES-D, 
another psychological parameter, also correlated with both PSS and IFN-g production 
and met all the requirements to run a mediation analysis.  CES-D did not mediate the 
changes PSS driven increases in IFN-g production (p=0.419) (data not shown).  These 
data demonstrate that within a population stress is associated with an increase in daily 
cortisol production and an increase in IFN-g production which is partially mediated by 
the acetylation of histones at the IFNG locus. 
 
Categorization of individuals by immune phenotypes 
 
The above date demonstrates that individuals grouped by their stress scores or 
clustered by stress and the biological phenotype of stress exhibit altered immune 
function characterized by decreased NKCA and increased IFN-g production. The Ward 
Method of Cluster Analysis was used to reclassify the women based on Natural Killer 
cell activity (NKCA) and IFN-g production from ex vivo derived PBMC at T1 
independent of cancer or cancer free groupings.  I questioned whether the reverse  
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Figure 30. Wards Method of Classification by NKCA and IFN-g production.  (A) A 
dendogram representing the Euclidean mean squared distance between patients 
classified by their NKCA and IFN-g production. (B) Scatterplot of NKCA and IFN-g 
representing the groups created using the Wards Method of cluster analysis 
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also held try, in that I investigated whether women grouped by their immune function 
(NKCA and IFN-g production) would exhibit differences in daily cortisol production 
and stress levels.  A dendogram of the Ward Method classification is shown in Figure 
30A.  Four groups emerged from this analysis and are shown on a scatterplot of NKCA 
standardized to CD56 percentages vs. IFN-g production (Figure 30B).  Group 1 
consisted of women who exhibited high IFN-g production and low Natural Killer cell 
lytic activity. Group 2 consisted of women who exhibited both low IFN-g production 
and NKCA.  Group 3 consisted of women who exhibited high NKCA and low IFN-g 
production.  Group 4 consisted of 5 women who were statistical outliers.  This analysis 
allowed us to determine whether women who exhibit alterations in immune parameters 
differ in their psychological parameters, diurnal cortisol rhythms, and epigenetic patterns.  
The PSS scores for women in group 1 were increased compared to women in group 3 
(Figure 31A).  Stress has been attributed to alterations in diurnal cortisol rhythms. 
Figure 31B shows that women in group 1 exhibited a reduced decline in cortisol 
throughout the day as measure by the slope from 30min post awakening to bedtime 
compared to group 3.  These results imply that women who exhibit decreased NKCA 
and increased IFN-g production also exhibit increased stress and changes in cortisol 
diurnal rhythms.   
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Figure 31. Analysis of stress parameters within individuals clustered by immune 
parameters.  Boxplots representing the (A) PSS scores and (B) cortisol levels between 
individuals clusterd using Wards method of classification based on NKCA and IFN-g 
production.   
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Conclusion 
 
In summary, our analysis of ex vivo derived PBMC from women diagnosed with 
DCIS and a matched control group demonstrated that increases in the level of perceived 
stress is associated with increases in daily cortisol production.  Classification of these 
individuals by perceived stress and the biological manifestation of stress, cortisol 
production, demonstrated that analysis of immune function within these groups show a 
stress induced immune phenotype of increased proinflammatory cytokine production 
and reduced NKCA.  This dichotomous phenotype within stress individuals could also 
be used as a classification scheme in that individuals grouped by this dichotomous 
immune phenotype also exhibited differences in stress and cortisol production.  
Mediation model testing demonstrated that histone acetylation patterns within 
proinflammatory cytokine regulatory regions partially mediated the stress induced 
increases in cytokine production.  These results not only characterize the immune 
phenotypes associated with stress but also demonstrate that an epigenetic mechanism is 
at play and partially mediates these effects.
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CHAPTER FOUR 
 
DISCUSSION 
 
Analysis of an in vitro system to investigate the effects of chronic glucocorticoid 
treatment on NK cell effector function 
 
Glucocorticoid induced dichotomy in NK cell effector function 
 
It is well-established that stress is associated with a reduction in NK cell 
functional activity, which may be mediated by altered adrenergic as well as 
glucocorticoid activity [200,247,248,249].  This investigation focused on chronic 
exposure to the synthetic glucocorticoid, dexamethasone, with the observation that 
chronic GC treatment suppressed NKCA and increased stimulated proinflammatory 
cytokine production. We conclude this is within a single cell population as 85-98% of 
NK92 cells were perforin, granzyme B, and IFN-g positive independent of treatment.  
Additionally, chronic GC treatment was associated with changes in MFI but not the 
percent of cells positive for each individual effector protein. The gene products (mRNA) 
for NK cell lytic granules were quantitatively reduced by GC treatment, and such 
reductions related to reduced functional capacity of NK92 to mediate lysis of K562 cells.  
These observations are in agreement with a number of systems investigating the effects 
of GC on NK cell function both from ex vivo derived CD56+ cells as well as multiple 
NK cell lines including; NK92, NK3.3, and YT [117,118,119].  All demonstrate that GC 
treatment reduced NKCA, in part, through reductions in effector molecule production.
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In contrast, upon cellular activation, the production of the IFN-g and IL-6 gene products 
were quantitatively increased by chronic GC treatment. Chronic GC treatment primed 
NK92 cells to produce more proinflammatory cytokine when stimulated, regardless of 
the stimulant tested (PMA/ionomycin, IL-12, or IL-2), each of which signals through a 
different cellular pathway.  These observations suggested that some common 
mechanism downstream of transcription factor activation mediated these effects.  
The molecular mechanisms underlying the effects of GC remain incompletely 
understood.  Many studies have focused on mechanisms upstream of GC binding to its 
receptor, including modified extracellular or intracellular GC concentrations or GR 
mutations, splice variants, or insufficient GR expression.  Here we demonstrated that 
chronic GC did not alter steady state GR protein levels or the sensitivity of GR to a 
subsequent high anti-inflammatory concentration (10-7M) of GC after chronic GC 
treatment (Figure 15B-C).  From these studies we conclude that our observations are not 
the result of GR resistance, because no changes in GR levels or sensitivity were 
observed.   
Additional studies also report mechanisms downstream of GC binding to GR that 
involve the GC signaling pathways which regulates the transcription of many genes 
involved in the immune response [250,251]. By interacting with JAK-STAT signaling 
pathway and with transcription factors such as NF-κB and activated protein-1 (AP-1), 
GR has been shown to alter the transcription of immune relevant genes [252,253].  
Although activated glucocorticoid receptor (GR) can directly interact with 
proinflammatory transcription factors like AP-1 (Fos-Jun heterodimers) and NF-κB 
(p65-p50 heterodimers) [109,254,255], chronic GC treatment did not alter the steady 
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state levels of NF-κB or AP-1 nor did it impact the ability of cellular stimulation to 
induce NF-κB or AP-1 nuclear translocation in NK92 cells (Figure9 E-F). These data 
demonstrate that the enhanced cytokine production did not result from chronic GC 
treatment induced enhancement of nuclear NF-κB or AP-1 signaling.  This suggested 
that some other mechanism primes NK cells for enhanced cytokine production with the 
likely possibility being changes at the epigenetic level. 
 
Glucocorticoid induced promoter specific epigenetic modifications 
 
Our lab has previously demonstrated that GC through GR can induce epigenetic 
modifications at NK cell effector genes. These epigenetic modifications are associated 
with altered gene transcription [117,118],when induced with high concentrations of GC 
(10-7M) for 24 hours [117,118].  The effects of GC on cellular function are known to be 
dependent on both the dose and duration of exposure.  Therefore, the epigenetic pattern 
associated with NK cell effector genes was assessed using chromatin 
immunoprecipitation during chronic GC treatment.  The levels of H4K8Ac, H3K4me3, 
H3K9Ac, H3K9me3, H3K27Ac, and H3K27me3 were assessed at days 2 and 5 during 
chronic treatment and compared to the levels in untreated cells.  H3K9me3, a marker of 
constitutive heterochromatin, was at or below the limit of detection for all genes 
investigated [125,126,127,128].  This was expected as NK92 are fully differentiated NK 
cells and have the potential to express both cytokine and lytic molecules which should 
be located in euchromatic regions.  H3K27me3 (associated with silenced genes) was 
poorly represented at all regulatory regions investigated.  H3K4me3 is typically present 
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at transcription start sites, is strongly correlated with transcription potential and was 
measurable at all regulatory regions investigated[129,130]. This pattern of H3K4me3 
with no H3K9me3 or H3K27me3, indicates genes present in euchromatin with the 
potential for expression.  H3K9Ac is typically represented at active promoters and 
enhancers and the level of H3K9Ac at a given region correlates with the level of 
transcription[127].  Chromatin immunoprecipitation demonstrated a quantitative 
reduction in the acetylation of H3K9 at the PRF1 and GZMB promoters.  The reduction 
in H3K9Ac at the PRF1 and GZMB promoters is the likely epigenetic modification that 
likely contributes to the reduced production of transcripts for both of these effector 
proteins.  
Chromatin immunoprecipitation demonstrated increased acetylation of H4K8 
and H3K27 for both the IFNG enhancer and the IL6 promoter.  Conceptually, the 
histone proteins possesses highly basic amino-terminal tail domains located outside of 
the core nucleosome particle, which are accessible to multiple post-translational covalent 
modifications, including acetylation and methylation[256].  Lysine acetylation 
neutralizes the charge of histone proteins, whereas deacetylation restores the positive 
charge of lysines. Following acetylation, nucleosome mobility is enhanced, increasing 
accessibility of the promoter for transcription machinery[257]. Thus, acetylated lysine 
residues increase access of transcription factors for regulatory regions of immune 
response genes.  By enhancing this downstream target (chromatin accessibility), GC can 
prime genes for altered transcription upon cellular activation and transcription factor 
nuclear localization. Hence, the data presented here demonstrate that GC enhanced 
cytokine production is in part due to increased proximal promoter and enhancer 
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accessibility. The increase in H4K8Ac and H3K27Ac at the –22kb IFNG enhancer and 
at the IL6 promoter are the likely major epigenetic modifications that contribute to the 
increased production of transcripts for both of these effector proteins upon cellular 
stimulation.  
The question becomes, how do these specific and independent histone tail 
modifications contribute to the control of the lytic molecule vs. cytokine regulatory 
regions?  First, the cell line being used is a fully differentiated NK cell line, with the 
potential to express both lytic and cytokine genes and thus the expression potential of all 
genes investigated are equivalent, in that, they are all located within euchromatic 
regions, indicated by the lack of H3K9me3. What separates these lytic and cytokine 
genes are the transcriptional profiles prior to GC treatment.  Real-time analysis 
demonstrated that the relative number of transcripts for the lytic molecules is roughly 
10,000 times that of the cytokine genes in resting cells, as the mRNA isolated from 
NK92 cells in culture had to be diluted 1:10,000 to obtain the same C(t) value as those 
of the cytokine genes from unstimulated cells (data not shown).  PRF1 and GZMB are 
constitutively expressed genes in NK cells, whose protein products accumulate and are 
stored in cytoplasmic granules.  The cytokine genes on the other hand exhibited a small, 
almost undetectable, level of basal expression and are held poised until cellular 
stimulation (Figure 7C). Thus PRF1 and GZMB were highly transcribed and exhibited 
histone tail modifications (high H4K8Ac, high H3K9Ac, and high H3K27Ac), which 
marked them as such.  In contrast, the cytokine genes exhibited low H4K8Ac, low 
H3K9Ac, and low H3K27Ac which suggested lower transcription than the lytic 
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molecules and potentially less accessible chromatin, and possibly lacking the docking 
sites for transcriptional machinery.  
Specifically, H4K8Ac is a docking site for the bromodomain containing protein 
complex SWI/SNF [258].  Recruitment of SWI/SNF, via the increased H4K8Ac after 
chronic GC treatment, would make the cytokine regions more accessible to transcription 
factors and other transcriptional regulators through the nucleosome remodeling 
functions of the SWI/SNF complex[259].  This is indeed true as the IFNG enhancer and 
IL6 promoter exhibited a 37% and 18% increase in accessibility after chronic GC 
treatment, respectively (Figure 12A).   These observations are in agreement with 
experiments testing the histone code hypothesis investigating the contribution of 
individual histone marks to the step-by-step activation of transcription.  These 
experiments demonstrated that H4 acetylation occured first, which creates a docking site 
for the SWI/SNF complex[258].  The H4K8 modification cannot induce transcription 
but requires GCN5 or other histone acetyltransferase mediated acetylation of H3K9 and 
H3K14 that provides a docking site for transcription factor II D (TFIID)[258].  TFIID is 
required for the formation of the transcription initiation complex and thus a critical step 
in transcriptional regulation[260].  I speculate that prior to cellular stimulation H3K9Ac 
is limited, most likely due to the actions of resident HDACs and lack of histone 
acetyltransferase activity/recruitment at cytokine regulatory regions.  Without TF 
activation, nuclear translocation, and recruitment of a histone acetyltransferases such as 
GCN5, TFIID association and thus transcription is limited.  This scenario explains why 
basal transcription was unaffected even with the observed increase in H4K8Ac.  
Therefore, the GC dependent loss of HDAC1 and HDAC3 from proinflammatory 
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cytokine loci and subsequent increase in H4K8Ac primes these regions for enhanced 
transcription upon stimulation, due to the increased acetylation of H4K8 and increased 
chromatin accessibility due to the hypothesized recruitment of the SWI/SNF complex.   
In contrast to the cytokine loci, H3K9Ac is reduced at PRF1 and GZMB most 
likely due to the recruitment of HDAC2 during chronic GC treatment.  HDAC2 has been 
shown to directly deacetylate the amino terminal tail of H3 and has been shown to 
inhibit the activity of histone acetyltransferase-containing complexes.  In either senario, 
HDAC2 recruitment could reduce the availability of docking sites required for TFIID 
recruitment and therefore decrease the transcriptional rate of the lytic genes. 
Preliminary ChIP analysis with anti-RNApol II antibody demonstrates that 
chronic GC treatment resulted in increased RNApol II at the PRF1 and IL6 promoters, 
as well as, at the IFNG enhancer (Figure 12B).  The increase in H4K8Ac at cytokine loci 
and decrease in H3K9Ac at lytic molecule loci could exhibit a similar effect on RNApol 
II recruitment. That is, the presence of H4K8Ac could allow for the binding of the 
SWI/SNF complex which would allow access of the RNApol II holoenzyme[261], and 
poise the cytokine gene loci for transcription. No change in RNApol II recruitment was 
observed at the TNF promoter which also displayed no change in histone tail 
modifications following chronic GC treatment (Figure 12B).  We hypothesize that the 
increase in RNApol II is stalled RNA polymerase as no concomitant changes in basal 
transcription were observed.  Furthermore, no increase in H3K9Ac was observed at the 
cytokine loci and therefore suggest no change in transcriptional rates. 
As described PRF1 and GZMB undergo high rates of transcription and would 
continually recruit RNApol II during normal cell function due to the high levels of 
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H4K8Ac, H3K9Ac, and H3K27Ac.  The higher levels of RNApol II in untreated cells at 
the loci which code for lytic molecules compared to the cytokine regulatory regions is 
indicative of this higher level of transcription (Figure 12B). The decreased levels of 
H3K9Ac seen in at the PRF1 and GZMB promoters following chronic GC treatment 
could decrease the docking site for TFIID.  The increased presence of RNApol II after 
chronic GC treatment at the PRF1 promoter is likely stalled RNApol II, as transcripts 
from PRF1 were decreased 50% after chronic GC treatment.  Interestingly, the GZMB 
promoter exhibited decreased RNApol II binding after chronic treatment. Why the 
GZMB promoter is regulated differently than the other NK cell effector genes tested 
remains to be determined.  These experiments were performed using total anti-RNApol 
II antibody and was not specific for the stalled or active forms which can be 
differentiated by the presence of specific serine phosphorylation on the RNApol II 
enzyme.  These observations clearly delineate the contribution of the GC dependent 
histone tail modifications in the epigenetic control of NK cell effector gene transcription. 
In summary, chronic GC treatment imparts a dichotomous regulation of NK cell 
effector function through promoter specific epigenetic modifications.  These promoter 
specific changes in histone acetylation patterns are congruent with the transcriptional 
profile of NK cells after chronic GC treatment.  These changes in histone acetylation are 
associated with not only changes in the chromatin structure but also changes in the 
RNApol II deposition.  The next question becomes what is the mechanism by which GC 
mediates these changes in promoter specific acetylation patterns. 
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Glucocorticoid regulation of histone modifying enzymes 
 
Activated GR can alter histone acetylation and thus gene expression by directing 
the interaction of chromatin with histone acetyl transferase complexes and/or interaction 
with histone deacetylase (HDAC) complexes[118,146]. In accordance with the observed 
decrease in H3K9 acetylation, 2 days of GC exposure exhibited increased levels of 
HDAC2 at both the perforin and granzyme B promoters.  These promoter specific 
increases in HDAC2 corresponded with global increases in the level of cellular 
phosphorylated HDAC2.  Phosphorylated HDAC2 has been shown to be located in the 
nucleus and enzymatically active[242].  These observations were confirmed using 
multispectral flow cytometry and co-localization (similarity dilate) of HDAC2 with 
nuclear DAPI staining after chronic GC treatment (Figure 14F-G).  The data presented 
for the NK cell lytic molecules are consistent with the described transrepression 
mechanism for glucocorticoid action mediated by the HDAC2 / co-repressor 
complex[118,146] and is in full agreement with many observations for the decreased 
immune function in the presence of GC. 
The cytokine genes; 1) were regulated in the opposite manner, 2) with different 
histone modifications associated with transcription potential, and 3) with chromatin 
accessibility altered at the cytokine loci and not the lytic molecule promoters.  These 
observations suggested that these dichotomous effects were regulated by two different 
epigenetic mechanisms. One possible basis for this difference is differential 
enrichment/absence of HDACs. 
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Chronic GC treatment reduced the levels of resident HDAC1 and HDAC3 bound 
at the proinflammatory cytokine regulatory regions in NK92 cells, which 
mechanistically explains the increases in histone acetylation and chromatin accessibility 
observed.  The role of HDAC1 and HDAC3 in the control of proinflammatory cytokine 
regulation has been clearly demonstrated previously for both IFNG and IL6 [262].  
Herein, loss of HDAC3 from these regions corresponded to a total cellular decrease in 
HDAC3 protein level (Figure 14B).  It has been previously shown that GR can interact 
with HDAC3[147] and HDAC1[118,145].  We previously confirmed the interaction of 
GR and HDAC1 and demonstrate here that in NK92 cells, GR and HDAC3 co-
immunoprecipitate (Figure 15F).  Furthermore, the cellular levels of both 
GR[263,264,265] and HDAC3[266,267] are regulated by the proteasome pathway.  I 
speculate that the time dependent decrease in total HDAC3 protein and HDAC3 at 
cytokine regulatory regions likely result from a direct interaction of HDAC3 with ligand 
activated GR and subsequent targeting for proteasomal degradation.   
Reports demonstrate that although RU-486 can antagonize the transrepression of 
genes by GR[268], RU-486 can also act as a GR agonist in a gene specific manner[269].  
We demonstrate that GC and RU-486 synergistically decrease HDAC3 protein levels in 
NK92 cells (Figure 15E). Dual staining for IFN-g and HDAC3 in GC and RU-486 
treated cells revealed that the level of IFN-g in NK92 cells related inversely to the level 
of HDAC3 (Figure 15E).  We hypothesize that both GC and RU-486 induce nuclear 
localization of GR, interaction with HDAC3, and its subsequent proteosomal 
degradation, relieving HDAC3 mediated inhibition (deacetylation) of the IFNG and IL6 
loci.  These data together demonstrate that GC can dichotomously regulate NK cell 
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effector function through two independent mechanisms.  The first involves the classical 
repression mechanism via HDAC2-mediated decreases in H3K9Ac which can be 
inhibited by RU-486; the second involves the epigenetic priming of proinflammatory 
cytokine loci through reductions in HDAC1 and HDAC3, increasing H4K8Ac.  
We hypothesize that direct interactions between GR and HDACs are mediating 
these changes in the association and loss of specific HDACs from the regulatory 
regions of NK cell effector genes.  Our data suggests that these promoter specific 
alterations in HDAC recruitment are gene specific, as HDAC2 was detected at both the 
IL6 promoter and IFNG enhancer but was unchanged at day 2 or day 5.  This was in 
contrast to the dramatic increase in HDAC2 at PRF1 and GZMB promoters (Figures 
13A-D).  GR recruitment to these regulatory regions was assessed by ChIP but 
quantification of GR levels at genomic loci was unsuccessful.  We hypothesize that 
quantification of GR recruitment activated with such a low concentration of ligand was 
hindered by the limit of detection for the ChIP assay.  Evidence indicates that the 
binding of ligand activated GR to chromatin in living cells is extremely rapid with off 
and on rates of seconds to minutes [270,271].  Further studies investigating GR binding 
and occupancy to genomic loci using photobleach microscopy experiments highlight 
that once ligand bound GR is recruited to regulatory regions it only remains there for a 
few seconds before new unbleached fluorophore conjugated GR replaces it[272]. 
Finally, GR rapidly engages and disengages the chromatin template, during which 
chromatin remodeling undergoes dynamic exchange [273,274].  Thus, I hypothesize 
that the effect of GC through GR is a cumulative effect of ligand binding over days and 
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thus changes in the occupancy of GR at these regions could not be detected. As such, it 
is unlikely that it is possible to detect promoter specific recruitment of GR in our 
chronic low level GC treatment system using ChIP.  
Phospho-HDAC2 was increased as early day 2 of chronic glucocorticoid 
treatment (Figure 14E). The nuclear translocation, enzymatic activity, and degradation 
of HDACs are regulated by post-translational modifications[275].  Phosphorylation of 
HDAC2 on Ser394 results in nuclear translocation and enzymatic activity[242,275,276]. 
This increase in phospho-HDAC2 is evident throughout treatment and corresponds to 
increased nuclear HDAC2 localization and recruitment to the PRF1 and GZMB 
promoters. Further, decreased HDAC3 protein was observed after chronic GC treatment 
(Figure 14A-B). The phosphorylation of Ser394 on HDAC2 is regulated by casein-
kinase-2 (CK2)[242]. Interestingly, a recent report demonstrates that CK2 can also 
phosphorylate HDAC3[267].  In contrast to HDAC2, the phosphorylation of HDAC3 by 
CK2 precedes its degradation[267].  These studies demonstrate CK2 to have opposing 
functions on HDAC2 and HDAC3 regulation.  The results presented herein demonstrate 
that HDAC2 and HDAC3 are dichotomously regulated during chronic GC exposure; 
these observations could be explained by activation or increased CK2 mediated 
phosphorylation of HDAC2 and HDAC3 precipitating the dichotomous regulation of 
NK cell function.  The implications for these findings are interesting as a specific CK2 
inhibitor is available.  Further investigation using this specific CK2 inhibitor could 
provide data supporting this hypothesis.  Preliminary experiments using this CK2 
inhibitor proved ineffective as CK2 is involved in a number of cellular processes 
including cell cycle regulation.  NK92 cells treated with an inhibitor of CK2 
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demonstrated a significant decrease in both cellular proliferation and viability and thus 
no conclusions could be drawn from these experiments (data not shown). 
In unpublished data we screened for potential changes in HDAC and HAT gene 
expression to investigate whether chronic GC treatment altered the expression of other 
histone modifying enzymes besides Class I HDACs described in this work.  
Quantification of HDAC1, 2, 3, and 4 as well as SIRT1 mRNA levels following chronic 
GC treatment demonstrated that HDAC1, 2, and 4 mRNA levels were unchanged 
throughout treatment (Figure 32A).  However, HDAC3 mRNA levels were decreased at 
day 5 of treatment as demonstrated previously (Figure 32A).  Furthermore, SIRT1 
mRNA levels were increased after chronic GC treatment (Figure 32A).  Whether the 
minimal but significant increase in SIRT1 contributes to the dichotomous phenotype 
observed remains to be investigated. Whether the increase in mRNA levels 
corresponded to changes in SIRT1 protein levels after chronic GC treatment NK92 cells 
was not investigated.  The role of SIRT1 in the regulation of immune function has not 
been investigated and might provide an additional pathway by which GC regulate NK 
cell function. 
Additionally, GR has been shown to interact with a number of HATs including 
CBP, PCAF, and p300.  Analysis of HAT mRNA levels demonstrated that chronic GC 
treatment slightly but significantly increased P/CAF and CBP transcript levels (Figure 
32B).  Although global increases in P/CAF and CBP transcript levels were observed in 
Figure 32B concomitant increases in cellular protein levels were undetected (data not 
shown, the thesis work of Karen Krukowski).  Additionally, preliminary ChIP 
experiments revealed no change in the recruitment of CBP, P/CAF, or p300 at any  
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Figure 32.  Quantitative expression analysis of coactivator and corepressor 
complexes during chronic GC treatment. (A) Relative	  transcript	  levels	  of	  HDAC1,	  2,	  3,	  4	  and	  SIRT1	  in	  NK92	  cells	  harvested	  at	  indicated	  days	  during	  treatment	  and	  standardized	  to	  transcript	  levels	  in	  untreated	  (black	  bars)	  cells	  set	  to	  1.	  (B) Relative	  transcript	  levels	  of	  N-­‐CoR,	  SMRT,	  p300,	  CBP,	  and	  P/CAF	  in	  NK92	  cells	  harvested	  at	  indicated	  days	  during	  treatment	  and	  standardized	  to	  transcript	  levels	  in	  untreated	  (black	  bars)	  cells	  set	  to	  1. 
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regulatory region investigated (data not shown).  The role of these or other histone 
acetyltransferases still remains to be investigated.  These preliminary results suggest that 
acetyltransferases are not recruited to the cytokine regulatory regions following chronic 
GC treatment, therefore it is believed that the concomitant increase in histone 
acetylation results from the loss of HDAC mediated inhibition and resident HAT activity 
rather than recruitment of additional HATs.  Additionally, there was not a decrease in 
HAT levels at the lytic molecule regulatory regions.  These data in total suggest that the 
recruitment of HDAC2 to these regions mediates the decrease in H3K9Ac directly or 
inhibits the activity of a resident HAT activity at these regions. 
These data demonstrate that the GC induced promoter specific alterations at NK 
cell effector genes are the result of altered deposition of histone modifying enzymes.  
These promoter specific changes in HDAC recruitment occur concomitantly with global 
changes in HDAC subcellular localization.  Therefore we investigated whether these 
changes in HDAC distribution imparted global changes across the epigenome. 
 
Glucocorticoid induced global epigenetic phenotypes 
 
In addition to the promoter specific epigenetic changes associated with GC 
treatment, we previously published that NK lytic function, NKCA, correlates with global 
histone acetylation patterns as well[117].  In the data presented by that study, nuclear 
localization of phosphorylated enzymatically active HDAC2 was increased after chronic 
GC treatment and thus might exert genome wide changes in histone tail modification in 
addition to the promoter specific changes described herein. HDAC2 has been shown to  
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Figure 33. Global histone modifications after chronic GC treatment in NK92s.  
Representative histograms of global (A) H4K8 acetylation, (B) H3K9 acetylation, and 
(C) H3K4 trimethylation by flow cytometry in untreated (black line) and chronic GC 
treated (shaded) NK92 cells.  (D) Quantification	  of	  MFI	  from	  flow	  cytometric	  analysis	  of	  global	  histone	  modifications	  in	  untreated	  (black	  bars)	  and	  chronic	  GC	  treated	  cultures	  (white	  bars)	  where	  the	  MFI	  of	  untreated	  cells	  is	  set	  to	  100%. 
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deacetylate both H3 and H4 histone proteins.  After chronic GC treatment a significant 
decrease in global H4K8Ac as measured by flow cytometry was observed, compared to 
untreated cells (Figure 33A and D).  I hypothesize that HDAC2 recruitment in a gene 
specific manner directly regulates transcription and that the nuclear accumulation of 
HDAC2 also results in the loss of H4K8 acetylation at susceptible loci across the entire 
genome.  These susceptible loci are most likely a combination of regulatory as well as 
non-regulatory intergenic regions to account for a greater than 10% decrease in total 
H4K8 acetylation across the genome after chronic GC treatment (Appendix Figure 33D).       
 
Conclusions 
 
To our knowledge this is the only demonstration that a dichotomous NK 
phenotype is demonstrable in a cell line.  Furthermore, we demonstrate that GC alone 
can impart this dichotomous phenotype.  Chronic GC treatment mediated these effects 
through changes in the transcription of NK cell effector genes.  These transcriptional 
changes occurred via specific histone acetylation patterns imparted by GC induced 
HDAC redistribution.  Cellular HDAC redistribution also imparted a global change in 
H4K8 acetylation.  These pathways were then used to investigate changes in immune 
cell function during periods of psychological stress, known to result in dysregulation of 
glucocorticoid production in vivo.
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Ex vivo analysis of human derived PBMC 
Introduction 
 
These in vitro observations may relate to the chronic effects of GC 
dysregulation; in humans.  A large number of studies have shown psychological distress 
to impact immune function[277,278,279,280].  The stress response results from internal 
or external stimuli that activate ‘‘fight or flight’’ and “defeat/withdrawal” responses 
associated with the sympathetic nervous system (SNS) and hypothalamic-pituitary-
adrenocortical (HPA) axis activation. It is well established that specific central nervous 
system pathways act to translate social stimuli into peripheral biological signals that 
regulate inflammatory responses [281].  For instance, stress activates neuroendocrine 
and autonomic pathways such as the HPA axis and the SNS, resulting in the release of 
GC, catecholamines, and pro-inflammatory cytokines such as IL-1, IL-6, and TNF alpha. 
The release of these sympathetic, neuroendocrine, and immune factors has a profound 
influence on immunity, behavior, and physiology in both humans and rodents; and 
triggers peripheral biological responses that, in turn, signal back to the CNS to complete 
a bi-directional communication circuit[282,283,284,285]. The effect of psychological 
distress on NK cells has been attributed to stress-induced activation of the hypothalamic-
pituitary-adrenocortical (HPA) axis [245].  Individuals experiencing chronic 
psychological distress exhibit HPA dysregulation resulting in altered GC 
levels[202,203] and disruption of the diurnal cortisol rhythm [162,179].  
 
Effects of Perceived Stress on HPA axis regulation 
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Preliminary analysis between cancer and cancer-free groups in our study yielded 
no significant differences in diurnal cortisol rhythms or immune function (Figure 22).  
Furthermore, analysis of the cancer-free group demonstrated that 37% of these 
individuals exhibited PSS scores greater than 14 (Figure 21).  Literature demonstrates 
that within the cancer-free population the average score for healthy “non-stressed” 
individuals is 12, while a score of 14 is the standard cutoff for stress.  Thus investigating 
the impact of stress on hormonal and immune function was precluded by this relatively 
high number of individuals in the cancer free group exhibiting intermediate levels of 
perceived stress.  In order to gain insight into how the perception of stress alters HPA 
activity, individuals were regrouped by dividing them into low, intermediate, and high 
stress groups using a tertile split based on the scores obtained from the PSS.  Analysis of 
total cortisol levels as judged by area under the curve (AUC) demonstrated a 
quantitative increase in AUC values as stress increased from low, to intermediate, to 
high levels (Figure 20B).  Pearson correlations confirmed that psychological stress, as 
measured by the perceived stressor scale, positively related with the AUC values (Figure 
23A).  These data demonstrate that as perceived stress increased, altered HPA axis 
regulation was observed, which was characterized by an increase in HPA activity.  
 
Analysis of Immune Function between high and low stress  
 
Abundant evidence indicates that psychological stress precipitates immune 
alterations and additionally the effects of GC have been readily demonstrable in 
peripheral blood mononuclear cells (PBMC)[246].  An additional layer of categorization 
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was applied by regrouping individuals based on their perception of stress as well the 
biological manifestation of stress (cortisol production) using Wards method of cluster 
analysis (Figure 21).  This grouping allowed investigation into the immune phenotypes 
associated with both the perception of stress as well as the biological manifestations of 
HPA activation.  
It has been demonstrated previously, that prior adverse events in which GC is 
dysregulated can “prime” inflammatory responses, promoting excessive cytokine 
production in response to subsequent stressors or stimuli [286-294].  In experimental 
animals, stressors have been shown to potentiate neuro-inflammation [295-299].  Our 
analysis demonstrates that circulating plasma IL-6 levels as well as IFN-g production 
from stimulated PBMC were quantitatively increased in individuals who exhibit high 
stress (Figure 22).  Pearson correlations were used to determine how HPA activity was 
related to this apparent increase in proinflammatory cytokine production.  AUC values 
positively correlated with both IFN-g and IL-6 production from stimulated PBMC 
(Figure 23D-E).  Additionally, IL-6 and IFN-g production were positively correlated 
(Figure 23C).  These data suggest that the proinflammatory cytokines, IFN-g and IL-6, 
are coordinately regulated in the PBMC of individuals and that increased perceived 
stress and the accompanying increase in HPA activity results in a proinflammatory 
phenotype. 
Natural killer cells are especially responsive to GC and NKCA is especially 
responsive to psychological stress, with ample evidence demonstrating psychological 
stress to reduce NKCA[199,300]. Analysis of ex vivo derived PBMCs yielded reduced 
NKCA standardized to percentage CD56+ in the PBMC of individuals exhibiting both 
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the psychological and biological phenotypes of stress (Figure 22). These observations 
demonstrate that psychological stress, as classified by the phenotype of increased 
perceived stressor and increased daily cortisol production, corresponded with reduced 
NKCA and increased proinflammatory cytokine production.  This dichotomous 
phenotype was confirmed using Pearson correlations demonstrating a significant 
negative correlation between NKCA standardized to CD56+ cell percentages and IFN-g 
production from stimulated PBMC (Figure 23B). 
There are examples in which an apparent similar dichotomous phenotype has 
been demonstrated.  For example Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome (ME/CFS) is a disease characterized by fatigue, pain and muscle aches, as 
well as cognitive impairment [301].  Inflammatory pathways play a key role in the 
pathophysiology of ME/CFS [302] and encompass low-grade inflammation, with 
increased circulating levels of cytokines, including IL-1alpha and beta and IL-6 
[303,304] as well as immunosuppression characterized as lowered NK cell lytic activity 
and decreased lymphocyte expression of activation markers, such as CD69[305,306,307].  
Of particular relevance, the dichotomous phenotype was demonstrated in CD56+ 
lymphocytes derived from these patients. 
Many studies have investigated the regulation of NK cell effector function 
during periods of psychological distress[199,202,203,300].  Some studies suggest that 
the expression levels of CD56 on human NK cells is related to effector function, in that, 
CD56bright NK cells are more proinflammatory while CD56dim NK cells are more 
cytolytic.  No significant differences in the percentages of CD56+ cells were observed 
between our cancer and cancer free groups or any grouping investigated.  Furthermore, 
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no change in the ratio of CD56bright vs CD56dim were observed within individuals in any 
of the grouping or cluster strategies I used (data not shown).  From these observations 
we conclude that chronic exposure to GC in vitro or psychological stress did not alter 
the expression of CD56 or the ratio of CD56bright vs. CD56dim populations.  
The above data demonstrate that clustering individuals based on their perceived 
stress as well as daily cortisol production yielded significant differences in immune 
function (i.e. enhanced proinflammatory cytokine production and reduced NKCA). In 
the reverse, classification of individuals based on the immune phenotypes of NKCA and 
IFN-g production from ex vivo derived PBMC yielded significant differences in both 
perceived stress and cortisol production (Figure 26A-B).  These observations in total 
demonstrate that stress imparts altered immune function within individuals who exhibit 
increased HPA activity.  Secondly, this dichotomous immune phenotype of enhanced 
proinflammatory cytokine production and reduced NKCA within PBMC can be used to 
characterize individuals with both increased perceived stress and HPA activity.  
 
Perceived stress and global epigenetic patterns 
 
We have previously published that stress is associated with a reduction in the 
global acetylation of H4K8 within CD56+ cells[308].  In that study, individuals with 
low, medium, and high stress exhibited high, medium, and low H4K8Ac MFI in the 
CD56+ NK cell population, respectively.  In the current study, NK cells were gated as 
the CD4-CD8-CD56+ cell population and the MFI of acetylated H4K8 was calculated 
from this gate. A representative schematic of the gating parameters to determine the MFI 
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of histone acetylation is presented in Figure 34A.  A significant negative correlation was 
observed between PSS scores and the global levels of H4K8 acetylation in CD56+ NK 
cells (Figure 34). A representative histogram containing two individuals who exhibit 
high PSS scores (average global MFI = 5719), two individuals who exhibit intermediate 
PSS scores (average global MFI = 16259), and two individuals who exhibit low PSS 
scores (average global MFI = 25548) (Figure 34B and D).  These observations confirm 
our previous findings and suggest that epigenetic mechanisms may mediate immune 
dysregulation within the NK cell population.  
 
Histone acetylation as a meditor of stress induced IFN-g production 
 
To determine if epigenetic mechanisms could explain the enhanced cytokine 
production after PBMC stimulation, promoter specific epigenetic changes were 
investigated within the regulatory loci of proinflammatory cytokine genes.  H3K9 can be 
acetylated as well as methylated.  The acetylation versus methylation of H3K9 are 
present in distinct chromatin regions.  Acetylation of H3K9 is enriched in euchromatic, 
actively transcribed regions while tri-methylation of H3K9 is enriched in silenced 
heterochromatic regions.  H3K9 modifications were used as a tool to investigate the 
epigenetic patterns at proinflammatory cytokine loci to gain further insight into their 
regulation during periods of stress.  By calculating the ratio of H3K9Ac/H3K9me3 a 
relative index of active (turned on) to inactive (turned off) proinflammatory cytokine 
loci could be obtained.  The ratio of acetylated H3K9 to trimethylated H3K9 was 
quantitatively increased at both the IFNG and IL6 loci when compared between 
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Figure 34. Global H4K8 acetylation levels with CD56+ cells at T1. (A) Gating 
scheme for assessment of global H4K8 acetylation MFI within CD4-CD8-CD56+ cells 
by flow cytometry.  (B) Representative histogram depicting 5 patients from cancer 
group who exhibit low (PSS<14), intermediate (15-21), and high (22+) stress.  PSS 
scores of individual patients are depicted above arrows.  (C) Scatterplot representing the 
relationship between PSS scores and global H4K8 acetylation at T1. (D) Table depicting 
patient identification, PSS score, and global H4K8 acetylation MFI within CD56+ cell 
population at T1. 
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high and low stressed individuals (Figure 22E-F).  These results demonstrate that 
individuals with increased perceived stress and increased HPA activity also have a a 
higher percentage of PBMC with a signature of more open chromatin structure at the 
proinflammatory regulatory loci and thus a higher potential for cytokine gene expression.  
This relationship was apparent in the population indicated by a significant positive 
correlation between the ratio of histone acetylation to histone methylation at the IFNG 
locus and stimulated IFN-g production from PBMC in this study (Figure 24B).  In total 
these data demonstrate that as stress increases the biological manifestation of this stress 
is increased HPA activity and an epigenetic priming of cytokine loci for expression.  
Furthermore, this priming was related to expression from these loci and constitutes a 
potential mechanism for the proinflammatory phenotype of psychological stress.  
In order to determine whether the stress-associated increase in IFN-g production 
was mediated by changes in histone acetylation a mediation model was investigated.  
The results of the mediation analysis indicate that PSS directly influences IFN-g 
production and indirectly influences IFNG expression by its effects on histone 
acetylation.  In a full mediation model, the direct effect of PSS on IFN-g production 
would have become insignificant when the role of histone acetylation was added to the 
model.  The model demonstrates only partial mediation because the path between PSS 
and IFN-g production (path c) stays significant (Figure 29). These data demonstrate that 
the enhanced proinflammatory cytokine production observed during stress is partially 
mediated by the epigenetic priming of cytokine regulatory loci via histone acetylation 
but additional mediators are present.  
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Conclusion 
  
A stressor constitutes a challenge to the individual which manifests as 
physiologic alterations [309], and the results observed herein suggests that these effects 
can be integrated at an epigenetic level.  The interplay between the environment and the 
epigenetic landscape remains poorly understood; this is particularly true with regard to 
the endogenous signals that alert the immune system to danger and/or threat. The ability 
of GR, when ligand activated by GC, to sense environmental signals of danger or stress 
due to changes in GC, appears to actively control or sense the environment affecting the 
epigenetic landscape and consequently alter gene expression programs essential to 
immune function[310]. The overlapping yet specialized physiological contribution of 
GC is to perform essential functions. For NK cells, which migrate to diverse sites within 
the body and continually survey for both infectious and malignant challenges, such a 
scenario may be functionally important in protection of the host. The findings presented 
herein indicate that GC are a means by which immune functions can be epigenetically 
primed for altered activity in response to environmental signals such as psychological 
stress. 
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Comparative analysis of ex vivo and in vitro systems 
  
In this body of work in vitro chronic low level glucocorticoid exposure was used 
as a model to understand the mechanisms of GC regulation of immune function in vivo 
during periods of psychological stress.  In this study, the psychological stress attributed 
to breast cancer diagnosis resulted in increased daily cortisol production.  These 
observations were made at or within two weeks of diagnosis at timepoint 1 (T1).  
Chronic GC treatment in vitro lasted for 5 days and would fall within the timeframe 
window of our T1 timepoint.  In unpublished data, when chronic GC treatment was 
extended to 10 days a similar dichotomous phenotype was observed but maintained its 
effects and was not exacerbated by the extended time (data not shown).  
Both chronic low level GC exposure in vitro and increased daily cortisol levels 
in vivo corresponded with enhanced production of IFN-g and IL-6 protein upon cellular 
stimulation.  These results highlight that the effects of GC on cytokine transcription 
occurs via a priming mechanism, as both systems exhibit no change in basal cytokine 
production but only after cellular stimulation.  In both systems promoter specific histone 
acetylation patterns were associated with enhanced cytokine production.  We did 
observe differences in the specific acetylation marks which regulate cytokine production 
between our two system.  In vitro H4K8 and H3K27Ac were markers IFNG and IL6 
epigenetic priming while H3K9Ac was a marker in ex vivo derived PBMC.  Both 
observations involve changes in histone acetylation and thus correspond with 
transcriptional activation.  These differences could be explained by a number of 
mechanisms.  Our in vitro system uses an immortalized clonal cell line; how cellular 
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transformation and continued proliferation impacts the epigenetic regulation of NK cell 
effector genes is unknown and could mask changes in specific histone acetylation marks 
which are more maliable than DNA and histone methylation.  This is in contrast to the 
heterogenous pool of NK cells in the circulation, which exhibit different levels of 
activation, expression of CD56, and differentiation states.  Additionally, our ex vivo 
observations use whole PBMC which include B cells, T cells, and NK cells.  The ratio 
of H3K9Ac to H3K9me3 presented would represent the relative number of PBMC 
acetylated at the IFNG enhancer and thus would indicate that these immunological 
effects are not confined to the NK cell subset as they only represent 5-15% of circulating 
PBMC.  Additionally, our in vitro culture system cannot test the interaction of the many 
immune cell populations present in whole PBMC.  Furthermore, circulating immune 
cells experience constant signaling from the host in addition to GC.  In that humans are 
continually exposed to foreign agents from commensal bacteria, diet, as well as 
pathogens.  How these constant normal commensal relationships and constant low level 
exposure to pathogens effects and interacts with GR signaling in circulating immune 
cells is beyond the scope of this project.  Although the specific histone mark is different 
the overall conclusions are the same, that increased daily exposure to GC increases 
histone acetylation at proinflammatory regulatory regions.    
  A number of studies suggest that the enhanced proinflammatory cytokine 
production associated with psychological distress occurs via a mechanism involving 
glucocorticoid resistance.  These hypotheses are based on observations, in a model of 
depression, where the EC50 of dexamethasone inhibition of stimulated cytokine 
production was increased in ex vivo derived PBMC.  The authors hypothesize that this 
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results from GC resistance via changes at the level of the GR, although no direct 
evidence of any such changes in GR was demonstrated.  Additional studies demonstrate 
that enhanced transcription of the NF-κB regulon occurs during psychological 
stress[311,312].  Authors of these studies suggest that this results from alterations in GR 
and/or NF-κB functional activity.  The results from both our systems are parsimonious 
with the latter as IFN-g and IL-6 investigated here are part of the NF-κB regulon.  
However, neither of the previous studies directly test the mechanism for enhanced 
production of proinflammatory cytokine.  We propose that these observations can be 
explained by the epigenetic priming of specific genes within the NF-κB regulon as 
demonstrated in this body of work.  Epigenetic priming would produce the same 
phenotype without any direct changes in the functional capacity of either GR or NF-κB.  
We did not directly test the functional capacity of GR or NF-κB within ex vivo derived 
PBMC, but we did directly test both in vitro during chronic GC treatment.  Chronic GC 
treatment exhibited no effect on GR or NF-κB levels nor the functional capacity of 
either transcription factor.     
This body of work focused on the mechanisms governing the enhanced cytokine 
production associated with psychological stress.  We were also interested in the 
mechanisms regulating the reduced lytic potential of NK cells after chronic GC 
treatment and during periods of psychological stress.  Our in vitro data demonstrates that 
NK cell lytic molecules are also regulated epigenetically after chronic GC treatment.  
This is characterized by reduced H3K9 acetylation at both the PRF1 and GZMB 
promoters (Figure 11A-B).  Although reduced NK cell lytic activity was observed in 
individuals exhibiting increased perceived stress; relationships between NKCA and lytic 
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molecule production, as measured by flow cytometry, exhibited a trend towards a 
positive relationships but did not reach significance (data not shown).  As described in 
the introduction, NKCA is a complex process and is regulated at multiple stages.  
Furthermore, perforin and granzymeB are constitutively produced and stored in lytic 
granules until degranulation occurs.  The timeframe in which reductions in lytic 
molecule transcription would correspondingly exhibit reductions in the protein levels of 
these molecules in vivo remains unclear, as the exact half-life of lytic molecules within 
CD56+ granules in vivo has not been investigated. Thus further analysis of lytic 
molecule transcription as well as protein production would yield the most insights into 
the regulation of these molecules in regards to psychological stress.  
The lytic activity of NK cells is also regulated by the surface expression of KIRs.  
A number of reports suggest that psychological stress can alter the expression of both 
NK cell activing and inhibitory receptors[121,313,314].  An additional complication is 
the variability of NK cell activating and inhibitory receptor expression between 
individuals[314].  The expression of KIR expression was not assessed in this study and 
we cannot exclude the contribution of receptor expression on NK cell functional activity 
during periods of stress.  Investigation of NKp30 and NKp46 expression on NK92 cells 
following chronic GC treatment exhibited no significant changes in surface expression 
(Table 4).  
Our lab has previous published that PSS is also associated with global changes in 
histone modifications[308].  Specifically the acetylation of H4K8 is reduced across the 
entire genome in individuals with high stress[308].  These observations were validated 
in this study demonstrating that PSS scores negatively relate with global H4K8 
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acetylation in the CD56+ cell population (Figure 34C).  Global reductions in H4K8-
acetylation were also observed in our in vitro system and suggest that this phenotype can 
be used as a marker of NK cell function activity.  Our in vitro observations demonstrate 
that as early as day 2, phospho-HDAC2 levels are increased in the nucleus and remain 
elevated throughout treatment.  I would speculate that individuals would exhibit 
increased PSS and AUC would have increased nuclear localization compared to low 
PSS and AUC individuals.  Prelimary results from 3 high stress and 3 low stress 
individuals show this trend (Appendix Figure 31).  Thus global H4K8 acetylation seems 
to be a marker for the immune phenotypes observed during stress and possibly could be 
used as a diagnostic tool. 
Chronic GC treatment resulted in alterations in both HDAC2 and HDAC3 that 
regulated the transcription of lytic molecules and cytokines, respectively.  These in vitro 
observations suggest the HDAC2 and HDAC3 are dysregulated within the CD56+ cell 
population during periods of psychological stress. The results from in vitro chronic GC 
treatment would suggest that HDAC3 is involved in the regulation of these 
inflammatory processes.  Total HDAC3 protein levels were decreased following chronic 
GC treatment, additionally HDAC3 levels were decreased at the IFNG and IL6 loci 
corresponding with the increased histone acetylation.  I would speculate that individuals 
who exhibit increased PSS and AUC would exhibit decreased HDAC3 protein levels 
within the CD56+ cell population. 
In conclusion, in vitro chronic GC treatment of an NK cell line was used to 
investigate the molecule mechanism(s) which mediate altered immune function during 
periods of psychological stress.  This body of work characterized a dichotomous 
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phenotype of reduced NKCA and enhanced proinflammatory cytokine production after 
chronic low level GC treatment.  These observations were continued using ex vivo 
derived PBMC from individuals diagnosed with breast cancer as a model of 
psychological stress.  Analysis revealed that the perceived stress of cancer diagnosis 
corresponded with increased daily cortisol production.  Increased perceived stress, with 
the accompanying increases in cortisol production, corresponded with decreased NKCA 
and enhanced cytokine production, a dichotomous phenotype similar to that observed 
following chronic GC treatment in vitro.  Lastly, this enhanced cytokine production was 
partially mediated by the acetylation of proinflammatory cytokine loci.  These 
observations demonstrate that GC through epigenetic pathways mediate changes in 
immune function.   
 
Stress induced immune changes: A benefit or detriment to the host 
 
With the observations that psychological stress results in altered immune 
function, the question becomes whether this is a dysregulation of the immune system 
and is thus detrimental or somehow beneficial to the host.  Acute stress such as the flight 
or flight response are scenarios in which the host has a higher probability of injury and 
subsequent infection.  Acute stress, accompanied by a rapid increase in cortisol and 
other adrenocorticoids, leads to an influx of newly differentiated immune cells into the 
circulation from the bone marrow.  Additonally, these factors redistribute circulating 
innate immune cells, such as NK cells, to migrate from the circulation into the peripheral 
tissues to potentially detect injury or infection.  These changes in surface adhesion 
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molecule expression by NK cells have been shown in acute stress models in both mice 
and humans, and have been shown to involve both GC and adrenergic receptor mediated 
mechanisms.  Thus it is hypothesized that acute stress prepares the immune system for 
the potential of injury or infection leading to a more rapid immune response that is 
evolutionarily beneficial for host survival.   
Whether the immune regulation associated with chronic on-going stress as 
demonstrated in this work is evolutionarily beneficial or not is of intense debate.  Most 
literature regards the immune alterations associated with chronic stress as detrimental to 
host health and quality of life.  Chronic stress has been repeatedly associated with 
decreased NKCA.  The decreased NKCA associated with stress is of particular 
relevance to breast cancer because epithelial tumors are responsive to the immune 
protective effects of NK cells and IFN-g[206,207,208,209].  The importance of NK cell 
activity is highlighted by findings involving the relationships between cancer and 
NKCA.  First, high levels of NKCA in cancer patients correlate with a good 
prognosis[214,215,216,217].  Impaired NKCA also correlates with invasiveness of 
human malignancy[218].  NK cell infiltration into primary tumors is associated with 
fewer metastases to the lymph nodes and less lymphatic invasion[214].  Lastly, overall 
survival for patients with high and low NKCA was 71 vs. 30 weeks, respectively and 
NKCA was an independent prognostic factor for overall survival [215]. 
The second phenotype highly associated with chronic stress is a low grade 
inflammatory phenotype.  Over the last decade inflammation has been attributed as a 
leading factor in the progression of a number of diseases.  Low grade inflammation has 
been associated with multiple disease states including atherosclorosis, heart disease, 
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activation of autoimmune diseases, and arthritis.  Thus both of the immune phenoypes 
associated with chronic stress are implicated in poor health outcomes and reduced 
quality of life.  So why would these detrimental phenotypes persist evolutionarily? 
One newly developed view, does not ask the question why the inflammatory 
state of chronic stress detrimental but when would these effects be beneficial in the life 
of a host.  More specifically when, evolutionarily, would this proinflammatory state be 
beneficial to the host thus promoting survival and such alleles would be passed on to 
future generations.  Termed the Pathogen Host Defense (PATHOS-D) hypothesis, it 
suggests that in infancy and early childhood the adaptive immune response is not at fully 
potency and does not contain the full arsenal of pathogen specific immune cells (i.e 
memory T and B cells) primed and ready to fight infection[315].  Thus a robust innate 
proinflammatory response to infection early in life would be beneficial.  This is in 
contrast to adulthood, most relevant to this study in which the adaptive immune system 
is fully functional and able to mount a quick and pathogen specific response.  These 
hypotheses imply that perhaps in childhood these effects are beneficial and the resilience 
of childhood homeostatic mechanisms permits eventual resolution of these detrimental 
effects but in adulthood they are maladaptive to the host[315].  
These hypotheses are obviously in their infancy but provide interesting concepts 
for future investigation.  Here in I have uncovered a potential mechanism by which 
chronic stress imparts these immune phenotypes.  Epigenetics provides a means by 
which the activity of the immune system can be modulated in response to the 
environment without direct changes to the DNA sequence.  Furthermore, epigenetic 
changes allow for the transcriptional priming of genes, in essense, a preparing of the 
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immune system.  The characterization of these epigenetic mechanisms provides 
researchers with potential avenues for therapies to overcome the effects of stress on the 
immune system but also avenues in which to modulate the activity of NK cells for other 
immune based disorders.  
 
Clinical Significance and Future Work 
 
Research into the alterated immune function during periods of stress have also 
illucidated genetic, social, and intervention mechanisms that can ameliorate or dampen 
the effects of stress on these biological outcomes and quality of life.  Of particular 
relavence to our lab are the results from our published work regarding the Mindfulness 
Based Stress Reductions (MBSR) paradigm[202].  MBSR stems from contemplative 
Eastern spiritual practices that use meditation to cultivate conscious awareness (i.e., 
mindfulness) of one’s experience in a non-judgmental or accepting manner (Kabat-Zinn, 
et al., 1990).  In this study enrollment into the MBSR program could ameliorate some 
aspects of the immune dysregulation associated with the stress of breast cancer diagnosis 
compared to a group of women who were similarly diagnosed but enrolled in a control 
eduction group[202]. These observations involving the positive aspects of MBSR can 
now be expanded to investigate the mechanisms uncovered in this body of work.  Does 
MBSR mediate these effects through restoration of HPA activity or through a secondary 
pathway which can overcome these epigenetic mechanisms? 
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Conclusions	  
 
To our knowledge this is the only demonstration that dichotomous NK 
phenotype is demonstrable in a cell line.  Here, we demonstrate the effect of chronic GC 
on the active promoter and enhancer landscape of NK effector genes.  Chronic GC 
treatment regulates 2 members of the class I HDAC family imparting both promoter 
specific and genome wide changes in histone acetylation patterns.  The ability of the 
immune system to sense and interpret environmental stimuli and appropriately modify 
gene expression is a fundamental tenet of immune responsiveness. Whether the stimulus 
is exogenous or endogenous (as in the case of GC), the final decoding of the message 
occurs at the genome level, resulting in either activation or repression of transcription.  
Taking part in the epigenetic landscape and chromatin structure, which determines 
accessibility of regulatory elements such as promoters and enhancers for transcription 
factors that carry out cell-type specific gene expression programs. This may be of 
particular relevance to understanding the effect of GC on immune responsiveness during 
stressful events.  We further demonstrate that cancer diagnosis, a stressful event, 
culminates in the overactivity of the HPA axis resulting in immune cells exposed to 
increased levels of cortisol for a period of days.  Furthermore, stress was also associated 
with a dichotomous regulation of immune function characterized by decreased NKCA 
yet enhanced proinflammatory cytokine production.  Mechanistically, the increased 
IFN-g production associated with stress was mediated in part by promoter specific 
acetylation patterns within the IFNG locus.  Lastly, stress is associated with genome 
wide changes in acetylation patterns.  These observations provide mechanistic insights 
157 
 
and diagnostic tools to more fully characterize the immune regulation during 
psychological stress. 
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